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Reabsorbing ~7% of the sodium load, the distal convoluted tubule plays key roles in blood 
pressure (BP) homeostasis. Here, Na-Cl co-transport (NCC) is the major route for apical Na 
entry making thiazide diuretics (NCC inhibitors) a mainstay hypertension treatment. 
Predictive adaptations of sodium excretory rhythms are supported by an intrinsic renal clock, 
which regulates transporter activity according to physiological need. Peripheral clocks can 
be influenced by glucocorticoids, which also have a circadian rhythm. We therefore 
hypothesized that NCC’s diurnal rhythm is regulated by glucocorticoids. C57BL6 mice were 
kept on a 12h light cycle with subjective day starting at 7am. Urine was collected in 12h 
periods and kidneys harvested at 1am (night) and 1pm (day). Slc12a3 (NCC encoding gene) 
mRNA and NCC protein abundance were similar between day and night but NCC 
phosphorylation at threonine 53 was significantly higher at night compared to day. Plasma 
and urinary corticosterone levels were elevated at night. Glucocorticoid inducible leucine 
zipper (GILZ) and serum and glucocorticoid inducible kinase (SGK1) transcripts also 
increased at night. Chronic corticosterone infusion flattened the plasma corticosterone 
rhythm within an intermediate physiological range. The diurnal rhythm of pT53 NCC was 
dampened in these mice but not in vehicle-treated mice. Blood pressure was monitored in the 
mice by radiotelemetry. After 2 weeks of baseline measurements mice received chronic 
corticosterone or vehicle for 3weeks, during the last 10 days of which they received ~80 
mg/kg hydrochlorothiazide in their drinking water. At night systolic BP (SBP) was 
unaffected by any treatment whereas during the day SBP significantly increased following 
corticosterone but was unaffected by vehicle. Cosinor analysis of SBP in corticosterone and 
vehicle treated mice showed a marked reduction in rhythmicity, increased MESOR and 
reduced amplitude. In animals receiving corticosterone HCTZ partially rescued daytime 
SBP. This manoeuvre also improved SBP rhythmicity, reduced MESOR and increased 
amplitude. These data indicate that NCC phosphorylation has a diurnal rhythm that is in part 
regulated by glucocorticoids. They also show that alteration of the glucocorticoid rhythm 
affects the blood pressure rhythm in part through its effect on NCC phosphorylation. These 
findings may be clinically relevant in the pathogenesis of hypertension in conditions 
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1.1. Non-dipping blood pressure (BP) and cardiovascular disease risk 
Hypertension, defined as an average systolic blood pressure (SBP) over 140 mmHg and 
diastolic blood pressure (DBP) over 90 mmHg, is the leading risk factor for the global 
burden of disease [1]. Approximately 1/3 of adults have hypertension and this proportion is 
predicted to increase as the rate of new hypertensives outstrips the population expansion: by 
2025 1.5 billion people will be affected [2]. It is not only hypertension per se, but the daily 
rhythm of BP that is an important risk factor for disease. Indeed, even if office or 24-hour 
BP is normal, abnormalities in circadian rhythms of blood pressure can confer an elevated 
risk of cardiovascular disease (CVD) [3, 4].  
 
BP has long been known to have a circadian rhythm. In healthy individuals this is 
characterised by a morning surge prior to waking, a plateau during the day followed by a 
nocturnal decline. This nocturnal decline is ~10-20% of the day time BP in healthy 
individuals, but is attenuated in approximately half of hypertensive patients [5, 6]. This 
attenuation is known as “non-dipping”, usually defined as nocturnal BP that declines by less 
than 10 % compared to mean daytime levels [7]. Non-dipping is associated with a plethora 
of cardiovascular pathologies, including increased left ventricular hypertrophy [8], 
atherosclerotic plaques [9], micro albuminuria [10], cerebrovascular disease, congestive 
heart failure, vascular dementia [11], stroke, and myocardial infarction [12]. In a population-
based study, normotensive individuals with non-dipping BP had ~double the risk for 
cardiovascular mortality compared to normotensive dippers [13]. Hypertensive non-dippers 
had a >5 times greater risk of CV-related mortality (Figure 1.1.) [13].  
 
In other major diseases non-dipping is also a feature. It is present early in the development of 
diabetes preceding and predicting micro albuminuria [14] and is also associated with 
metabolic syndrome [15]. BP rhythmicity is lost during the earliest stages of chronic kidney 
disease (CKD)[16] and creatinine clearance deteriorates faster in non-dipper CKD patients 
compared to dippers [17]. Understanding the origins of non-dipping blood pressure and how 




Figure 1.1: Relative Hazard or cardiovascular mortality in patients with non-
dipping/dipping high/normal blood pressure.  
Figure adapted from [13] 
 
1.2. The kidney and the circadian rhythm of blood pressure 
The development of non-dipping BP is multifactorial and loss of nocturnal dip has been 
associated with poor sleep quality [18], loss of vascular compliance [19] and increased 
sympathetic drive [20]. Given that the kidney, through regulation of extracellular fluid 
volume (ECFV), is a major regulator of long term BP [21], it is not surprising that renal 
impairment may also cause non-dipping. Renal function normally has a circadian rhythm 
with increased glomerular filtration rate (GFR), renal blood flow (RBF) and sodium 
excretion during the day compared to the nighttime (Reviewed in [22, 23]). Clinical studies 
show that the diurnal variation in BP is strongly correlated with renal sodium excretion [24]. 
Hypertensive and pre-hypertensive patients have a blunted diurnal pattern of sodium 
excretion with a larger proportion of the daily sodium output excreted at night [25, 26]. Both 
dietary sodium restriction and thiazide diuretics can rectify this non-dipping BP [27, 28]. 
Renal transplantation can rescue BP dipping in some cases [29], although pre-transplantation 




Combined, this evidence infers a direct link between abnormal circadian BP rhythms and 
inappropriate renal sodium transport. Indeed, the kidney regulates BP by modulating renal 
sodium excretion and ECFV in response to changes in renal arterial perfusion pressure 
(RAP). This mechanism, called pressure natriuresis (PN), stabilises BP in the long term. For 
example if BP rises, the kidney senses this as a change in RAP and responds by increasing 
sodium excretion and thus reducing extracellular fluid volume (ECFV). Conversely if BP is 
low the kidney enhances renal tubular sodium reabsorption thus increasing ECFV (Reviewed 
in [21]). Mathematical models published by Guyton et al in 1972 predict that this PN system 
is one of infinite gain, such that any change in BP can be matched with an appropriate 
change in sodium excretion to bring BP back to a set point [31-33]. It follows that 
hypertension can only be sustained if the PN response is impaired.  
 
The PN response adapts with changes in dietary sodium intake. For example if sodium 
intake is high, the PN curve shifts to the left and the slope steepens (Figure 1.2) so that a 
greater amount of sodium is excreted with a smaller change in BP to prevent an expansion of 
ECFV.  The change in PN slope is modulated by hormonal and neuronal systems such as the 
renin-angiotensin-aldosterone system (RAAS) and renal sympathetic nerve activity, which 
trigger renal (renal sodium transporters activation/inactivation) and extra-renal (vasodilation) 
adaptations. Failure of these systems to respond appropriately to sodium intake can lead to 
an impaired PN response. In hypertension this usually means a shallower right shifted PN 
curve [34].  
 
Fukuda et al hypothesised that PN impairment resulting in a diminished sodium-excretory 
capacity is a key step in the development of non-dipping [35]. Thus, if sodium intake is 
habitually high, an impaired PN means that the daytime excretory capacity is easily 
surpassed. Therefore sodium excretion may need to spillover into the nighttime in order to 
maintain 24-hour sodium balance. BP therefore remains high at nighttime because not 








Figure 1.2: Pressure natriuresis curve 
Shifting of the pressure natriuresis curve occurs as an adaptation to dietary sodium intake. 
Low sodium intake causes a shift of the PN curve to the right through an activation of the 
renin angiotensin aldosterone system (RAAS) and increased renal sympathetic nerve activity 
(rSNA). Conversely high sodium shifts the PN curve left through an inhibition of the RAAS 
and rSNA. These shifts cause a change in sodium excretion to maintain mean arterial 
pressure (MABP) at a set point. Figure adapted from [34, 36].  
 
1.3. Circadian control of renal sodium transport 
Vogel and Zadek first described rhythms in urinary excretion in the 1800s (Reviewed in: 
[22]). These are synchronised with activity and feeding but are unlikely to be merely cause 
and effect. Electrolyte excretory rhythms have been shown to persist over extended periods 
under experimental conditions where external factors are kept constant [37, 38], suggesting 
that these rhythms are under the control of an intrinsic renal clock.  
 
The 24-hour rotation of the Earth confers a predictable daily cycle of fluctuations in 
temperature and light to the environment. Endogenous biological oscillators or clocks, which 
are pervasive within the biosphere, are an evolutionary adaptation to these cycles (Reviewed 
in: [39]). They allow the organism to schedule behavioural and biological functions at the 
appropriate time within the daily cycle and coordinate internal physiology. 
 
Endogenous molecular clock machinery has been identified in nearly every peripheral tissue 
in the body. Nucleated cells operate via a simple transcription and translation feedback 
(TTF) loop involving 4 core clock genes: bmal1, clock, cry and per. The transcription factors 
brain and muscle arntl-like 1 (bmal1) and circadian locomotor output cycles kaput (clock) 
are positive activators of the TTF loop. These are produced and form heterodimers, which 
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bind to E-box response elements within promoter regions of target genes. These target genes 
include period (per, homologs 1,2,3) and cryptochrome (cry, homologs 1,2). Per and cry 
proteins are transcribed, translated and accumulate in the cytoplasm where they form 
heterodimers and homodimers of various combinations before translocating to the nucleus. 
Upon reaching a critical nuclear concentration, they inhibit bmal1 and cry1, thus repressing 
their own transcription. When per and cry concentrations decrease below a level required for 
efficient bmal1 and clock repression, a new transcription cycle can begin.   
 
In order for these transcription and translation oscillatory loops to function, the RNA and 
protein products of the core clock genes must undergo controlled and rapid degradation. 
Post-translational modifications modulate this degradation. In particular, phosphorylation of 
per protein by casein kinase 1ε destabilises per and increases its turnover [40]. Other 
accessory components of the molecular clock include rev-erbα, DBP and RORA, which 
modulate the activity of the loop (Figure 1.2,[41]). Importantly in addition to regulating each 
other to sustain oscillation the clock components also transactivate genes that mediate 
downstream physiological functions.  
 
Components of the core molecular clock are expressed in the kidney with robust rhythmicity. 
Furthermore a significant number of renal genes exhibit a circadian profile of expression. 
Zuber and colleagues demonstrated in microarray analysis of DCT/CNT and CCD micro-
dissected kidney segments, that 356 and 504 genes respectively, exhibited a circadian 
expression pattern (defined by amplitude >1.8 and ~24-hour period)[42]. Using RNA 
sequencing Hogenesh and colleagues looked at circadian rhythms in several whole organs, 
including the kidney, with greater resolution (2-hourly compared to 4-hourly)[43]. Of the 12 
organs studied, the kidney, with circadian gene expression in 13 % of genes, was second 






Figure 1.3: Transcription translation feedback loop model of the endogenous clock 
The molecular clock mechanism consists of a “Core Clock Loop” in which bmal1 and clock 
heterodimers bind E-box regions within promoters of per and cry genes activating their 
transcription. Per and cry constitute the negative arm of the loop. These accumulate in the 
nucleus where they form combinations of homodimers and heterodimers. These dimers 
translocate to the nucleus where they inhibit bmal1 and clock activity thus inhibiting their own 
transcription. Phosphorylation of per by casein kinase 1 (CK1E) accelerates the degradation 
of per adding another level of control to the clock. Post-translational modifications modify the 
accumulation of per in the cytoplasm leading to the ~24-hour rhythm.  The “Accessory Loop” 
is also triggered by clock and bmal1 heterodimers. These bind E-box regions in the 
promoters of rev-erbα and rora genes. RORA activates bmal1 transcription through a RORE 
element in the bmal1 promoter. REV-ERBα competes with RORA for the RORE binding site 
of bmal1 and inhibits its transcription. Glucocorticoids (GC) can modulate transcription of 
both per1 and rev-erbα by binding glucocorticoid response elements in their promoter 
regions. The GRE in the per1 promoter causes transactivation and increased production of 
per1 whereas the rev-erbα gene promoter contains a negative GRE (nGRE), which 





A micro-array approach identified several gene families with rhythmic expression, including 
the solute carrier (SLC) family of genes and those encoding enzymes involved in the 
metabolism of xenobiotics [42]. Genes involved in sodium and water homeostasis have also 
been identified as being circadian including the vasopressin receptors (V2R, V1aR) and the 
aquaporins: AQP2 and AQP4 [42]. A candidate gene approach has uncovered several more 
important renal transporters with circadian rhythms. The sodium hydrogen exchanger 
(NHE3) in the proximal tubule exhibits circadian oscillations of both its mRNA and protein 
[46]. These oscillations are directly regulated by bmal1/clock through their interaction with 
an E-box region in the NHE3 promoter region[46]. Similarly ENaCα, which is the rate-
limiting transcript for epithelial sodium transport in the distal nephron, displays a circadian 
rhythm of expression. This rhythm is per-dependent and can be modulated by aldosterone 
through aldosterone’s induction of per, which requires both MR and GR [47].  
 
The importance of circadian clocks in renal physiology and BP homeostasis is exemplified 
by gene-targeting approaches in mice (summarised in Table 1.1). Many of these models have 
sodium transport defects and all exhibit changes in BP level or rhythm. Interestingly some 
clock mutants were able to maintain their diurnal rhythm of BP (KS bmal1-/-, clock-/- and 
per1-/-) while others are not (cry1/2-/- and global bmal1-/-). Most of these clock mutants 
have deformations in their corticosteroid rhythms. Therefore although the intrinsic renal 
clock is likely important and can function autonomously [48], in vivo the kidney clock is 




Table 1.1: Effects of targeted disruption of clock genes on blood pressure (BP) and sodium balance 
“Rhythmic” in the context of Aldo/GC defect means that difference in daytime versus nighttime corticosteroids is intact. SS (salt sensitive) BP, KS 
(kidney specific, in this case Cre Bmal1lox/lox/Ren1d/Cre mice)
Clock gene BP effect BP dipping? ENa defect Aldo/GC defect Transporters defects? References 
bmal  non-dipping unknown 
Aldo unknown 




bmal (KS*)  dipping  
Aldo  (rhythmic?) 
GC unknown 
αENaC, NCC, ROMK, AQP2, 
AQP3, AQP4 
[51] 
clock  dipping  
Aldo  arrhythmic 
GC rhythmic 







Aldo   (arrhythmic) 





per1  dipping  
Aldo  (arrhythmic) 










1.4. Entraining renal clocks to the external world 
Molecular clocks can only approximate 24 hours and require periodic entrainment by 
external cues or Zeitgeibers. Zeitgeiber translates as “time giver” and describes exogenous 
stimuli, which act to synchronise molecular clocks. The photoperiod is the most dominant 
environmental Zeitgeiber and this information is conveyed within an opaque organism by the 
activation of the central or master clock within the superchiasmatic nucleus (SCN) of the 
hypothalamus in the brain (Figure 1.3). The SCN receives light information via non-image 
forming photoreceptors called photosensitive retinal ganglion cells (pRGC). These ganglion 
cells express their own photopigment, melanopsin and sense light independently of rods and 
cones [59]. They signal directly to the SCN through the retinohypothalamic tract and activate 
several signalling pathways within the SCN (Reviewed in [45]). These signals culminate in 
chromatin remodelling and the induction of clock genes, adjusting the “metronome” of the 
SCN.  
 
The SCN then relays this rhythm via neuronal and hormonal signals to the billions of 
individual clocks within every cell of the body, thus daily establishing “phase coherence” of 
the organism. Initially this arrangement was thought of as a master and slave situation 
whereby the peripheral slave clocks are fully dependent or, answer only to, the master clock. 
However it is now apparent that the peripheral clocks are cell-autonomous and self-
sustained. An analogy for this that I particularly like is that of an orchestra and a conductor 
[60]. Each orchestra performer is capable of playing his/her own tune and each section has a 
slightly different melody/harmony but the conductor sets the tempo and unifies the 
performers. Importantly adjacent peripheral cells do not appear to couple their molecular 
clocks via paracrine signalling therefore the SCN is required for phase coherence of cells 
within the same tissue [61]. Extending the orchestra analogy, it is as if the performers within 
the same section cannot hear each other thus are dependent on the conductor’s signalling to 
keep in time. Whole-organ RNA sequencing experiments by Hogenesch and colleagues 
show that while the clock genes oscillated in phase in all 12 organs studied (including 
kidney), the vast majority of other circadian gene expression is organ-specific with very little 
overlap of circadian genes between organs [43]. Therefore although the peripheral clock is 
“in time” throughout the body, its effects are organ dependent. 
 
Most data on circadian clock origin, mechanism and function have been obtained in 
nocturnal rodents but humans are diurnal. The genes and networks of the circadian 
oscillators are highly conserved between mice and humans [62]. Therefore the mouse 
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represents a tractable model for disease relating to human circadian disorder. The major 
difference between nocturnal and diurnal animals appears to be in how the SCN signals are 
interpreted by the brain. Nocturnal and diurnal animals’ SCN clocks are entrained to light in 
the same manner with increased SCN neuronal firing during light conditions. However, 
downstream peripheral clocks in nocturnal and diurnal animals are in anti-phase to each 
other. Therefore nocturnality or diurnality arises from signals downstream of the SCN but 
upstream of any circadian entrainment relay centres such as the pituitary, which are in phase 
with the periphery. These pathways are not well defined but comparisons between diurnal 
and nocturnal rats indicate that the interaction between the SCN and ventral 
subparaventricular zone (SPVz) may modulate the effect of SCN signals at its targets[63]. 
Others indicate a developmental difference in how and when the SCN connects to the 
hypothalamus may confer diurnality [64].   
 
1.5. Glucocorticoids (GCs): peripheral clock synchronisers  
How the SCN transmits signals to the rest of the body is the subject of on-going research. A 
major candidate for peripheral clock entrainment is glucocorticoids (GCs). These steroid 
hormones have a robust and striking circadian rhythm, their receptors are ubiquitous and 
they regulate the mRNA expression of ~20 % of the genome [65]. Furthermore 
glucocorticoid receptors (GR) are not expressed in the SCN [66] so GCs are unlikely to 
modulate central clock function through their cognate receptor. 
 
GC release is usually governed by the hypothalamic pituitary adrenal (HPA) axis particularly 
during stress (Figure 1.4). Corticotrophin releasing factor (CRH) from the hypothalamus 
triggers adrenocorticotropic hormone (ACTH) release from the pituitary, which ultimately 
increases production and secretion of GCs from the adrenal zona fasciculata. The circadian 
rhythm of GCs is under the control of the SCN [67]. The SCN projects to the hypothalamus 
both directly and via several other brain regions (including the subPVZ potentially important 
for nocturnality/diurnality). Translation of these signals mainly through the paraventricular 
nucleus of the hypothalamus stimulates CRH-releasing neurones and arginine vasopressin 
(AVP) releasing neurones triggering rhythmic ACTH excretion, which stimulates 




Figure 1.4: Hierarchical arrangement of the circadian timing system and integration 
with the HPA axis 
Light detected by retinal ganglion cells entrain the SCN clock. The master clock integrates 
with the hypothalamus, which can also receive stress signals from high brain regions. This 
results in the release of arginine vasopressin (AVP) and corticotrophin releasing hormone 
into the median eminence triggering the release of adrenocorticotropic hormone (ACTH), 
which stimulates glucocorticoid (GC) release from the adrenal. GCs go on to entrain 
peripheral clocks such as those in the kidney. The GC rhythm can also be directly stimulated 
by the SCN through neuronal connections.  For clarity the hypothalamus and pituitary are 




There is also evidence for direct neuronal connections between the SCN and the adrenal 
gland, since rhythmic corticosterone release persists in hypophysectomised rats [69] but not 
in hypophysectomised adrenal denervated rats [70]. 
 
GCs have been shown to strongly entrain molecular clocks in many peripheral tissues. 
Following SCN ablation in rats, a single bolus dose of the synthetic GC, dexamethasone 
induced the synchronisation of 60% of the circadian transcriptome of the liver [71].  In 
corneas of adrenalectomised (ADX) rats dexamethasone treatment improved rhythmicity 
[72]. In human peripheral mononuclear cells, exogenous GCs increased PER1 expression 
and after several days of treatment caused an 11-13 hour phase shift of PER2-3 and BMAL1 
expression [73].  Administration of exogenous GCs causes a strong phase resetting of the 
circadian oscillators in fibroblasts [74]. And a single injection of GC causes a phase shift of 
peripheral clocks in the kidney and liver in in vivo rat experiments [75]. In primary mouse 
mesenchimal stem cells GCs stimulated the transcriptional oscillation of 10 of the known 
clock genes (per1-3, cry 1-2 rev-erbα, dbp, npas2, bmal1) [76].  
 
GCs act by binding to GR in the cytoplasm, which then dimerise and translocate to the 
nucleus.  GR act like transcription factors to transrepress or transactivate genes by binding to 
glucocorticoid response elements (GREs) and can therefore target clock genes directly or 
indirectly. GREs have been found in both the core and accessory loops of the circadian clock 
including per 1 [77], per2 [76, 78] and Rev-verbα [79]. Interestingly clock genes also seem 
to play a role in the transcriptional activity of the GCs. BMAL and CLOCK dimers can 
modulate the effects of GCs through enzymatically targeting the GR and attenuating its 
binding to GREs[80]. Cry1 also appears to associate with and modulate the activity of GRs 
[54].  
 
It is important to note that GCs are not the only peripheral clock entrainers and many clock 
protein rhythms are maintained in ADX rats [75]. However GCs do seem to be a dominant 
stimulus for changing the phase of peripheral clocks. There is evidence that GCs act to 
oppose the uncoupling of SCN and periphery during phase advancement. This is exemplified 
in ADX animals or GR ablation in peripheral tissues [81]. In these animals, peripheral clocks 
entrain more rapidly to feeding cues than adrenal intact animals despite being out of sync 
with the SCN. Rhythmic GC synchronises peripheral clocks, providing resistance to sporadic 




1.6. GCs in the regulation of renal sodium transport 
Renal sodium excretion is controlled by complex neuro-hormonal interactions. The RAAS is 
a major regulatory pathway for BP control, being activated by volume depletion to produce 
angiotensin II and ultimately aldosterone. Aldosterone promotes sodium retention by 
activating transporter pathways in the aldosterone-sensitive distal nephron (ASDN) through 
the mineralocorticoid receptor (MR, Figure 1.5). Aldosterone has a circadian rhythm much 
akin to GCs and is key in the circadian rhythm of the epithelial sodium channel within the 
connecting tubule (CNT) and collecting ducts (CD) [47]. Furthermore all clock mutant 
animals described thus far exhibit aldosterone rhythm abnormalities (Table 1.1).  
 
GCs may have a role in circadian control of renal transport by regulating clock genes, which 
then regulate sodium transport. GCs are not normally considered a major regulator of sodium 
transport in the ASDN even though GRs are expressed in cells of the distal convoluted 
tubule (DCT), CNT and CD [82, 83] (Figure 1.5). Moreover GCs bind MR with a similar 
affinity as aldosterone [84]. However, in the epithelial cells of the distal nephron the enzyme 
11β-hydroxysteroid dehydrogenase 2 (11βHSD2), converts active glucocorticoids 
(corticosterone/cortisol) into their inactive metabolites (11-dehydro-corticosterone/cortisone) 
(Figure 1.6).  These metabolites have little affinity for MR/GR and therefore 11βHSD2 
allows aldosterone to access the receptors (Reviewed in: [85]). The presence of both 
11βHSD2 and aldosterone defines the ASDN.  
 
It is likely that the paradigm of an “aldosterone sensitive distal nephron” does not extend to 
the DCT. In C57BL6 mice, double-immunofluorescence staining indicated that 11βHSD2 
and DCT markers were not co-expressed [86]. 11βHSD2 mRNA was not detected in 
microdissected DCTs [86]. Another approach using HSD2iCre-ROSA26 reporter mice 
showed 11βHSD2 was present in the connecting tubule (CNT) and collecting duct (CD) but 
not in the DCT [87]. In other older studies in mice 11βHSD2 immuno-staining was present 
but very low and only confined to the most distal ends of the DCT[88]. Similarly in rats 
expression of 11βHSD2 was low restricted to the most distal portions of the DCT [89]. 
Therefore 11βHSD2-expression is low if present at all in the DCT. Consequently, in the 
DCT GCs may have a major direct effect on sodium transporter activation and circadian 
rhythm in the DCT. Furthermore in an environment of habitually high sodium intake, 
sodium restriction and thus raised aldosterone is likely a rare occurrence. Therefore, one 




Figure 1.5: Nephron with localisation of MR, GR, 11βHSD2 and NCC 
Glucocorticoid receptor (GR) is expressed throughout the tubule and glomerulus, whereas 
mineralocorticoid receptor (MR) expression tapers off towards the thick ascending limb of 
Henle’s loop (TALH). 11βHSD2 expression is low/absent in the DCT where the thiazide 
sensitive sodium chloride co-transporter (NCC) is expressed. PCT, proximal convoluted 
tubule, PST, proximal straight tubule, LOH, loop of Henle, CNT, connecting tubule, CD, 
collecting duct.  
 
In common with many regions of the nephron the sodium gradient in the DCT is established 
and maintained energetically by the basolateral K+/Na+ATPase, which extrudes sodium into 
the renal interstitium from where it is taken back into the circulatory system. This provides 
an electrochemical driving force that allows passive influx of luminal Na+ through the 
sodium transporters. In the DCT, passive influx of sodium across the apical membrane 
occurs through the thiazide-sensitive sodium transporter (NCC, Figure 1.6). There are two 
studies that demonstrate GC-mediated activation of the NCC.  In adrenalectomised rats, both 
aldosterone and dexamethasone can increase the number of [3H]-metolazone binding 
sites[90]. [3H]-metolazone is a thiazide-like diuretic and its binding was used to roughly 
quantify the number of NCC channels in the apical membrane. They also found that the 
effect of dexamethasone and aldosterone on NCC quantity was additive, indicating two 
mutually exclusive GR and MR-mediated pathways of NCC upregulation [90]. Another 
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group found that dexamethasone caused an increase in thiazide-sensitive sodium 
reabsorption in micro-perfused DCTs of ADX rats [91].  
 
 
Figure 1.6: Glucocorticoid signal transduction machinery  
Glucocorticoids (cortisol in humans or corticosterone in rodents) can bind both the classical 
low affinity glucocorticoid receptors (GR) and high affinity mineralocorticoid receptors (MR). 
In vivo, glucocorticoids are usually prevented from binding MRs in aldosterone-sensitive 
tissues, by 11βHSD2, which converts cortisol to inactive cortisone (or corticosterone to 11-
dehydro-corticosterone in mice). GR and MR form homodimers and translocate to the 
nucleus where they can trans-activate or trans-repress genes. GR and MR may also form 












1.7. The thiazide sensitive co-transporter 
NCC, encoded by the gene slc12a3, is part of the solute carrier (SLC) protein family and 
transports sodium via an electro-neutral route. It consists of 12 trans-membrane domains 
with intracellular amino and carboxyterminal regions (Figure 1.7). Although only 
responsible for the reabsorption of around ~7% of the total sodium load it is physiologically 
important for sodium and BP homeostasis. This is shown by the effectiveness of its 
inhibitors, the thiazide diuretics, for BP control. Thiazide-diuretics revolutionised BP 
treatment in the 1950s and are still a frontline-treatment for high BP today [21]. NCC’s 
physiological importance is further exemplified by rare-inherited diseases such as 
Gitelman’s syndrome in which hypotension and renal salt wasting arise from an inactivating 
mutation of the SLC12A3 gene [93, 94] and conversely Gordon’s disease, which causes 




Figure 1.6: 12-transmembrane domain structure of the thiazide-sensitive sodium 
chloride-cotransporter (NCC).  
Activation of NCC within the apical membrane of distal convoluted tubule cells requires its 
phosphorylation at key threonine and serine residues in the intracellular amino terminus as 
illustrated. The hormonal regulators that can ultimately cause an increase or decrease in 
NCC phosphorylation are listed. Enhanced NCC phosphorylation causes an increase in 





1.8. Activation and regulation of NCC  
NCC regulation occurs through alterations of both the amount of protein inserted into the 
apical membrane and through the activation of this apical membrane protein. Activation of 
NCC relies upon its phosphorylation. Phosphorylated NCC is found exclusively in the apical 
plasma membrane of the DCT [97] suggesting phosphorylation is involved in the activation 
of NCC rather than forward trafficking of NCC to the membrane. The major phosphorylation 
sites of NCC in mice include threonine 53 (T53), threonine 58 (T58) and serine 71 (S71). In 
a Xenopus laevis oocyte expression system, mutation of any of these three residues reduces 
the activity of NCC [98, 99]. In cell models of the DCT, the phosphorylation of NCC 
correlates with activity rather than an increase in surface expression and it has been 
speculated that phosphorylation may facilitate dimerization of NCC, which promotes activity 
of the transporter but this is yet to be confirmed in vivo [100]. NCC phosphorylation delays 
its ubiquitinylation, endocytosis and degradation [101]. In NCC mutant T58 phospho-
incompetent homozygous knock-in mice, a decreased NCC total and membrane abundance 
was found, indicating that phosphorylation at T58 may be important for its stability in the 
membrane [102].  
 
Much of the work on NCC intra-cellular regulation has been elucidated using Xenopus laevis 
oocytes and cell lines with aldosterone as the hormonal stimulator. Therefore in this section 
a provisional model is described with aldosterone as hormonal stimulator of the NCC 
regulatory pathways but note that GCs could activate the same pathways through MR. 
Furthermore other NCC regulators such as rSNA [103, 104], vasopressin [97], AngII [105] 
also contribute to NCC regulation through manipulation of these intracellular regulators. 
Finally although DCTs express GR, its role in NCC regulation is unclear. The model 
described here is a simplified summary of the major intra-cellular machinery that may be 
involved in NCC activation (Figure 1.8).  
 
Many of the known regulatory pathways centre around the with no lysine kinase proteins 1 
and 4 (WNK1 and WNK4 respectively). These two kinases emerged in the pursuit of the 
genetic basis for Gordon’s Syndrome [106]. This syndrome of hypertension with 
hyperkalaemia is hyper-responsive to thiazide diuretics, but does not involve any mutations 
of NCC. Instead, linkage studies found mutations in WNK1 and WNK4 [107], which 
triggered a surge of research into the regulatory effects of these kinases. The majority of 
studies, including those in animals and native DCT cell models, indicate that WNK4 acts as 
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an inhibitor of NCC activity. Indeed overexpression of wild type WNK4 in mice causes 
hypotension and a decrease in thiazide sensitive sodium transport [108], indicating an 
inhibitory role for WNK4. WNK4 is thought to inhibit NCC activity through the inhibition 
of the STE20/SPS-1-related-proline/alanine-rich kinase and oxidative stress response kinase 
1 (SPAK/OSR1) complex [109]. SPAK/OSR1 phosphorylates NCC at three residues present 
in its amino terminal (murine Threonine 53, threonine 58 and serine 71) promoting 
activation as described earlier.  
 
WNK4 also decreases the transport of NCC from the trans-Golgi network to the apical 
plasma membrane [110] and promotes the association of NCC with the mouse adaptor 
protein 3 (AP-3), which recruits NCC to lysosomes for degradation [111]. Another pathway 
through which WNK4 is thought to inhibit NCC activity is through the ERK1/2 pathway, 
which is promoted by WNK4-dependent phosphorylation [112]. That WNK4 is solely 
inhibitory is not clear-cut as conflictingly, several studies have alluded to a stimulatory role 
for WNK4 under some conditions. In cells WNK4 promotes SPAK/OSR1 phosphorylation 
and WNK4 null mice lack the ability to phosphorylate NCC and SPAK/OSR1 appropriately 
upon low salt or angiotensin II stimulation [113]. WNK4 is not constitutively active and 
although its expression is inhibited by aldosterone [112], the protein/s or pathways that 
activate WNK4 remain unidentified. It is likely that WNK4 can have both inhibitory and 
stimulatory roles on NCC regulation in the same cell depending on the stimuli present and its 
state of activation [114].  
 
WNK1 on the other hand is constitutively active upon expression [115]. It exists in two 
forms in the kidney: a long form (L-WNK1) that is ubiquitously expressed throughout the 
epithelia of the body and a truncated form that has its own separate promoter and is specific 
to the kidney hence its name kidney-specific WNK1 (KS-WNK1)[109]. L-WNK1 does not 
directly alter NCC activity but promotes its phosphorylation by phosphorylating 
SPAK/OSR1 and by direct inhibition of WNK4[116]. KS-WNK1 is a negative regulator of 
L-WNK1, therefore KS-WNK1 relieves WNK4 inhibition [117, 118].  Although no 
mutations have been found in WNK3 that link it to Gordon’s disease, it is nevertheless an 
important NCC regulatory kinase. WNK3 directly stimulates NCC, increasing its 
phosphorylation as well as apical abundance [109]. Furthermore, WNK3 and WNK4 are 
reciprocally inhibitory, therefore adjustments in the concentration of these kinases is thought 





Figure 1.7: Provisional model for the intra-cellular regulation of the sodium chloride 
co-transporter (NCC).  
Aldosterone is thought to upregulate the sodium chloride co-transporter in the distal nephron 
although it is not clear how this is achieved. MR activation, dimerization and translocation to 
the nucleus, promotes the transcription of NCC and inhibits WNK4 expression following 
prolonged aldosterone exposure. WNK4 is generally accepted to be an inhibitory regulatory 
kinase of NCC and how WNK4 is activated is still unknown. SGK1 and L-WNK1 inhibit 
WNK4 and thus promote NCC activity through relief of WNK4-mediated inhibition of the 
STE20/SPS-1-related-proline/alanine-rich kinase and oxidative stress response kinase 1 
(SPAK/OSR1) complex. Mouse protein 25 (mo25) is a positive regulator of SPAK/OSR1. 
SGK1 is also postulated to inhibit Nedd4/2, which can also ubiquitinylate NCC. Kidney 
specific WNK1 (KS-WNK1) is a negative regulator of L-WNK1 and thus promotes WNK4 
driven inhibition of NCC. Further WNK4-mediated inhibitory pathways include inhibition of 
the NCC-stimulatory kinase WNK3 and stimulation of inhibitory protein ERK1/2 and the 
adaptor protein 3 (AP3). AP-3 facilitates lysosomal transport and thus WNK4 redirects NCC 
to the lysosome. (Red connectors represent inhibition through phosphorylation (P) or 
otherwise, while green arrows indicate stimulation by phosphorylation (P) or otherwise. 
Interrupted green arrows represent unknown or controversial events.) 
 
Although interactions between WNKs and NCC have been the subject of much 
investigation, less attention has been paid to the connection of these pathways to stimulatory 
hormones or neuronal activity. There is evidence that GR can interact with a nGRE in the 
WNK4 promoter and is essential in the development of salt-sensitive BP induced by β 
adrenergic stimulation [103].  Chronically, aldosterone increases NCC transcription and 
inhibits WNK4 transcription through MR activation [112]. Acutely, however, the 
aldosterone-induced increase in NCC abundance [119] is a post-transcriptional phenomenon 
as no changes in NCC mRNA are seen [116]. Increased NCC abundance could be achieved 
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through prolonging its half-life through adjustments of the WNK1 and WNK4 pathways 
(Figure 1.8). However, the only transcript within this NCC pathway that aldosterone has 
been shown to increase in DCT cells acutely thus far is SGK1 [120, 121]. SGK1 could link 
aldosterone stimulation, WNK4 kinase pathways and NCC upregulation. In vitro, SGK1 
inhibits WNK4 through phosphorylation and this relieves the inhibition upon NCC thus 
promoting its activity [122]. Furthermore sgk1-/- mice fail to phosphorylate and upregulate 
the expression of NCC under low salt conditions despite dramatically increased plasma 
aldosterone levels [123]. Negative regulators of WNK4 and WNK1 have recently been 
discovered and include kelch-like family member 3 (KLHL3) and cullin3. These proteins 
form the KLHL3-Cullin E3 ligase. This complex ubiquitinylates WNK1 and WNK4 and 
promotes their degradation [95, 124, 125]. Very recently, aldosterone has been shown to 
mediate the interaction between NEDD4/2 and WNK1 through SGK1 [126]. NEDD4/2 
targets WNK1 for degradation. Aldosterone-induced SGK1 upregulation therefore causes an 
inactivation of NEDD4/2, limiting its interaction with WNK1 and thus allowing more 
WNK1 to accumulate [126].  
 
Finally, we know from experiments on NKCC1, that the role of phosphorylation in 
regulating the rate of ion transport can be overridden by changes to the cytoskeleton 
(protein-protein interactions)[127]. It is therefore possible that this could be an important, if 
not overlooked, aspect of NCC regulation too.  
 
1.9. Does the clock regulate NCC?  
There are clearly many aspects to the regulation of NCC that are not understood including 
the role of the molecular clock in to the NCC signalling cascade. The clock must integrate 
with this pathway at some level, since per1 and bmal-KS null mice demonstrate altered NCC 
expression [51, 56] (Table 1.1). Clock genes could directly affect NCC activation by acting 
as transcription factors to genes within the NCC regulation pathways. Work by Gumz and 
colleagues has shown that E-BOX binding sites, which per1 and cry1 interact with, exist on 
WNK4 and WNK1 [56]. It is unclear how or if these affect in vivo NCC activation.  
 
The second major question is how are clocks activated in the DCT? Does GC-entrainment of 
the renal clock have a role in this signalling cascade and how? As explored, GCs can alter 
the level of per1, per2 and rev-erbα directly through GREs and thus influence the renal 
clock. But GCs could also interact with the NCC pathway independently of the clock, for 
example through induction of SGK1, which as the name suggests is a GC-induced kinase.  
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1.10. Summary, hypothesis and aims 
Rhythmic renal sodium transport likely contributes to a circadian rhythm of BP. GCs are a 
major entrainer of peripheral circadian clocks. Limited 11βHSD2 expression in the DCT of 
the kidney means that this nephron segment’s circadian rhythms are likely influenced by 
GCs over mineralocorticoids. Here, NCC is the major apical sodium transporter and has key 
roles in BP homeostasis.  
 
In my thesis I hypothesise that: 
 
Glucocorticoids impose a diurnal rhythm on NCC, which contributes to the diurnal 
rhythm of blood pressure. 
 
The overarching aim of this work was to investigate the presence of a circadian rhythm for 
NCC activity and it’s relationship with GCs and BP. The diurnal rhythm of sodium 
excretion, corticosteroid secretion, BP and NCC phosphorylation is initially defined in 
Chapter 3. The effect of GC manipulations on NCC phosphorylation and sodium excretion is 
investigated in Chapter 4. Temporal variation of components of the NCC regulatory 
pathways and clock machinery and the effect of GCs on these was investigated in Chapters 3 
& 4. An attempt to define temporal changes in NCC function (by looking at temporal 
thiazide-sensitive sodium transport) was made in Chapter 5. The indirect effects of temporal 
variations in NCC activity were investigated by monitoring thiazide-induced changes in 
rhythmic BP in mice undergoing chronic GC treatment (Chapter 5). Finally the receptor 
(MR/GR) through which GCs stimulate NCC phosphorylation was investigated in Chapter 6.  
 
Circadian comes from the latin circa-diem meaning “about a day”. In chronobiology the term 
is used stringently to only include ~24-hour processes that have autonomous rhythmicity i.e. 
can occur in the absence of exogenous stimuli or Zeitgeibers. In this thesis “diurnal” is used 
in place of circadian to denote processes that occur daily but are yet to be defined as truly 








All experiments were performed in line with United Kingdom Home Office regulations and 
in accordance with the Animals (Scientific procedures) Act 1986. Breeding and husbandry 
was carried out in the Biological Research Facility, University of Edinburgh. Mice were 
housed in groups (n < 5, unless otherwise stated) and given ad libitum access to water and 
standard chow, (rat and mouse maintenance diet 1: Special Diet Services) containing 0.25% 
Na, 0.38 % Cl and 0.67 % K, unless otherwise stated. All mice used were adults aged 
between 2-4 months. Mice were housed at 50% humidity and 22-26oC with 12:12 light:dark 
cycles starting at 7am local time, unless otherwise stated.  
 
2.1.2. Source of Animals and Breeding 
Male C57BL6J/Ola mice used for breeding and experiments were bought in from Harlan and 
allowed at least a week between transportation and the start of any experiment, to minimise 
stress.  
2.2. Qualitative Immunofluorescence Staining 
2.2.1. Perfusion fixation of the kidney  
Deep anaesthesia was achieved using 50 mg/kg Pentobarbital Sodique, (Tocris) and the 
kidneys and aorta accessed via a laparotomy. The intestines and other internal organs were 
gently brushed to the side using a cotton bud, in order to clearly visualise the left kidney and 
the descending aorta. The left renal artery/vein bundle was occluded using a micro-
haemoclamp and the kidney was removed and snap-frozen and stored at -80oC. The aorta 
was gently isolated from the overlying connective tissue using a cotton bud and blunt 
forceps. A micro-haemoclamp was applied anteriorly just below the renal vascular branches 
and another was applied about 2 cm postural to this. An abdominal incision was made and 
the aorta was catheterised using p50 tubing primed with filter-sterilised 140 units/ml heparin 
saline (porcine heparin sodium salt, Sigma-Aldrich) attached to a heparin saline filled 
syringe. Care was taken to ensure no air bubbles were present within the tubing or aorta. The 
anterior micro-haemoclamp was moved to hold the catheter in place and correct positioning 
within the aorta was confirmed by the pulsatile backflow of blood into the tubing. The vena 




The aorta catheter tubing was connected to a peristaltic perfusion pump (Gilson Minipuls® 
3) with PVC perfusion tubing (2.79 mm internal diameter, Scientific Laboratory Supplies). 
The peristaltic perfusion tubing was primed with heparinised PBS (140 units/ml heparin 
(porcine heparin salt, Sigma) in PBS) for 1 minute followed by 4 % PFA (Paraformaldehyde, 
Sigma-Adrich) for 20 seconds at a rate of 15 ml/min. The mouse was perfused for 4 minutes 
before the right kidney was excised and its poles removed. The kidney next immersed in 4% 
PFA at ten times their volume (5-7 ml) for 24 hours at 4oC. They were then transferred to 
70% ethanol for up to 1 week before embedding in paraffin wax (pole end down). Sections 
(5 µm) were dried onto glass slides at 37oC over night.  
 
2.2.2. Immunofluorescence with tyramide signal amplification 
Double-immunostaining, (using two different fluorophores to detect two different targets on 
the same sample), was performed by the Immunodetection and Imaging Facility at The 
University of Edinburgh. Slides were processed in batches using a Leica BOND-MAXTM 
robot, following de-waxing and hydration. An antigen retrieval step was included and 
involved heating in the presence of Novocastra Bond Epitope Solution 1, pH 6 (ER1, Leica). 
Slides were then heated to 125oC for 10 seconds, cooled to 90oC over 40 minutes and loaded 
onto the BOND-MAXTM robot, which carried out the following steps: peroxidase block (3% 
H2O2 in wash buffer, 10 minutes), serum block (serum from the species that the secondary 
antibody was raised in, diluted 1:5 in TBS; 10 minutes), primary antibody (Table 2.1, 2 
hours), HRP-conjugated secondary antibody (Table 2.1, 30 minutes) and tyramide-labelled 
fluorophore (either Cy5 or Cy3, 10 minutes). Three 4-minute washes (0.1% Tween in TBS) 
were carried out between each of the above steps. After the first immunofluorescence 
detection step, antigen retrieval was performed, by heating samples in ER1 solution for 10 
minutes on the robot and the second detection step was performed, exactly as the first above. 
Finally the slides were counter-stained with DAPI and a glass coverslip was mounted on an 
aqueous medium (PermaFluorTM, Thermo Scientific).    
 
2.2.3. Image acquisition and analysis  
Images were acquired using a Zeiss LSM 510 Meta Confocal Laser Scanning Microscope. 
DAPI, Cy3 and Cy5 were excited using a blue diode 405 nm laser and HeNe 546 and 633 






Table 2.1: Primary and secondary antibodies used in immunofluorescence  
 
2.3. Western analysis of renal protein and phosphoproteins  
Western analyses of phosphoproteins involved in the regulation of NCC were performed on 
whole kidney to gain insight into some of the molecular pathways controlling sodium 
transport.  
 
2.3.1. Tissue harvest procedure 
Mice were acclimatised to various treatments; 12 hour light cycles (with light on at 7 am 
local time/ZT0 and lights off at 7 pm local time/ZT12) and housed either singly or in groups 
of 2 for at least a week (described in methods sections of results chapters: Chapter 3, 4, 5) 
prior to cull. Mice were then culled by cervical dislocation within 1 minute of removal from 
the holding room. A laparotomy was performed and using a pair of curved 7 cm curved 
forceps the left kidney was prised from the renal artery, decapsulated and snap frozen on dry 
ice and stored at -80oC for western analysis. The right kidney was excised and frozen in the 
same way, but halved after decapsulation for qPCR analysis. A terminal plasma sample was 
taken via cardiocentesis (see plasma sampling post mortem section).  
 
In initial culls, mice were housed in groups of three and culled by an increasing concentation 
of carbon dioxide followed by a cervical dislocation to confirm death. However using this 
approach, we noted that the mouse culled third in every batch of three displayed a lower 
level of phosphorylation compared to the other mice (Figure 2.1), regardless of the time 
point of cull (the phenomenon occurred both at night and during the day time culls). The 
reason for this is not known but one possibility relates to an increase in plasma potassium 
levels following death by CO2 [128]. Plasma potassium in mice culled by CO2 was almost 
twice as high (7 mmol/l) as mice culled by ketamine/xylene overdose [128]. It is also shown 
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that an oral gavage to increase plasma potassium to 10 mM induces a rapid and sustained 
decrease in the phosphorylation of NCC at pT53 [129]. We do not know if this accounts for 
the phenomenon observed in the third mouse of each batch but we rejected this approach. 
For all experimental data in results chapters, mice were housed either single or in pairs and 
culled by rapid cervical dislocation. No kidney weights were taken at the time of cull, but all 
mice were of similar body weights and no differences were found in renal protein abundance 
(assessed post-homogenisation by BCA assay).  
 
 
Figure 2.1: Reduced phosphorylation in the third mouse, in mice culled by CO2 in 
batches of threes 
(A) Western blot of pT53 NCC and coomassie gel, red squares demarcate the “third mouse” 
sample in each of the 4 groups culled. All mice herein were culled during the active phase, 
i.e. at night (B) densitometry analysis, with pT53 NCC normalised to the coomassie. Data 
are mean ±95% CI, *p<0.05. 
 
2.3.2. Kidney homogenization and sample preparation 
In order to minimise any dephosphorylation or protein degradation a buffer containing 
phosphatase and kinase inhibitors and protease inhibitors was prepared. All solutions were 
bought from Sigma-Adrich unless otherwise stated. Protein and protease inhibitor buffer 
(PIB): 250 mmol/l sucrose, 10 mmol/l thriethanolamine, 2 mmol/l EDTA, 50 mmol/l NaF, 
25 mmol/l Na β-glycerophosphate, 5 mmol/l Na pyrophosphate, 1 mmol/l Na orthovanadate, 
dH2O pH to 7.6. A 200 mmol/l stock solution of Na orthovanadate was in the biologically 
active monomeric state. This was achieved by dissolving 2.94 g Na orthovanadate in 60 ml 
dH2O and adjusting the pH to 10. This caused a colour change to yellow (indicating a change 
to decavanadate). The solution was then boiled until transparent (indicating a change to 
monomeric vanadate) and pH readjusted to 10. PIB was filter sterilised 0.45 µm filter and 
frozen at -20oC in 20 ml aliquots. The buffer was defrosted on ice and protease inhibitors 
added prior to use (10 µl per 1 ml protease inhibitors (Protease inhibitor cocktail set III, 
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Calbiochem, Merck-Millipore). Frozen, decapsulated whole kidneys were kept on ice-water 
slurry and immersed in 2 mL of ice-cold PIB. The kidneys were homogenised in a mixer 
mill (Mixer Mill MM301, Retsch®) for 60 seconds at top speed three times, cooling on ice 
between mixes. The homogenate was incubated (on ice-water slurry, 15mins) and 
centrifuged (4oC, 4000 g, 15 minutes). The supernatant was collected and the pellet re-
suspended in 1 ml ice-cold PIB, homogenised and centrifuged as previous and the 
supernatants were pooled. Aliquots of protein were made at this point to take forward for 
protein quantification and for western analysis. All aliquots were made up on ice-water 
slurry in a cold room (4oC) to minimise any dephosphorylation or protein degradation. 
Aliquots were stored at -80oC, thawed once for use and then discarded.  
2.3.3. Protein preparation and Gel Electrophoresis  
The protein content of the kidney homogenates was quantified by BCA assay (PierceTM, 
Thermo ScientificTM) according to the manufacturer’s instructions. A protein load of 10-20 
µg was loaded for electrophoresis as this was in the linear range of detection for NCC and 
phospho-NCC (Figure 2.2). While on ice, protein samples were adjusted to the desired 
concentration with protein isolation buffer (PIB), LDS sample buffer (NuPAGE®, 4X) and 
DTT (final concentration of 100 mM) and the sample preparation heated (70 oC, 15 minutes) 
to reduce the proteins. Half and double protein loads from one or two designated lane(s) 
were prepared to run as linearity controls The samples were centrifuged briefly and vortexed 
before loading. Fifteen well, 3-8 % Tris-Acetate precast protein gels (NuPAGE®, Novex ®, 
Life Technologies) were rinsed and loaded into an electrophoresis cell (SE300 MiniVE, 
Hoefer®). Electrophoresis running buffer (Tris-Acetate SDS running buffer, NuPAGE®) 
was poured into the gel chambers, 250 µl antioxidant (NuPAGE®) was added to each 
chamber and the tank was ½ filled. To remove excess gel storage buffer each well was 
flushed with 100 µl running buffer twice. Protein samples (10 µl) and protein ladder 
(HiMarkTM, Life Technologies) were resolved on the gels at constant voltage (100 V) for 60 
minutes.  
 
2.3.4. Protein Transfer 
Transfer buffer contained 25 ml 20X NuPAGE ® Transfer Buffer, 100 ml absolute 
methanol, topped up to 500 ml dH2O with 500 µl NuPAGE® antioxidant added fresh with 
every use. Following use it was stored at 4oC and could be re-used u to 3 times. Gels were 
removed from their plastic casing and equilibrated in cold (~4oC) transfer buffer for 15 
minutes. PDVF membrane (AMERSHAM Hybond®-P, GE Healthsciences) was cut to size 
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and immersed for 10 seconds in absolute methanol and then allowed to equilibrate for 10 
minutes in transfer buffer. Extra-thick filter paper (BioRad®) was soaked in transfer buffer. 
Avoiding bubbles, the membrane followed by the gel was assembled between two pieces of 
filter paper in a BioRad Trans-blot SD semi-dry electrophoretic transfer cell (BioRad®). The 
gel was transferred for 30 minutes at constant voltage (10 V). 
 
2.3.5. Immunoblotting  
The membrane was removed from the transfer apparatus and rolled into a 30 ml Falcon tube 
and incubated (RTo, 1 hour) with 20 ml blocking buffer (5% w/v non-fat dry milk powder in 
wash buffer: 0.2%v/v Tween in phosphate buffered saline (PBS: 20 tablets for 2 l, Dulbecco 
A, OxoidTM). Primary antibody (see Table 5 for dilution) was added to 5 ml blocking buffer 
and incubated with the membrane (4oC, overnight). The membrane was washed with wash 
buffer (3 x 10 minutes). The HRP-conjugated secondary antibodies were diluted in 5 ml 
blocking buffer as appropriate (see Table 2.2) and incubated with the membrane (RTo, 1 
hour). The membrane was washed as previous and incubated with ECL reagent (PierceTM, 
Thermo ScientificTM) (RTo, 5 minutes). Excess ECL reagent was removed and the 
membranes were covered in clear plastic film, exposed to X-ray film, developed (Compact 
4x, Xograph) and scanned. The membrane was then rinsed in wash buffer and stored in PBS 
for up to a month. 
 
2.3.6. Coomassie blue staining for normalization 
Coomassie blue staining was adapted for use as a loading control to normalise the immuno-
blot results for the amount of protein loaded on the gel. A dose curve indicated that 
densitometry of the Coomassie blue staining was linear in range of 10-40 µg protein (Figure 
2.2). Regular housekeeping genes such as β actin and GAPDH were previously found to 
supersaturate at these protein loading concentration [130]. The bottom of the gel, just above 
the 55 kDa mark, was trimmed and incubated in Coomassie blue solution (Coomassie Blue 
R (0.025 g), methanol (40 ml), acetic acid (7 ml) and dH2O (53 mL)) on a rotary shaker 
(RTo, 3-4 hours). The solution was replaced with de-staining solution 1 (in mL: methanol 
200, acetic acid 35 and dH2O 265) and incubated (RTo, 30 minutes). De-staining solution 1 
was replaced with de-staining solution 2 (in ml: methanol 25, acetic acid 35 and dH2O 440) 
and incubated overnight. De-staining solution 2 was changed once the next day and gels 




Table 2.2: Concentration and source of primary and secondary antibodies used for 
Western analysis 
 
2.3.7. Stripping and re-probing the membrane 
Following analysis of phosphorylated NCC the membrane was stripped and re-probed for 
total NCC or NKCC2. This protocol could not be used the other way around since the 
phospho-antibodies failed to detect a signal once the membrane had been stripped. Stripping 
and re-probing made little difference to the quantity or the linearity of NCC/NKCC2 
detected. The membrane was incubated in stripping buffer (glycine (3.75 g), SDS (0.25 g), 
Tween20 (2.5 ml), pH to 2.2 and topped up to 250 ml) for 10 minutes on a rotary shaker at 
room temperature. This step was repeated before washing the membrane for 10 minutes 
three times. The membrane was then immediately transferred to blocking buffer and 
subjected to all the steps undertaken as per “Immunoblotting” section.  
 
2.3.8. Densitometry and quantification 
The band intensity was quantified by densitometry analysis using Image J (a detailed method 
is available: http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-
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a reference load was prepared from a pool of homogenate and run on each gel in order to 
normalise the data to account for inter-run differences. Gel lanes were normalised for 
differences in protein loading as quantified by densitometry of the Coomassie stained gel 
segments and further adjusted so that the control group (for consistency this is defined 
throughout this work as “day time” and/or vehicle group) = 1.  
 
 
Figure 2.2: Defining the linear range of detection for total NCC and coomassie. 
(A) Protein loads from 12-48 µg were loaded and immunoblotted for anti-NCC. The bottom of 
the gel was coomassie stained. (B) Example of how densitometry was performed. A region 
of interest was selected within ImageJ and the relative intensity of each pixel was given 
across the distance selected. To quantify this intensity over distance an area under the curve 
was taken. (C) Results of densitometry analysis of (A) indicate both anti-NCC and 
coomassie are within the linear range between 12-48 µg of protein, with R-square values of 
0.93 and 0.95 respectively and both p values <0.0001. 
 
2.3.9. Selection of antibodies for analysis of NCC phosphorylation 
2.3.9.1. Comparison of Total NCC antibodies 
The total NCC antibody identified three products of sizes: ~ 111, 128, 143 kDa. The 
predicted molecular weight of NCC is 110 kDa [131], with higher bands thought to be as a 
result of N-glycosylation, which is essential for surface expression and activity of NCC 
[132]. The literature gives a range of sizes of NCC in whole kidney homogenates depending 
on the gel system and conditions used. For example, Fenton et al find a diffuse protein 
band(s) at ~100-150 kDa using the StressMarq antibody [97], Loffing and colleagues reports 
a triplet band very similar to ours at ~130 kDa [129] and Ellison’s group report a double 
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band at ~111 kDa and a very faint thin band at <111 kDa using a Bis-Tris gel system [133]. 
This lower band is likely to be the core non-glycosylated protein with the heavier two bands 
(which are often seen in the literature as a single large band) being the glycosylated protein 
[132]. Experiments in which whole kidney homogenate is incubated with a de-glycosylating 
agent, such as N-glycosidase, result in the complete disappearance of the two heavy bands, 
leaving behind only the ~110 kDa band i.e. “core non-glycosylated NCC [132].  
 
In order to assess whether the reported differences in protein sizes and banding patterns were 
a result of a discrepancy in the antibodies’ target epitopes, three different antibodies to NCC 
were tested under the same conditions. Professor Ellison’s antibody was a generous gift. 
Stressmarq (Bioline) and Chemicon (AB3553, Millipore) antibodies were purchased. Whole 
kidney homogenate was prepared and samples of 10, 20, 40 µg total protein loaded on a 
single gel three times along with a ladder (HimarkTM, Life Technologies). The western 
analysis was run as described in Methods (2.3.4 - 2.3.8) but after transfer the membrane was 
cut into 3 sections and incubated overnight with the Ellison, StressMarq or Chemicon and 
anti-NCC antibody. All membranes were probed with a goat anti-rabbit HRP-conjugated 
secondary antibody (Santa Cruz) and visualised using chemiluminescence. All three total 
antibodies showed the same thick middle two bands at the same molecular weight ~120-150 
kDa when resolved on the same gels (Figure 2.3). The thin, lower molecular weight band 
was present with both stressmarq and chemicon but was not detected using the Ellison 
antibody under the conditions used here. The origin of the thin, higher molecular weight 
band present with StressMarq is not clear. The chemicon antibody resolved the best with our 
gel system and was comparable with the other available antibodies.  
 
 
Figure 2.3: Comparison of total NCC antibodies. 







2.3.9.2. Specificity of phospho antibodies for NCC over NKCC2 
The NCC phospho-motifs are conserved in other related transporters, particularly NKCC2. 
Threonine 53 and 58 on NCC shares homology with Threonine 96 and 101 on NKCC2 
(Figure 2.4). The pS71 antibody is unlikely to cross react with NKCC, as there is not a 
homologous serine site. Other groups have raised similar concerns, particularly with the 
specificity of the pT58 NCC phospho-antibody [105] [134].  Immunofluorescent staining 
showed total NCC antibody was restricted to the apical and sub-apical membrane of the 
cortex. However, pT58 immunofluorescent staining was much more abundant, with 
detection in the medulla as well as the cortex [105] [134]. There is no basolateral staining 
with anti-pT58, indicating that it is unlikely to cross react with NKCC1, which is located on 
the basolateral membrane [135]. In this short series of validation experiments we utilise 
immunoprecipitation (IP) to separately “pull down” NCC and NKCC2 and probe the IP 
products using pT58, pT53 and pS71 antibodies.  
 
Figure 2.4: Sequence alignment of the N-terminal region of SLC12 electro-neutral NaCl 
co-transporters, exhibiting several homologous phosphorylation sites 
Grey highlights regions on mouse NKCC1/NKCC2 and human NCC that are homologous 
with mouse NCC. Black highlights phosphorylation sites that are important for transporter 
activation. Adapted from [136]. 
Superparamagnetic beads (DynabeadsTM Protein G, Life Technologies) were resuspended in 
a homogenous solution by gentle shaking and rolling on a roller at room temperature. 50 µL 
was added to a 1.5 ml eppendorf tube and placed on a magnet (Dynal magnetic particle 
concentrator, Invitrogen). Within 1 minute the beads stuck to the side of the tube and the 
clear supernatant was aspirated and discarded. Primary antibody was diluted in Antibody 
washing and binding buffer (ABB, DynabeadsTM Protein G Immunoprecipitation Kit, Life 
Technologies) 10 µl anti-NKCC2 (Dario, Alessi, Dundee) in 190 µl ABB or 20 µl anti-NCC 
(Chemicon, Millipore) in 180 µl ABB and added to the beads. The antibody-bead solution 
was removed from the magnet and incubated for 10 minutes at room temperature on rotation 




The mixture was placed back on the magnet and supernatant removed. 400 µl kidney 
homogenate (approximately 2500 mg protein) was added to the beads, taken off the magnet 
and incubated for 1 hour at 4oC.  The homogenate-bead-antibody mixture was placed back 
on the magnet and supernatant removed. The beads-antibody-antigen was washed 3X in PIB 
by removing the mixture from the magnet resuspending the mixture by pipetting carefully up 
and down and removing the supernatant once placed back on the magnet. The antigen was 
eluted with 20 µl elution buffer (Dynabead® Protein G Immunoprecipitation Kit, Life 
Technologies), 3 µl DTT (Sigma-Adrich) and LDS (NuPAGE®, Life Technologies) and 
heated at 70oC for 15 minutes. The mixture was placed back on the magnet for a final time 
and the suspension was separated on 3-8% Tris acetate gels and immunoblotted as 
previously described. A standard kidney homogenate (no IP) was prepared 
contemporaneously and separated by electrophoresis alongside the IP sample.  Following 
transfer to a membrane, the membrane was cut in 4 with each piece containing a ladder, IP 
product and 12 mg total protein from whole kidney homogenate. Each piece of membrane 
was probed with anti-pT53, pT58, pS71 or NKCC2 antibodies. There was some cross 
reactivity with NKCC2 for the pT58 antibody (Figure 2.5) and therefore this antibody was 
not used to detect NCC specific phosphorylation. All experiments in this work are carried 
out using the pT53 and pS71 antibodies, which do very specifically bind NCC (Figure 2.5).  
 
 
Figure 2.5: Cross-reactivity of anti-NCC antibodies 
Immunoprecipitation was used to “pull down” NCC or NKCC2 from 2500 µg of total kidney 
homogenate. These immunoprecipitation products (+) were then separated on 3-8% Tris 
Acetate gel, transferred to Hybond P membrane and immunoblotted for the NCC phospho-
antibodies and NKCC2. 12 µg of total kidney homogenate (-) was run alongside the IP 





2.4. Estimating the abundance of mRNA transcripts by Q-PCR 
Real time quantitative RT-PCR was performed on whole kidney to gain an insight into some 
of the molecular pathways controlling sodium transport. Tissue was harvested as per “Tissue 
Harvest Procedure” see 2.3.2.  
 
2.4.1. Sample preparation  
2.4.1.1. Extraction of RNA 
mRNA was prepared from half kidneys using RNeasy spin columns (QIAGEN) according to 
the manufacturer’s instructions. Briefly, half kidneys were removed from -80oC onto 
ice/water slurry. A steel bead and 600 µl RLT buffer (QIAGEN) was added to the 2 ml 
eppendorf tube containing the kidney, which was then homogenised for 2 minutes at top 
speed (Mixer Mill MM301, Retsch®). The samples were centrifuged at 8 000 g (Heraeus 
Biofuge pica, DJB Labcare) for 3 minutes to pellet the debris. 150 µl of supernatant was 
removed to a fresh 2 ml eppendorf and 300 µl 70% ethanol and 150 µl RLT buffer was 
added and the sample mixed briefly by inversion and loaded on to a spin column (QIAGEN). 
The spin steps were carried out exactly as instructed in the product manual and RNA finally 
eluted in 50 µl RNAse free water (QIAGEN). A DNAse step was carried out using DNA-
freeTM Kit (Ambion® Life technologies). Briefly 5 µl 10X DNAse1 buffer and 1 µl nDNasel 
was added to the 50 µl RNA sample gently mixed and incubated at 37oC for 30 minutes. 5 µl 
inactivation reagent was added and vortexed thoroughly before centrifugation at 16 000 g for 
2 minutes. The supernatant was carefully transferred to a clean tube. RNA was stored at -
80oC until use.  
 
2.4.1.2. Quantification and quality control of RNA 
2 µl of the RNA sample was taken forward to quantify the RNA concentration using a 
Nanodrop 1000 spectrophotometer. This gives a sample concentration in ng/mL based on the 
absorbance at 260 nm. RNA concentrations were 200-700 ng/µl. RNA purity was also 
assessed using the A260/280 and A260/230 ratios given by the Nanodrop analyser. A 
A260/280 ratio of <1.7 is indicative of contamination by phenols, which can affect 
downstream applications. All samples taken forward for reverse transcription had A260/280 
ratios 1.7-2.1. The A260/230 ratios were usually in the range of 1.8-2.2. Several samples 
were lower than this indicating the presence of co-purified contaminants. An agreement 
about the acceptable lower limit of this ratio is not available but the RNA spin column 
manufacturers have expressed that this ratio is very likely a result of contamination by 
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guanidine thiocyanate salt. Experiments using high concentrations of this salt (up to 100 
mM) in real time PCR, did not compromise the reliability of the assay [137] and therefore 
the very small volume taken forward to reverse transcription (as a result of a high yield of 
RNA), was unlikely to affect the qPCR results. To check the RNA was intact, 500 ng of each 
sample mixed with 6X DNA Gel loading dye (Life technologies) and resolved at 80 V for 1 
hour on a 0.8 % agarose, 0.5 % TBE gel and stained with 0.05 % ethidium bromide. This 
enabled the detection of two clear sharp bands of 28S ribosomal RNA and 18S ribosomal 
RNA. The top 28S band was approximately twice the intensity as the lower 18S band and no 
smearing was detected, indicating intact RNA  (Figure 2.6). 
 
Figure 2.6: Representative example of agarose gel electrophoresis of RNA samples. 
500 ng of each RNA sample was resolved on a 0.8 % agarose in 0.5 % TBE buffer and 
visualised with 0.05 % ethidium bromide. The clear, sharp bands of 28S (top) and 18S 
(bottom) rRNA indicate that the RNA preparations were not degraded. Furthermore, the 
intensity of the 28S band was approximately double that of the 18S band in each sample.   
 
2.4.1.3. Reverse transcription 
Reverse transcription was carried out on 500 ng RNA using a AB High capacity RT kit (Life 
Technologies) using a total reaction volume of 20 µl. Constituents per sample include (in 
µl): 10X RT buffer (2), 25 X dNTP mix (0.8), 10 X RT random primers (2), Reverse 
transcriptase (1) and 500 ng RNA & nuclease free water mix (14.2). Prepared RT samples 
were briefly centrifuged and run under the following RT PCR conditions: 2 5oC (10 
minutes), 37 oC (120 minutes), 85 oC (5 minutes), 4 oC (continuous). Included in each RT 
PCR round were a no template control and a no reverse transcriptase control. Resultant 
cDNA samples were stored at -20 oC prior to dilution for qRT-PCR.  
 
2.4.2. qRT-PCR Assay  
2.4.2.1. 2.3.3.1. Assay design  
Assays were designed using the Roche Universal Probe library “assay design centre” 
application (URL: 
 http://lifescience.roche.com/shop/CategoryDisplay?identifier=Universal+Probe+Library). 
All assays were designed so that the amplicon spanned an intron excluding the first or last 
intron (to avoid targeting any SNPs, as these areas have a higher frequency of SNPs [138]). 
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Primers were also run through the Integrated DNA technologies oligo analyser tool 
(https://www.idtdna.com/calc/analyzer) to flag up those with any hairpins, self-dimers and 
heterodimers. All primers were purchased from Eurofins Scientific. The assay was rejected if 
the standard curve error exceeded 0.05 (i.e. the mean squared error of the data points making 
up the standard curve) or the efficiency was outwith the range 1.7-2.1 and a second or third 
assay attempted (Table 2.3). PCR products were ran with loading dye (DNA Gel Loading 
Dye, 6X, Life Technologies) on a 4 % TBE agarose gel with 0.05 % ethidium bromide to 





Figure 2.7: Representative example of qRT-PCR products resolved on a 4 % TBE 
agarose gel with 0.05% ethidium bromide 
Expected lengths of qRT-PCR products are in brackets. The cDNA ladder used was a 10 bp 
Trackit ladder (Life Technologies). 
 
 
Table 2.3 (overleaf): Table of qRT-PCR assays. 
Efficiency and error values here are those from exploratory qRT-PCR performed in Chapter 
3. All other assay’s efficiency and error values were not wildly different from those presented 





gene protein accession number forward primer reverse primer probe 
amplicon 
(nt) error efficiency 
Rn18s 18S rRNA NR_003278.1 ctcaacacgggaaacctcac cgctccaccaactaagaacg 77 110 0.013 1.750 
Tbp TBP NM_013684 gggagaatcatggaccagaa gatgggaattccaggagtca 97 90 0.020 2.067 
HPRT HPRT NM_013556.2 cctcctcagaccgcttttt aacctggttcatcatcgctaa 95 91 0.022 1.946 
per1 PER1 NM_001159367.1 gcttcgtggacttgacacct tgctttagatcggcagtggt 71 100 0.037 1.750 
per2 PER2 NM_011066 gcttcgtggacttgacacct tgctttagatcggcagtggt 5 69 0.016 1.784 
clock-201 CLOCK NM_007715.5 ccagtcagttggtccatcatt tggctcctaactgagctgaaa 76 107 0.015 1.996 
cry1 CRY1 NM_007771.3  ggcagagcagtaactgatacga tgactttcccaccaacttca 52 68 0.011 2.100 
cry2 CRY2 NM_009963.4  ggagcatcagcaacacagg ccgcttggtcagttcttcac 11 67 0.018 1.998 
arnt1 var1 BMAL1 NM_001243048 gaatacattgtctcaaccaacactg ttagctgcgggaaggttg 97 76 0.037 2.082 
arnt1 var2 BMAL1 ENSMUST00000106637.1 agtacgcctccccctgat tgtctggagtccctccattt 79 67 0.007 2.010 
Sgk1 SGK1 NM_001161845 gattgccagcaacacctatg ttgatttgttgagagggacttg 91 129 0.019 1.940 
TSC22d3 v2 GILZ NM_010286.3 tccgttaaactggataacagtgc tggttcttcacgaggtccat 49 89 0.015 1.700 
MR Nr3c2 NM_001083906 caaaagagccgtggaagg tttctccgaatcttatcaataatgc 11 78 0.015 1.786 
GR Mr3c1 NM_008173  tgacgtgtggaagctgtaaagt catttcttccagcacaaaggt 56 78 0.035 1.720 
Hsd11b2 11βHSD2 NM_008289.2 cactcgaggggacgtattgt gcaggggtatggcatgtct 26 60 0.024 1.817 
Slc12a3 NCC NM_019415 cctccatcaccaactcacct ccgcccacttgctgtagta 12 60 0.017 1.945 
Oxsr1 OSR-1 NM_133985 tgccttcaaaaggatccaga tggaaaaatttgtgcctcaac 84 65 0.024 1.846 
Stk39 L-SPAK ENSMUST00000102715 gtacgagctccaggaggttatc tcttgcctgggtttgcat 27 75 0.014 1.700 
Stk39 KS-SPAK JN368425 ttaccgtcattcctaactttactgc gaatgcgcttactccaaaatct 18 146 0.039 1.913 
Wnk1 WNK1-L AY309076 cttttgccaagagtgtgataggt caacggattcatcatatttctcc 92 78 0.024 1.775 
Wnk1 WNK1-KS AY311934 / AY309076 tgctgctgttctcaaaagga acttcaggaattgctactttgtca 20 77 0.009 1.970 
Wnk4 WNK4 NM_175638 tccgatttgatctggatgg gggcaggatgaactcattgta 26 74 0.026 1.729 
Nedd4 NEDD4 NM_010890    acgtgctgttcactgctgat tcacaactcgtgtgtcatcg 1 60 0.023 1.754 
Cab39 MO25-alpha NM_133781 tgagaaggagcctcagacaga aaaatttgagccacgtcttttt 17 132 0.016 1.814 





2.4.2.2. qRT-PCR and Analysis 
An 8-point standard curve was prepared by pooling all cDNA samples. The top standard 
consisted of a pool of all assay samples diluted 1:8 with nuclease-free water, serial dilutions 
(1:2) were made for standards 2-7 and the final with the last standard left as a blank (just 
water). The final standard curve consisted of 1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512 and 
blank. Samples were diluted 1:32, so as to fit in the middle of the standard curve.  The 
standard curve and samples were aliquotted and stored at -20oC such that only 2 freeze-thaw 
cycles were required to complete all qRT-PCR analyses. qRT-PCR assays were performed 
using the probes and primers outlined in Table 2.3.  
 
Each assay was setup in a 10 µl total reaction volume comprising 2 µL cDNA, 0.1 µl of each 
primer (from a 20 µM stock, Eurofins Scientific), 0.1 µL probe (Universal Probe Library, 
Roche) and 5 µl MasterMix (PerfeCTa, FastMix® II, Quanta Biosciences) and 2.8 µl 
nuclease-free water (QIAGEN). Each standard and sample qRT-PCR reaction was 
assembled on a 384 well plate in triplicate using repeat multichannel pipettors to minimise 
inter-replicate variability. No template and reverse transcriptase (RT) negative controls were 
run alongside each assay. Reactions were run on a Roche Lightcycler 480 using the 
following cycling conditions: 95oC for 5 minutes, 95oC for 10 seconds, 60oC for 30 seconds, 
repeated for 60 cycles, then 40oC for 30 seconds. Quantitation was achieved using the 
automated LightCycler 480 software, which identifies the threshold cycle (Cp) value for 
each well by finding the maximum value from a plot of second derivative of fluorescence 
versus time (Figure 2.8). Each triplicate value was analysed and replicates excluded if the Cp 
standard deviation was >0.5. Results were accepted if the standard curve was adequate, as 
assessed by efficiency within the range 1.7-2.1 and error <0.5 (i.e. the mean squared error of 





Figure 2.8: Example standard curve for a qPCR assay (TBP) 
(A) Plots of florescence intensity versus cycle number for 7 point serial dilutions of pooled 
cDNA template and no template negative control (green) performed in triplicate.   (B) 
Standard curve constructed from Cp values obtained from A (there are three data points for 
each concentration).  
 
2.4.2.3. Selection of endogenous control genes 
Endogenous control genes were used to normalise the experimental gene values. Following a 
literature search, a panel of three endogenous control genes was selected to include tat box 
binding protein (TBP), hypoxanthine-guanine phospho-ribosyltransferase (HPRT) and 18S 
ribosomal RNA [139] [118] [140]. The expression of these control genes did not differ 
across any of the experimental groups (Figure 2.9) and CT values were approximately 25-33, 
22-28, 7-15 for TBP, HPRT and 18S respectively. Test gene CT values ranged from 22-37. 
The level of endogenous control genes was normalised such that day/vehicle/sham was equal 
to 1 (so as not to give greater weight any one of the control genes, this may be particularly 
important for 18S which has much higher expression than HPRT and TBP) and the mean of 
all three control-genes was taken. The experimental gene expression was calculated as the 
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mean level normalised to the mean of the control genes and adjusted so day/vehicle/sham 
was equal to 1 and log10 transformed to normalise the spread of data.  
 
 
Figure 2.9: Exogenous control genes in C57BL6 mouse kidneys 
(A)-(C) Abundance of TBP, 18S and HPRT during the day versus at night adjusted such that 
day= 1 (D) Mean value obtained for all 3 assays.  Each “experimental” gene was expressed 
relative to this mean abundance of these 3 genes as shown in (D). Data here are from 
experiments described in chapter 3 and are presented as mean ±95 % CI. P values are from 
unpaired Student’s t tests. No differences were found in any of the endogenous control 
genes between any of the experimental groups (n=15).  
 
2.5. Metabolic Cage Experiments 
2.5.1. Experimental design 
This section outlines general methods that apply for all metabolic cage experiments carried 
out. Metabolic cage protocols for individual experiments are outlined within the brief 
methods section for chapters 3-5. Mice were single housed in metabolic cages with 12 hour 
light dark cycling (starting at 7 am).  There was a ~10 % loss of body weight in all mice, 
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which stabilised out after 4-5 days but did not return to pre-experimental body weight. Food 
intake, water intake, urine output and body weight were measured at least daily.  
 
2.5.2. Gelled diet 
To minimise the contamination of urine with food, a gelled diet was used all metabolic cage 
experiments unless otherwise stated. The mice adapted well to the diet and considerably less 
was scattered out of the food hoppers compared to standard powdered diets previously used 
in our lab group. The gelled diet also increased urine flow permitting collection of a urine 
sample during the day. One sachet of gelatin (Dr Oetker, UK) was dissolved in deionised 
water (750 ml, heated to ~70oC). The gelatin-water was thoroughly mixed with powdered 
RM1 diet (250 g, Special Diet Services) in a zip-lock bag. A hole was made in the bottom of 
the bag and diet “piped” out into strips and stored at 4oC for up to 1 week or at -20oC for up 
to 1 month. The resulting sodium content was 0.21% dry weight. Approximately 40 g gelled 
diet was given in double food hoppers daily to allow ad libitum feeding.  
   
2.5.3. Urine Analysis 
2.5.3.1. Urinary Electrolyte Analysis by Flame Photometry 
A flame photometer (BWB-1, BWB technologies) was used to analyse sodium potassium 
and calcium levels in urinary samples collected from metabolic cages. Urine was diluted 
1:50 with “blank” diluent (BWB technologies). Results in ppm were then converted to molar 
values and multiplied by urinary flow rate to get µmol/hour(s).  
 
2.5.3.2.  Urinary Steroid Analysis by ELISA 
Urine was extracted and assayed according to the method developed by Dr Emad Al Dujaili 
[141, 142]. Briefly, 1800 µl diethyl ether (CROMOSOLV®, Sigma Aldrich) was added to 
200 µl urine and very thoroughly vortexed for 15 minutes using a multi vortex. To test the 
recovery of extraction a sample of known aldosterone/corticosterone concentrations was 
extracted along with the test samples. Samples were placed in an -80oC freezer for 15 
minutes and top ethyl layer poured off into a clean glass tube (12x75 mm). Samples were 
desiccated at 50oC under nitrogen. Samples were reconstituted in 0.5 ml assay buffer (20 ml 
Blocking buffer (0.5g BSA (Sigma Aldrich) in 100 ml PBS) in 80 ml PBS), thoroughly 
vortexed and incubated at room temperature for an hour (reconstituted samples could also be 
vortexed and incubated overnight at 4oC). Two 96 well ELISA assay plates (medium-bind, 
Griener Bio-One), 1 for each aldosterone or corticosterone assay, were coated with 200 µl 
diluted steroid-3-carboxymethyloxime-BSA conjugateor (50 µl conjugate diluted in 20 ml 
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PBS) and incubated overnight at 4oC. Plates were washed 3 times with wash buffer 0.05% 
Tween 20 (Sigma Aldrich) in PBS) and incubated with 190 µl blocking buffer (0.5 g BSA in 
100 mL PBS) for 1 hour at 37oC. The following 5 standards were prepared in assay buffer: 
aldosterone: 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM and corticosterone: 0.2, 1, 4, 20, 100 
ng/ml (0.6, 2.9, 11.5, 57.7, 288.6 nM) and 50 µl of each standard and sample was loaded 
onto the plate. Antibodies were produced in house and described in [141], [142]. 100 µl 
diluted antibody (corticosterone antibody: 60 µl antibody +12 mLs assay buffer or 
aldosterone antibody: 40 µl + 12 ml assay buffer) was added to each well and the plates 
incubated in the dark at room temperature for 2 hours.  
 
Plates were washed four times and 100 µl HRP-goat anti-rabbit IgG enzyme conjugate 
(Upstate, 10 µl in 11 ml for corticosterone) or HRP–Donkey-anti-sheep IgG enzyme 
conjugate (produced in-house, 10 µl in 11 ml for aldosterone) added to each well and 
incubated in the dark at room temperature for 1 hour. 100 µl substrate (11 ml 0.2 M sodium 
acetate/citrate buffer pH to 4.2 with sodium citrate, 0.300 ml 10 mg/ml tetramethylbenzadine 
in DMSO and 0.060 ml hydrogen peroxide) was added to each well and incubated for 15 
minutes. 50 µl stop solution (2 M sulphuric acid in water) was added to each well and plate 
read at 450 nm (MRX plate reader, Dynex). Results were extrapolated from a standard curve 
using a third order polynomial (Figure 2.6) and multiplied by 5 to get ng/ml. The aldosterone 
samples were just within the limit of detection but a detectable reduction in urinary 






Figure 2.10: Representative examples of cubic polynormial curves obtained from 
corticosterone (A) and aldosterone (C) assays, along with validation experiment 
results, showing the assay is capable of detecting a difference in aldosterone levels 
following a high salt diet (D), while corticosterone level remains unchanged (B).  
Data is mean ±95 % CI (A-D). Red circles (A&D) are the sample values and blue circles 
(A&D) are spiked samples to test recovery of extraction process. *p<0.05 by paired 




2.6. BP measurements by Radiotelemetry 
Radiotelemetry allows the remote, real-time analysis of BP, HR and activity in conscious, 
unrestrained mice and is the gold standard approach for cardiovascular physiology in 
rodents.  
 
2.6.1. Device calibration and setup 
Miniature radio telemeter devices PA-C10 (Data Science International) were electronically 
coupled with their receiver pads and assigned to a mouse. The offset of each device was 
tested and recorded (this was in the range of -2 to +2 mmHg). All details of the mouse, 
devices and offset could be recorded using the DSI software accompanying the devices.  
 
 
Figure 2.11: Diagram of components and set up of telemetry surgery 




2.6.2. Telemetry implant surgery 
All surgical work was carried out using aseptic technique [143]. To minimise stress caused 
by single housing, mice were single housed for a week prior to surgery in order to build a 
nest and acclimatise to single housing and conditions in the telemetry suite. Anaesthesia was 
achieved using isofluorane in oxygen, with initial induction at 3 % reduced to 1-2 % to 
maintain unconsciousness. The isofluorane delivery tubing was tapered using a 5mL syringe 
with the plunger removed, which fit snugly around the mouse’s face.  Buprenorphine 
(Vetergesic®) at a dose of 0.1 mg/kg was given subcutaneously along with a 1 mL bolus 
injection of 0.9 % sterile saline. Ocular lubricant (Lacri-lube®) was applied to the animal’s 
eyes to prevent them drying out during the procedure. The mouse was then positioned in 
dorsal recumbency and the ventral neck area was shaved and bathed in iodine scrub 
(Vetersept®). A ventral cervical skin incision was made and a subcutaneous pocket was 
made down the left flank of the animal (Figure 2.11 A). Blunt dissection was utilised to 
isolate the carotid artery (Figure 2.11, C) and separate it from the vagus nerve gently, 
ensuring the nerve was not disturbed. A tight double-knotted ligature was applied to the 
anterior end of the carotid artery (Figure 2.11, G) and loose ends secured with a large 
haemoclip (Figure 2.11, H) to produce light tension on the artery. A loose ligature was 
applied to the carotid artery and postural end was occluded with a micro-haemoclamp 
(Figure 2.11 B, Microserrefine, FST). A bent 23 gauge blue (Figure 2.11 F, BD Microlance, 
FST) needle was used to make an incision in the artery and to gently hold it open.  The 
device catheter (Figure 2.11 D, Data Sciences International) was fed gently into the carotid 
artery using vessel cannulation forceps and secured by tightening the loose ligature around it. 
The antithrombotic, gel-filled tip was extremely delicate and care was taken to avoid 
crushing it. A radio was used to gauge the level of interference caused by gripping the 
catheter and upon opening of the postural occlusion a pulsing sound was heard over the radio 
if the catheter was still patent.  
The micro-haemoclamp was gently removed from the postural end of the artery and the 
catheter fed in until resistance was felt (approximately 1-2 mm before the joint between the 
gel-filled segment and rest of the fluid filled portion of the catheter). Both anterior and initial 
securing ligatures were double knotted and tissue adhesive (3MTM VetBondTM) was applied 
to the knots. The device body was then fed into the pre-made subcutaneous pocket, this 
could be aided by wetting the pocket with <1 ml saline, and the wound was closed with 3-5 
silk sutures (size 5.0, non absorbable, Vicryl). Tissue adhesive was used to seal the wound 
and oxygen was fed through the nose cone for 3-5 minutes until consciousness was regained. 
The mouse was allowed to recover in a hot box (34oC) until full mobility was regained (<30 
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minutes) after which it was returned to its cage and allowed ad libitum access to vetergesic-
laced jelly (0.02 mg/ml buprenorphine in 45 ml water, 2 cubes jelly (Hartley’s, UK)) and 
mash (RM1 pellets soaked for >1 hour to overnight in drinking water). Body weight, wound 
healing and general activity were monitored for 5 days and accounting for device weight, 
body weight usually matched pre-operative levels within this time.  
 
2.6.3. `Collection and analysis of telemetry data 
The transmitter device was set to record once every half hour over a period of 1 minute. How 
the telemetry data are presented is outlined in each specific results chapter. Common to both 
chapters is the use of a cosinor analysis, the details of which are outlined here. Cosinor 
analysis is suited for analysis of rhythmic variables calculating midline estimating statistic of 
rhythm (MESOR), rather than the arithmetic mean as the central tendency. This rhythm 
adjusted mean (also known as the time-structured mean or chronome adjusted mean) is a 
more accurate estimation of central tendency than the arithmetic mean particularly in 
instances where the data is not equidistant – for example if there are missing data points. The 
cosinor analysis also calculates period, amplitude and acrophase (Figure 2.12). The period is 
the time taken for a full cycle, or the time from one peak to the next. The amplitude is the 
distance between the MESOR and the peak or half of the full extent of the oscillation. 
Acrophase is the time at which the peak occurs. The movement of the acrophase can give an 
estimate of any shifts in “phase” that is any movements in time of the wave. Finally 
“robustness” or prominence, which is the strength and endurance of a rhythm, is a measure 
of signal-to-noise ratio. Levels below 20 % are likely biological noise [144]. Mathematically 
robustness/prominence is calculated as the percentage of the variance accounted for by the 
cosinor model. Statistical significance of the goodness of fit did not exceed p<0.000001 for 
each analysis and was corrected for multiple tests (with 5 periods used for each analysis). 
The data was first smoothed using a moving average over 5 hours; this improved the 
“robustness” of the cosinor fit. The smoothed data for each individual mouse for each of the 
5-day bins was fitted to a cosinor curve using software designed by Refinetti et al (available 
at: www.circadian.org), which fits the data by the least squares method [144]). Acrophase 





Figure 2.12: Cosinor fit of an example baseline data set in order to visualise how 
period, amplitude, MESOR and acrophase are acquired from a cosinor curve fit. 
 
2.7. Manipulation of Plasma Corticosteroids 
2.7.1. Bilateral Adrenalectomy Surgery 
Mice were anaesthetised under isofluorane (as previous) without a nose-cone adaptation. 
Buprenorphine (Vetergesic® 0.1 mg/kg) and 0.3 ml of 0.9 % sterile saline was administered 
subcutaneously. Mice were positioned in lateral recumbency and an area just caudal to the 
rib cage and just ventral to the spine on both sides was shaved with hair clippers. Just prior 
to incision the area was scrubbed with iodine solution (Vetersept®) and a small 10-15 mm 
transverse skin incision made just beneath the ribs. A smaller incision was made in the 
abdominal wall just caudal to the last rib and adrenal gland located near the anterior pole of 
each kidney using 7 cm curved serrated forceps (Fine Science Tools, 11065-07). On the left 
side the spleen was gently moved laterally and on the right side the liver was gently held 
cranially to expose the adrenal gland. Once exposed a second pair of curved forceps was 
positioned underneath the adrenal gland and peri-adrenal fat and both were gently 
exteriorised while using the other forceps to tease the connective tissue, fat and blood vessels 
apart from the adrenal gland beneath the curved forceps. No haemostasis was necessary here 
as any bleeding from the adrenal blood vessels was minimal. Extra care was taken not to 
grasp the adrenal gland itself as this can cause it to tear and leave functioning residue within 
the peritoneum. The abdominal muscle was closed using a single silk suture (size 5.0, non 
absorbable, Vicryl) and skin closed using three Michel suture clips (7.5 x 1.75 mm, Fine 
Science Tools). The other adrenal gland was removed in the same way and the mice allowed 
to recover in a hot box (34oC) until full mobility was regained (this took <30 minutes) after 
which they were singly housed to prevent fighting, which may lead to greater chance of 
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sudden death in ADX animals. Mice had access to vetergesic-laced jelly and mash (as 
previous) as well as ad lib access to 0.9 % saline and tap water to maintain electrolyte 
homeostasis. Body weight, wound healing and general activity were monitored for 3 days 
post-operatively and body weight usually matched pre-operative levels within this time.  
 
2.7.2. Corticosterone Pellet experiments 
2.7.2.1. Pellet preparation 
Corticosterone silastic slow-release pellets were prepared for implantation in mice in order to 
inhibit their existing rhythm of plasma corticosterone. Corticosterone (1 g, Sigma, UK) and 
Silastic® (1.8 g, Silastic® F RTV rubber base, Dow Corning) were mixed together into a 
uniform paste in a weigh boat and curing agent (0.01 g, Silastic® F RTV curing agent, Dow 
Corning) added in a drop-wise fashion on a fine balance and mixed into the paste. The 
mixture was then aspirated into a 1 ml syringe. To remove bubbles from the mixture, the 
syringe was trimmed and inserted into a 15 ml falcon tube and centrifuged at 800 g for 10 
minutes to remove the bubbles. The mixture was incubated in the syringe and falcon tube at 
37oC overnight to set. The pellet was cut out of the syringe and it’s length: weight ratio 
calculated in order to work out the length of a 25 mg slice. The vehicle pellet was produced 
in the same way excluding the corticosterone and cut to the same length. This is a rough 
estimate of the release rate estimated by quantifying the level of corticosterone present by its 
UV absorption. The release rate of the pellet is estimated to be 3.67 mg/kg/day and is steady 
over 4 weeks. This was calculated by soaking a 25 mg pellet in a sealed glass flask of 27 ml 
of PBS at 37oC for up to 6 weeks (Figure 2.13) and analysing 200 µl sample from it weekly. 
The 200 µl sample was loaded into a microcuvette (10 mm Lightpath precision cell, Hellma) 
and measured at 240 nm on a UV machine (UV-1201 spectrophotometer, Shimadzu) and 
returned to the glass flask. Microcuvettes were rinsed with methanol between sample 
applications and air-dried. These data were plotted with reference to a 100 µm corticosterone 
standard. The change in corticosterone concentration was worked out to be approximately 10 
µM/day, which converts to a release rate of 0.1 mg/day thus giving a dose of around 3.7 
mg/kg/day (assuming a 30 g mouse, all experimental C57Bl6/J mice were within range 27-
32 g). The range of release rate values was between 3 mg/kg/day and 4.33 mg/kg/day (for 5 
pellets). The release rate appeared to taper off towards the end, this may be as a result of 
reaching the limit of detection with this setup. It was unlikely that all the corticosterone had 
leached from the pellet, as only 2.8 mg out of 25 mg was detected. Furthermore plasma 
samples taken at day 21 show flat lining of corticosterone levels, which is consistent with 




Figure 2.13: Release rate of corticosterone pellets over 4 weeks in vitro 




2.7.2.2. Pellet implantation surgery 
Mice were anaesthetised under isofluorane using a 5 ml syringe nose-cone adaptation, given 
buprenorphine (Vetergesic ®) and positioned in ventral recumbency. Hair was removed 
from the dorsal cervical area and scrubbed with iodine (Vetersept®). A small ~5 mm 
transverse dorsal cervical incision was made and a subcutaneous pocket made down the 
midline into which the Silastic® pellet was implanted. The wound was closed with a Michel 
suture clip (7.5 x 1.75 mm, Fine Science Tools). Mice regained consciousness in a hotbox 
(as previous) within 5 minutes and were returned to their home cages.  
 
2.7.3. Plasma corticosterone measurements 
2.7.3.1. Tail venesection 
Tail vessel micro sampling was performed just after the lights came on, ~ 7 am and just 
before lights out at ~ 6.45 pm, unless otherwise stated. Mice were removed from their home 
cages and placed on top of an empty cage. While securing the mouse by the tail <1 mm was 
snipped off the using sharp sterile scissors. The mouse was minimally restrained by the tail 
and allowed to explore the cage surface while the tail was gently massaged from base to tip 
until ~20 µl of blood was collected into a 300ul EDTA coated tube (Microvette CB 300 
EDTA, Sarstedt). Blood was collected within 1 minute of the mouse’s removal from its cage 
and placed on wet ice. The second sample was taken by gently nicking the scab from the tail 
wound and collected as before. Blood samples were centrifuged at 10 000 rpm for 5 minutes 




2.7.3.2. Plasma sampling post mortem 
A larger sample of blood could be taken post mortem by cardiocentesis. This was performed 
by roughly excising the ribcage to expose the heart and while holding the apex of the heart 
with 7 cm forceps a bent 23 gauge needle (attached to a 1 ml syringe rinsed with heparin 
saline (20units/L porcine heparin saline, Sigma Aldrich) was inserted into the right ventricle 
and blood very gently aspirated to prevent the ventricle heart collapsing. 
 
2.7.3.3. Plasma Corticosterone Assay 
Plasma corticosterone was measured using a commercially available corticosterone EIA kit 
(Enzo Life Sciences). All reagents were provided in the kit. Plasma corticosterone was 
extracted from plasma samples by incubating 10 μl of sample 10 μl of steroid displacement 
reagent (SDR: diluted 1:100 with assay buffer 15 (AB15)) for 5 minutes at room temperature 
(RTo) in sterile glass tubes. AB15 (280 μl) was then added along with 3 ml ethyl acetate 
(Sigma Aldrich) and the glass tube was vortexed thoroughly, incubated (RTo, 2 minutes) and 
vortexed again. The clear organic upper layer was aspirated to a new glass tube. The samples 
were desiccated under nitrogen at 60oC. Standards and samples were prepared in duplicate 
and assayed according to the manufacturer’s instructions. Absorbance measurements (405 
nm and corrected with 580 nm) were plotted against the known standard values using 
GraphPad software and the r2 value for the sigmoidal curve produced was >0.98 and the 
concentrations of the unknown samples were interpolated onto the line. 
 
2.8. Estimation of NCC activity in anaesthetised animals by renal clearance 
Renal clearance experiments enabled the measurement of mean arterial BP and the 
estimation of renal haemodynamic parameters  
 
2.8.1. Surgical protocol 
General anaesthesia was induced by intra-peritoneal injection of 100 mg/kg 
thiopentalbarbitol (Inactin®, Sigma). Small bolus doses of anaesthetic (50 mg/kg) were 
applied judiciously during surgery to maintain unconsciousness (as assessed by blink or toe 
pinch reflexes) but minimise cardiovascular suppression. Unconscious mice were kept in 
dorsal recumbency on a heated pad to conserve body heat during the surgery. Ligatures were 
made with size 5 suture silk (Fine Science Tools) and lidocaine-HCl (1 % w/w in 0.9 % 
saline, Sigma Aldrich) was used to provide local anaesthetic and maintain tissue moisture 





In order to maintain a clear airway throughout the surgery a tracheostomy was performed. A 
ventral cervical skin incision was made and the muscles immediately beneath were dissected 
to expose the trachea. An incision was made between the tracheal cartilage rings and a 
tracheostomy tube, contrived from a 1 cm piece of P90 tubing (Smith’s medical) was 
inserted and secured.  
 
2.8.1.2. Jugular Vein cannula 
In order to administer infusate, anaesthetic and drugs during renal clearance experiments, the 
jugular vein was cannulated. The left jugular vein was exposed and perivascular fat gently 
removed with fine forceps. The anterior end of the exposed vein was ligated and light 
tension was applied to elevate the vein. A small incision was made just postural to the 
ligature and a piece of P10 (Smiths medical) tubing containing 0.9 % saline connected to a 1 
mL syringe, was inserted and secured with a second ligature.  
 
2.8.1.3. Carotid Artery Cannula 
For continuous blood pressure monitoring and blood collection, the carotid artery was 
cannulated. The carotid artery was exposed between the tracheal muscle and salivary gland 
and gently isolated from the adjacent vagus nerve. The carotid was tightly ligated at the 
anterior end and tension applied to elevate the artery. The posterior end was ligated to 
prevent blood loss. A small incision between the ligatures was made and P10 tubing 
containing 20units/L porcine heparin saline (Sigma Aldrich) attached to a 1 mL syringe was 
inserted and secured with a third ligature. The anterior ligature was carefully untied to 
restore blood flow and the cannula was advanced further into the carotid and firmly secured.   
 
2.8.1.4. Bladder Catheter 
The bladder was catheterised for urine collections. The catheter tube was fashioned from a 
~1 cm length of P50 (Smiths medical) into which a ~10 cm length of P10 tubing was 
inserted to minimise the dead space. A lower abdominal incision was made, the bladder 
located and gently lifted out through an incision in the peritoneum. A hole was made in the 
bladder using a 23 gauge blue needle (BD Microlance) and the catheter was inserted and 






2.8.2. Renal Clearance protocol 
The particular renal clearance protocols used in each experiment are presented in the in-
chapter methods. Presented here is a general outline of procedures common to all protocols. 
Once surgery was completed a bolus of 0.1 ml/10gbw I.V. infusate (in mM: NaCl 100, KCl 
5, NaHCO3- 15, sodium para amino-hippurate (PAH, Sigma Aldrich) 25, and 0.25 % FITC-
inulin (Sigma Aldrich), pH to 7.4 by bubbling with CO2) was administered to hasten 
equilibration and replace fluid losses during surgery. The venous cannula was connected to 
an infusion pump (AL2000, World Precision Instruments) for administration of infusate at a 
constant rate of 0.2 ml/10gbw/hour.  The carotid cannula was connected to a ML224 Bridge 
Amp (AD Instruments) for continuous monitoring of arterial blood pressure through 
PowerLab data acquisition software. An equilibration period of 1 hour was allowed before 
any experimental collections. During all protocols 20 µl blood samples were taken prior and 
post urine collection and a final large terminal blood sample was taken via the carotid artery. 
These were collected into Lithium-heparinised capillary tubes or 500 µl Li-heparinised tubes 
(Microvette CB 300 LH, Sarstedt). Urine samples were collected into pre-weighed 500 µl 
eppendorf tubes containing mineral oil to prevent sample evaporation. Bolus injections of 
thiazides or vehicle were administered via the jugular vein cannula and the animal was 
euthanized via cervical dislocation following the final blood collection.  
 
2.8.3. Sample Analysis 
2.8.3.1. FITC-Inulin Assay 
FITC-inulin is freely filtered at the glomerulus but is neither secreted nor reabsorbed along 
the nephron, therefore its clearance gives a very accurate measurement of the glomerular 
filtration rate (GFR). The FITC fluorescence was measured in samples of urine and plasma. 
Briefly, urine and plasma samples were diluted 1:10000 and 1:100 respectively in HEPES 
buffer (as the fluorescence reaction is pH dependent). A five point 2 fold dilution series was 
performed for FITC standard curve with 1 mg/ml as top standard. These were diluted 1:100 
in HEPES buffer. 190 µl of samples and standards were loaded in duplicate into Microfluor 
black 96 well plates (Thermoscientific). The plate was then read on a microplate reader 
(infinite M1000, TECAN) with samples excited at 485 nm and read at 538 nm. GFR could 
then be calculated: 




2.8.3.2. PAH Assay 
In order to calculate renal blood flow (RBF), plasma and urinary para amino-hippurate 
(PAH) was measured. Effective renal plasma flow was calculated on the assumption of 
complete extraction of PAH from plasma into the urine [145, 146]. In brief, standards were 
prepared in serial dilution using water with 0.2 mg.ml-1 as the top standard. Plasma and urine 
samples were diluted in 3.2 % trichloroacetic acid (TCA, Sigma Aldrich). Plasma was 
vortexed and incubated for 5 minutes at room temperature, this step was repeated before 
centrifugation at 10 000 g for 3minutes to pellet and remove the plasma protein. Mix A (40 
µl 0.2 N HCl and 20 µl 0.1 % NaNO2) was added to the all the samples/standards, vortexed 
and incubated (RTo, 5 minutes). Mix B (20 µL 0.5% NH2S03NH4 and 20 µl 0.1% N-(1-
naphthyl)-ethylenediamine dihydrochloride) was added to the samples/standards, followed 
by a thorough vortex and incubation (RTo, 40mins). 200 µl was transferred into a clear 96 
well plate in duplicate. The absorbance was measured at 535 nm on a Victor plate reader 
(Perkin). Renal plasma flow (RPF) could then be calculated:  
RPF (clearance of PAH) = (Urinary [PAH] x Urinary flow rate)/ plasma [PAH] 
RPF was converted to RBF by adjusting for the cellular fraction using the haematocrit 
values.  
2.8.3.3. Electrolyte Analysis 
An electrolyte analyser (Roche, UK) was used to measure plasma and urinary sodium, 
according to the manufacturer’s guidelines. Urine was first diluted 1:5 with dH2O and in turn 
this was diluted again with 2:3 parts 120 mM NaCl. Plasma samples were run undiluted.  In 
order to account for any inter-animal changes in renal haemodynamics the fractional sodium 
excretion was calculated to assess tubular sodium reabsorption:  
FENa = (Urinary sodium x Urinary flow rate)/ (Plasma sodium x GFR) x100) 
2.9. Quantifying HCTZ by liquid chromatography-tandem mass 
spectroscopy (LCMS) 
 
The method for quantification of urinary and plasma HCTZ was developed by Dr Robert 
Hunter and Dr Natalie Homer [147]. The Clinical Research Facility carried out all analyses. 
20 µl plasma or urine was spiked with 20ng trichlorothiazide (TCTZ), which acted as an 
internal standard to correct for variations in HCTZ extraction efficiency. Samples were 
extracted with 200 µl ethyl acetate through agitation for 30 minutes and room temperature. 
The organic phase was desiccated to dryness at 40oC under nitrogen and reconstituted in 100 
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µl 5% acetonitrile and 95 % 0.5mM ammonium acetate. LCMS was performed using an 
Aria-Quantum CTC Turboflow autosampler and HPLC system (Thermo Fisher) used with a 
TSQ Quantum Discovery triple-quadropole mass spectrometer. A T3 Atlantis (100 x 2.1mm, 
3.5 µm, Waters, Manchester) HPLC column was used for quantitation with a flow rate of 0.3 
ml/min at 40oC with a mobile phase of 5mM ammonium acetate and 0.1 % formic acid in 
methanol. The mass spectrometer was operated in negative ion electrospray ionisation mode 
with 3-kv spray voltage, 60/5 sheath and auxiliary nitrogen gas and 1.5- mTorr argon 
collision gas. Results for each sample were compared to a pre-determined standard curve 
ranging from 10 – 5000 ng. 
 
2.10. Data analysis and statistics 
All data are presented and analysed using GraphPad Prism software version 6.0. Data are 
presented as mean ±95% confidence interval (CI). The number of biological replicates (n) 
for each experimental group is given in the figure legends along with the test used for 
statistical analysis. As two-way ANOVAs are used frequently in this work, these will be 
described in greater detail here. Two-way ANOVAs were used when analysing differences 
between groups that have been split by two independent variables, most commonly used in 
this thesis a treatment, such as adrenalectomy and a time point, such as day or night. The 
output for these tests, given in boxes within the figures, gives the p values for each of these 
independent variables as well as the “interaction” and “matching” (where appropriate). The 
interaction effect tests the null hypothesis that any differences within the first independent 
variable (eg. time of day) are the same for each group within the second independent 
variable (eg. adrenalectomy or adrenal intact). Repeated measures two-way ANOVA is used 
if the data are matched, for example if it is the same mouse that is treated with HCTZ it’s BP 
will be “matched” for before and after treatment. Where “matching” has been effective for 
controlling experimental variability this is marked as significant. Sidak tests were employed 
for post hoc analysis. This test gives high power (thus preventing false negatives), while still 
being stringent in adjusting the family-wise error rate in order to counteract the problem of 




3. Diurnal rhythm of NCC phosphorylation 
3.1. Introduction 
In the kidney 13% of genes exhibit a circadian profile of expression [43]. This does not 
include NCC (slc12a3) expression [42, 43]. However, as explored in chapter 1, NCC activity 
is regulated predominantly through posttranslational modifications, such as phosphorylation 
and ubiquitinylation. Therefore the primary purpose of this chapter is to investigate temporal 
variation in NCC phosphorylation.  
 
3.1.1. Aims 
1. Confirm the presence of a circadian rhythm of behaviour, BP, urinary excretion in 
normal C57BL6 mice under controlled 12-hour light and dark conditions.   
2. Determine whether there is any difference in NCC phosphorylation during the active 
phase (night) compared to the inactive phase (day) in C57BL6 mice.  
3. Explore potential mechanisms that may contribute to any such difference in activity. 
 
3.1.2. Strategy for addressing the chapter aims: 
1. The rhythms of urinary excretion, feeding and drinking behaviour were determined 
in conscious C57BL6 mice using metabolic cages. Radiotelemetry in conscious 
unrestrained C57BL6 mice was employed to define the rhythms of BP, activity and 
heart rate.  
2. NCC phosphorylation status was measured by probing whole kidney homogenate 
with phospho-antibodies. Tissue was collected when day:night BP differences were 
maximal i.e. between peak and nadir.  
3. Potential mechanisms for the rhythmic regulation of NCC were investigated by 
exploring the diurnal rhythms present in candidate genes and hormonal systems that 
could regulate NCC phosphorylation. This was further probed by defining the 
localisation of MR, GR and 11βHSD2 by immunohistochemistry.  
 
3.2. Methods 
Detailed methods of each of the procedures in this chapter are outlined in the main methods 
section, however for clarity, an outline of the experiments carried out and cohorts of mice 





3.2.1. Metabolic cage experiment  
Male C57BL6 mice (n=10) were housed in metabolic cages with a 12-hour light/dark cycle 
and allowed to acclimatize for 5days (See Methods 2.5). Food and water intake was 
measured and urine collected for 12-hour periods over 3 consecutive days (ZT0-12 “Day” 
and ZT12-0 “Night”).  
 
3.2.2. Telemetry  
Male C57BL6 mice (n=4) were implanted with radiotelemetry devices (PA C10, DSI). The 
mice were housed in a room with a 12-hour light/dark cycle with ad libitum access to 
standard RM1 diet and tap water. After 5 days postoperative recovery, recordings were taken 
every 30 minutes for 1 minute. The baseline data presented here is the mean at each half 
hour time point, averaged over 5 consecutive days and smoothed using a rolling average 
over 5 consecutive data points. Each 5-day data set for each mouse was fitted to a cosinor 
curve (See Methods 2.6).  
 
3.2.3. Timed Culls 
In order to assess NCC phosphorylation at night versus day, timed culls were performed. 
Two time points were selected. The rationale for selecting these time points was to remove 
the kidney during steady-state blood pressure at both peak and nadir, reasoning that the 
transporter activity may be at its highest and lowest at these time points. Kidneys underwent 
western analysis and RT qPCR (see Methods 2.3 & 2.4 respectively).  
 
3.2.4. Plasma corticosterone sampling 
The circadian rhythm of corticosterone was compiled using plasma samples collected from 5 
separate groups of male mice; each group was housed under the conditions previously 
described (Methods 2.1). Terminal plasma samples were taken at cull at ZT 6 and ZT 18 in 3 
separate cohorts (n=22). Plasma was also taken by tail venesection in 2 groups of conscious 
mice, one group (n=4) was sampled from at ZT0 and ZT12 and another group (n=10) was 
sampled from at ZT6 and ZT18 so as to be comparable with the terminal samples. Plasma 
was analysed by EIA (see Methods 2.7.3).  
 
3.2.5. Perfusion Fixation  
Male C57BL6 mice (n=3) were perfusion fixed between 8am-4pm and kidneys excised for 





3.3.1. Diurnal rhythm of food and water intake 
Consistent with literature reports [148], food and water intake exhibit a strong diurnal 
rhythm, with more consumed during the 12 hour night period (ZT12- ZT0) than during the 
12 hour day period (ZT0- ZT12) (Figure 3.1).  
 
 
Figure 3.1: Food (A) and water intake (B) and urine output (C) in C57Bl6 mice over 12-
hour day and 12-hour night. 
Water intake is that drank, with water in the gelled diet included in the food intake. Data are 




3.3.2. Diurnal rhythm of electrolyte excretion 
As shown in Figure 3.2, sodium and potassium excretion was markedly increased at 
nighttime (ZT12-ZT0) compared to the daytime (ZT0- ZT12).  
 
 
Figure 3.2: Urinary sodium (A) and potassium (B) in C57Bl6 mice.  
Urine was collected 12 hourly between ZT0 and ZT12 and electrolyte concentrations 
measured by flame photometry. Data are mean±95% CI. Data were analysed by paired 










3.3.3. Diurnal rhythm of BP, heart rate (HR) and activity in C57BL6 mice 
As shown in Figure 3.3 systolic blood pressure (SBP) and diastolic blood pressure (DBP), 
HR and activity were all increased at night (ZT12-0) compared to the day (ZT0-12). The 
mean period for SBP was 23.9 ±0.22 (95% CI) and the acrophase was roughly ~ ZT 18h10 
±0h47 (Table 3.1). Robustness is a measure of rhythmicity, or how well the data fit a cosinor 
waveform. Values of >20% are above noise-level and exhibit significant rhythmicity. SBP, 
DBP and activity exhibited significant rhythmicity, with robustness values exceeding 20%. 
However, HR was below threshold (at 12.5%) with high noise levels. 
 
Figure 3.3: 24 hour systolic blood pressure (A), diastolic blood pressure (B), heart rate 
(C) and activity (D) Data are mean±95% CI (n=4) Black line and white line indicates the 





Table 3.1: Parameters obtained from cosinor analysis of C57BL6 mice telemetry data 
SBP (systolic blood pressure), DBP (diastolic blood pressure), HR (heart rate). Data are 
mean± 95% CI. (n=4)  
 SBP DBP HR Activity 
Period (hours) 23h09 ± 0h22 23h09 ±0h18  23h48 ± 0h12 23.48 ±0h12  
Acrophase (ZT)  18h10 ± 0h47 18h09 ± 0h49 16h36 ± 0h14 17h06 ±0h05  
Amplitude (mmHg/ 
/ bpm/ counts) 
10.0 ± 1.8 9.8 ± 1.5 57.0 ± 22 6.24 ± 1.2 
MESOR (mmHg/ 
bpm/ counts)  
125.2 ± 1.6 95 ± 4.9 506.9 ± 6.6 7.17± 1.9 
Robustness (%) 26.3 ± 4.3 23.9 ± 3.3 12.5±5.0 28.5 ± 1.9 
 
 
3.3.4. Diurnal rhythm of NCC phosphorylation 
The peak of SBP as estimated by cosinor analysis was at approximately ~ ZT18h10 and with 
a period of ~ 24 h the nadir can be calculated as approximately 12 hours prior at ~ZT 6. 
Therefore these two time points, at which blood pressure was most different, were selected 
for kidney collection and quantification of NCC phosphorylation by western analysis. As 
shown in figure 3, pT53, pS71 and total NCC were measured in whole kidneys taken at night 
(ZT 18) or day (ZT 6). Phosphorylation of NCC at T53 showed a marked diurnal rhythm: the 
levels at night being significantly greater than during the day (p<0.0001, Fig 3.4). No such 
rhythm was evident for phosphorylation at S71 (p=0.13, Figure 3.4B) or total NCC (p=0.52, 
Figure: 3.4C). This experiment was also performed in a cohort of female C57BL6 mice. As 
shown in Figure 3.4D, pT53 was higher at night than during the day (p=0.009). No changes 
were observed for pS71 or total NCC (data not shown). The effect on pT53 was more 
variable than in the males, possibly due to heterogeneity of the oestrous cycles. Studies in 







Figure 3.4: Western blots for (A) pT53 NCC, (B) pS71 NCC, (C) total NCC in male 
C57BL6 mice and (D) pT53 NCC in female C57B6L6 mice and their corresponding 
densitometry analyses.  
Data are mean ±95% CI. Unpaired Student’s t tests were carried out on the densitometry 
analyses ****p<0.0001 **p0.001 ns p>0.05 (n=6) 
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3.3.5. Diurnal rhythm of renal mRNA transcripts 
Of 21 transcripts assessed, 5 were upregulated at night compared to day, including the clock 
genes: per2, cry1 and bmal1 (Figure 3.5). Both glucocorticoid-induced genes, SGK1 and 
GILZ were upregulated at night. None of the genes within the NCC regulation cascade were 
different at night, which is perhaps unsurprising as the proteins encoded by these genes are 
regulated on an acute scale by post-translational modifications such as phosphorylation. 
 
 
Figure 3.5: Renal gene expression in C57BL6 mice culled at night or during the day.  
Gene expression of each gene was normalised to the average expression of 18S, TBP and 
HPRT. Data are mean±95% CI. ****p<0.0001, ***p<0.001 with Sidak post hoc tests (n=15). 
 
The gene expression data sets were further analysed using correlation to identify transcripts 
whose expression associated with NCC pT53. This analysis was performed “within group” 
for day and night to avoid “between group” correlation, which is almost certainly present in 
many of the samples [149]. During the day, no positive correlations were identified (Table 
3.2); Stk39 (SPAK KS) displayed a moderate negative correlation with the level of NCC 
phosphorylation at T53. During the night several genes were positively correlated at a 
moderate level: per1, per2, clock, Nr3c2 (but not Nr3c1), Oxsr1 and Slc12a3. Stronger 
positive correlations were found between pT53 NCC and stk39 (SPAK-L) and SGK1.    
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Table 3.2: Correlation between phosphorylation at T53 and expression of genes 
involved in the circadian clock, corticosterone action and NCC regulation cascade. 
 
3.3.6. Circadian rhythm of corticosteroids 
Corticosteroids have a 24-hour rhythm. The following experiments aimed to define this 
rhythm, in the context of our ZT6 and ZT18 culls.  
 
3.3.6.1. Rhythm of plasma corticosterone 
Figure 3.6A, illustrates the general rhythm of plasma corticosterone in C57BL6 mice. It is a 
composite data set composed from a mixture of terminal or conscious plasma samples taken 
from several different groups of C57BL6 mice. Plasma corticosterone reached a peak of 
~300 nmol/l at ~ZT12 and a nadir of ~50 nmol/l at approximately ZT0 (Figure 3.6A).  Blue 
  DAY NIGHT 
 Gene Pearson’s r 
value 











per1 +0.34 0.22 +0.58 0.022 
per2 +0.12 0.67 +0.53 0.043 
clock-201 -0.042 0.88 +0.57 0.026 
cry1 -0.081 0.77 -0.13 0.63 
cry2 0.089 0.75 +0.48 0.072 











n sgk1 (SGK1) +0.12 0.67 +0.65 0.0082 
TSC22d3 (GILZ) +0.24 0.40 +0.51 0.052 
Nr3c2 (MR) +0.27 0.31 +0.57 0.023 
Nr3c1 (GR)  -0.32 0.24 +0.46 0.086 













Slc12a3 (NCC) +0.015 0.96 +0.55 0.034 
Oxsr1 (OSR1) -0.0046 0.99 +0.59 0.021 
Stk39 (SPAK-L) +0.31 0.27 +0.62 0.014 
Stk39 (SPAK-KS) -0.53 0.041 +0.30 0.28 
Wnk1 (WNK1-L) -0.19 0.49 +0.33 0.23 
Wnk1 (WNK1-KS) -0.23 0.42 +0.25 0.38 
Wnk4 +0.45 0.092 +0.44 0.11 
Nedd4  +0.15 0.60 +0.35 0.20 
Cab39 (MO25-α) -0.12 0.67 +0.37 0.17 
Cul3 (cullin3) -0.11 0.69 +0.35 0.20 
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arrows indicate the times of culls. Assessing only the plasma samples taken at these times 
(ZT 6 and ZT 18) in either conscious (Figure 3.6B) or terminal (Figure 3.6C) experiments, a 
trend towards elevated plasma corticosterone at ZT 18 is seen. This was statistically 
significant in the terminal samples (p=0.013) but failed to reach threshold (p=0.062) in 
conscious mice.  
 
Figure 3.6: Plasma corticosterone levels in C57BL6 mice. 
(A) Composite graph of plasma samples taken from several groups of mice, (B) 
corticosterone measured in terminal plasma samples, (C) corticosterone measured in tail 
micro-samples in conscious animals. Data are mean ±95% CI. Unpaired t-tests were carried 
out on terminal samples (B, n=22), paired Student’s t tests were carried out on conscious tail 
micro-sampling groups (C, n=8). No statistical analyses carried out on composite graph as 





3.3.6.2. Diurnal rhythm of urinary corticosterone and aldosterone 
Plasma aldosterone was not measured, as the assay requires a volume of plasma that exceeds 
the volume we were able to obtain following the removal of both kidneys during the timed 
culls. As a surrogate for plasma aldosterone, urinary aldosterone excretion was measured in 
12-hour urine samples collected over the day (ZT 0 – ZT12) and night (ZT 12 – ZT 0) as a 
surrogate for plasma aldosterone [142]. As shown in figure 3.7 the urinary excretion of both 
aldosterone (Figure 3.7A p<0.01) and corticosterone (Figure 3.7B, p<0.0001) was 




Figure 3.7: Urinary aldosterone (A) and corticosterone (B) in 12-hour day and 12-hour 
night samples from C57BL6 mice.  
Urinary aldosterone and corticosterone was measured in pooled 12-hour urine from day and 
12-hour urine overnight, collected between ZT0 and ZT12 and ZT12 and ZT0 respectively. 
Data are mean ±95% CI. Statistical comparisons were made using paired Student’s t tests, 
****p<0.0001 **p<0.001 (n=10) 
 
3.3.7. Localisation of NCC, GR and 11βHSD2 in the kidney 
Given the differences in the urinary excretion of corticosterone and aldosterone 
(corticosterone excretion is ~100X greater than aldosterone), it would be expected that 
aldosterone should only exert specific effects on NCC phosphorylation if MR in DCT cells is 
protected by 11βHSD2. The DCT can be split into 2 segments, with 11βHSD2 defining 
“DCT2”, in which both NCC and ENaC are present [150] and absence of both 11βHSD2 and 
ENaC characterising DCT1. As we have recently described [86], 11βHSD2 and NCC 
seldom co-localise in the mouse. In each of the DCTs examined here co-localisation was 
only found on 1-2 occasions (Figure 3.8, illustrated by blue arrows). MR staining was sparse 
in the kidney but colocalised with NCC in all of the DCTs examined (Figure 3.9 A). GR was 
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abundantly expressed throughout the kidney and co-localised with NCC in all sections 
examined (Fig 3.9 B).  
 
Figure 3.8: Immunofluorescent staining for NCC (green) and 11HSD2 (red) in 3 (A-C) 
male C57BL6 mice 
High-powered views of yellow-boxed regions are given on the right where blue arrows 
indicate regions in which 11βHSD2 and NCC staining are within the same cell/tubule. Bar, 





Figure 3.9: Representative images of immunofluorescent staining of (A) NCC (green) 
and MR (red) and (B) NCC (green) and GR (red) in male C57BL6 mice.  
High-powered views of yellow-boxed regions are displayed. Bar, 100 µm in large top/bottom 










In this chapter the diurnal variation in food intake, renal sodium excretion and BP was 
assessed in male C57BL6 mice, finding that each of these variables was higher in the 
subjective night when the mice were active. NCC did not have a diurnal rhythm at either the 
mRNA or protein levels but phosphorylation of the transporter at a site critical for its activity 
was higher at night than day. Since it was found that MR in the DCT is not protected from 
GC activation by 11βHSD2, it is likely that corticosterone rather than aldosterone plays a 
dominant regulatory role for this transporter.  
 
3.4.1. Rhythms of BP, feeding and urinary excretion 
These experiments aimed to confirm the day/night differences in BP, activity, heart rate, 
feeding, drinking and urinary excretion in C57BL6 mice under our experimental conditions 
(as outlined in Methods 2.1.1). Our findings confirm that the animals were asleep during the 
day as the activity as measured by radiotelemetry was minimal and feeding, drinking and 
urinating was all reduced during the 12-hour day collection (ZT0-ZT12). At nighttime all the 
parameters investigated increased including BP, HR, activity, feeding, drinking and urinary 
excretion. This is in keeping with the literature for C57BL6 mice [148, 151, 152] and 
confirms that the conditions in these experiments facilitate normal behaviour, with minimal 
disturbance of circadian behavioural rhythms by husbandry staff or the experimenter.  
 
We have shown in this work that the excretion of sodium and potassium have a strong 
diurnal rhythm of excretion, with twice as much excreted at night compared to the day. Such 
rhythms of electrolyte excretion have been defined in animal models and humans for 
decades [148, 153, 154]. This rhythm is the product of both hormonal factors and rhythmic 
feeding and drinking as it still persists to some extent even if a constant sodium load is 
applied [153]. Furthermore several groups suggest that perturbations to this rhythm of 
excretion affect an individual’s ability to reduce BP while at rest, i.e. if not enough sodium is 
excreted during the active phase, then BP is maintained at a high level in order to excrete it 
in the inactive phase [26]. Indeed high nocturnal (in humans) BP is correlated strongly with 
nocturnal sodium excretion [25, 155, 156].  
 
3.4.2. NCC has a diurnal rhythm of phosphorylation  
The acrophase of SBP in these animals was ~ ZT 18 and nadir was ~ ZT 6. These two time 
points, at which BP was most different, were chosen as a starting point for timed culls to 
measure NCC phosphorylation. The major finding of this chapter was that NCC 
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phosphorylation has a diurnal rhythm with increased phosphorylation at T53 at night 
compared to day. Transcript levels of slc12a3 were unchanged as was total NCC protein at 
these time points. NCC requires phosphorylation at several key residues in its amino 
terminus for its activity. These include but are not limited to T53, T58 and S71. 
Phosphorylation at T53 is associated particularly strongly with transporter activity, as 
measured by thiazide-sensitive sodium current in cells [99, 157], and in thiazide renal 
clearance experiments in mice [86] and rats [158]. Therefore phosphorylation at T53 and 
often T58 is commonly used as a surrogate for transporter activity. However, caution must 
be taken as transporter activity (as measured by thiazide-sensitive sodium transport) in vivo, 
does not always correlate with phosphorylation [86, 159], this is further discussed in Chapter 
5. Our initial immunoprecipitation experiments indicated that in whole kidney homogenate, 
the antibody that recognises phosphorylation of T58 in NCC also recognises phosphorylation 
of residues in NKCC1 and NKCC2 (with all these proteins running at similar apparent 
molecular masses on SDS gels).  
 
Interestingly, while large changes were seen in pT53, no changes in phosphorylation were 
seen at the S71 site.  A similar finding was made with mice treated with chronic furosemide 
treated, which displayed increases in T58, T53 phosphorylation and thiazide-sensitive 
sodium transport but no differences in pS71 [86]. It is possible that phosphorylation at this 
residue is not critical for transporter activity; the evidence for its involvement is less 
convincing than for the other phospho-sites [99]. However, SPAK, which phosphorylates 
NCC does not appear to discriminate between T53, T58 and S71 in vitro. Therefore it is 
more likely that the S71 phospho-antibody is not as sensitive as the pT53 antibody.  
 
The circadian clock allows predictive adaptations that prepare the body for daily activity 
such as feeding. NCC reabsorbs around 5-10 % of the total sodium load and has key roles in 
maintaining sodium homeostasis. Sodium intake is at its highest during the active phase, 
during which sodium requirement is greatest for the maintenance of sodium gradients for the 
myriad of metabolic functions this facilitates such as nutrient absorption, muscle contraction, 
action potential firing etc.  Therefore it makes sense to have an activated transporter during 
the active phase to match body sodium levels with demand and compensate for insensible 
losses through defecation and sweating, which is also increased during activity. However, 
we haven’t tested whether NCC phosphorylation is a predictive adaptation or if it occurs as a 
result of increased activity or feeding. It is not clear what effect acute sodium or electrolyte 
intake, which mice would experience daily during their active phase, would have on NCC 
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phosphorylation. Work by Sorensen et al offers some insights[129]. This group initially 
showed that a gavage of sucrose and 2% potassium caused rapid and sustained NCC 
dephosphorylation (lasting up to 6 hours) but this was not seen with a high sodium gavage 
[129]. The maintenance diet used throughout our experiments in this chapter is 0.67% w/w 
potassium and so we are unlikely to get this dramatic dephosphorylation with nighttime food 
intake. The group also then fasted the mice and presented mouse diet containing either 2% 
potassium or 0.5% potassium, the latter of which is much akin to our diet. The 2% K diet 
caused rapid NCC dephosphorylation but the 0.5% diet did not markedly alter NCC 
phosphorylation. Therefore it is likely that the NCC phosphorylation rhythm is not merely a 
feeding induced phenomenon and that hormonal and other factors are at work to balance 
extracellular sodium.  
 
Two papers, published after this work was started, have also examined temporal differences 
in NCC expression. Uchida’s group employed a similar approach to ours but addressed the 
question with increased temporal resolution, culling groups of mice every 4 hours over a 24-
hour period. That study reported much lower variability in NCC expression and 
phosphorylation than found in our laboratory and also defined a diurnal rhythm of NCC 
phosphorylation, rather than total NCC [160]. However, the peak (ZT12) and nadir (ZT0) 
were phase shifted by about 6 hours compared to our study; no difference in NCC 
phosphorylation was reported at points corresponding to our culls. We cannot fully account 
for this difference, as the day/night feeding conditions were the comparable to ours. 
However the study does not define exactly which phospho-antibody was being used. Cross-
referencing their methods, it seems that only the pS71 is being employed.  This raises the 
intriguing possibility that pS71 has a different cycle of phosphorylation compared to pT53 
but this remains to be substantiated. Interestingly, based on their findings, the group suggest 
that NCC is switched off on waking up to ensure enough excretion occurs during the active 
phase to counteract intake and switches on at the beginning of the inactive period to ensure 
enough sodium is absorbed at night, when intake is reduced.   
 
The second paper examined NCC rhythm in healthy humans, measuring NCC expression in 
urinary exosomes over 5 time points from 7am to 11.30pm [161]. Exosomes are a specific 
sub-type of micro-vesicle, 20-100nm in diameter, which are released from most cells in the 
body [162]. In the kidney, exosomes are a major route of apical membrane protein excretion 
into the urine.  The assumption is that these exosomes therefore may give a snapshot of the 
protein abundance of the apical membrane. NCC activity peaks during active phase (day in 
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humans; night in mice) coinciding with greatest need in terms of requirement for 
reabsorption. There are major caveats to this study: the authors do not correct for urinary 
volume or creatinine and rely on the assumption that temporal differences in total urinary 
exosomal release will be minimal within the same subject. The subjects were allowed to eat 
and drink freely and there is no indication of when eating or drinking took place. Hydration, 
nutrition status and the resulting urinary flow rate and concentration are likely to affect the 
concentration of urinary exosomes, therefore this assumption that total exosomal release is 
constant throughout the day is likely an oversimplification. This is perhaps also hinted at in 
the observation that all the urinary exosomal proteins studied in the paper (aquaporin 2, 
prostatin, NCC) follow a similar temporal pattern of concentration, which could simply 
reflect the pattern of total exosomal release throughout the day.  
 
3.4.3. Transcriptional changes: links to NCC phosphorylation rhythm? 
A panel of 21 genes was chosen for qPCR analysis. The rationale behind the selection of 
these genes was threefold. In the first instance it was to confirm the mice had a “normal” 
circadian rhythm – as indicated by the differential expression of key clock genes (bmal1, 
per1, per2, cry1, clock). Next was to identify any genes within the known NCC regulation 
pathway that may be differentially regulated at our time points. The current paradigm for 
how these transcripts contribute to the regulation of NCC is outlined in Figure 3.10. Finally, 
NCC is known to be regulated by corticosteroids, therefore genes involved in corticosteroid 
action such as the receptors (MR, GR), inactivating enzyme (11βHSD2) and induced genes 
(SGK1, GILZ) were tested to investigate any changes in these that could be linked to NCC 
activity.  
 
Various transcripts including SGK1, GILZ, per2, bmal1 and cry1, were upregulated during 
the active phase at ZT18 compared to the inactive day phase at ZT6 in C57BL6 mice. This is 
consistent with microarray experiments performed by two independent groups [42, 43]. 
Hogenesh and colleagues allowed mice to “free run” in dark/dark settings and culled 3 mice 
every 2 hours and whole kidney was taken forward to microarray analysis [43]. The resulting 
microarray and RNAseq data is available on their database: 
http://bioinf.itmat.upenn.edu/circa/query.  All the genes with a significant difference in gene 
expression in our q-RT-PCR experiments exhibit strong circadian rhythms as assessed by the 
JTK_CYCLE algorithm, which is defined and described in detail [163]. Genes that have 
circadian expression but were missed by our timed culls include PER1, cul3, wnk1 and 
mo25α. This appears to be as a result of either their zenith being near the day:night transition 
 
 71 
(WNK1, PER1), or as a result of low amplitudes (CUL3, mo25). In Zuber’s work culls were 
made every 4 hours of mice exposed to dark/light conditions. The DCT/CNT and CCD were 
micro-dissected from the collected kidneys. In conflict with our results and those of 
Hogenesh, Zuber did not find any diurnal variation in SGK1 expression in either DCT/CNT 
or CCD sections, which is perhaps owing to the temporal resolution not being high enough 
or amplitude not large enough for detection in their experimental setup.  
 
 
Figure 3.10: Diagram illustrating the current paradigm for the regulation of the sodium 
chloride co-transporter (NCC) including implicated clock genes. 
Corticosteroid (C) induced MR or GR activation, dimerization and translocation to the 
nucleus, promotes the transcription of NCC and inhibits WNK4 expression following 
prolonged corticosteroid exposure. WNK4 is generally accepted to be an inhibitory 
regulatory kinase of NCC and how WNK4 is activated is still unknown. SGK1 and L-WNK1 
inhibit WNK4 and thus promote NCC activity through relief of WNK4-mediated inhibition of 
the STE20/SPS-1-related-proline/alanine-rich kinase and oxidative stress response kinase 1 
(SPAK/OSR1) complex. Mouse protein 25 (mo25) is a positive regulator of SPAK/OSR1. 
SGK1 is also postulated to inhibit Nedd4/2, which can also ubiquitinylate NCC. GILZ on the 
other hand acts in opposition to SGK1. Kidney specific WNK1 (KS-WNK1) is a negative 
regulator of L-WNK1 and thus promotes WNK4 driven inhibition of NCC. Further WNK4-
mediated inhibitory pathways include inhibition of the NCC-stimulatory kinase WNK3 and 
stimulation of inhibitory protein ERK1/2 and the adaptor protein 3 (AP3). AP-3 facilitates 
lysosomal transport and thus WNK4 redirects NCC to the lysosome. Cullin 3 (CUL3) acts to 
promote NCC ubiquitinylation. Per1 has recently been shown to promote NCC and WNK1 
transcription and prevent the binding of clock and per2 to the WNK4 promoter. (Red 
connectors represent inhibition through phosphorylation (P) or otherwise, while green arrows 
indicate stimulation by phosphorylation (P) or otherwise. Interrupted green arrows represent 
unknown or controversial events, *indicates transcripts that were positively correlated with 





It is intriguing that many genes within the NCC regulation cascade that promote NCC 
activation, such as SPAKL, OSR1, WNK1, WNK4, N3cr2 (MR) are positively correlated with 
NCC phosphorylation at night, when phosphorylation is high but not during the day, when 
the system may be in a dormant or “off” state. Transcripts that positively correlated with 
NCC phosphorylation are highlighted in Figure 3.10 (with an asterix). pNCC is also 
correlated strongly with clock genes: PER1, PER2 and clock-201. Richard’s et al recently 
explored how the circadian clock may integrate with the downstream NCC regulatory 
pathways [56]. This group showed that PER1 regulated NCC transcription in vivo and 
pharmacological inhibition of PER1 nuclear entry (by inhibiting its phosphorylation with the 
drug casein kinase 1delta/epsilon) reduced NCC and WNK1 mRNA but increased WNK4 
mRNA [56]. They went on to demonstrate that PER1 block increases levels of Cry1/Cry2 
and Per2 mRNA. This PER1 blockade also increased occupancy of CLOCK and PER2 on 
the WNK4 promoter and decreased occupancy in the WNK1 promoter and Slc12a3 (NCC) 
promoter in mDCT15 cells. WNK1 is constitutively active upon expression and promotes 
NCC phosphorylation through the activation of SPAK/OSR1, which in turn phosphorylates 
NCC. It is therefore feasible that an increase in WNK1 mRNA could promote NCC 
phosphorylation over a relatively short period. This is particularly interesting in light of our 
work, as we’ve shown that although PER1 is not differentially expressed at our time points, 
it is strongly correlated with pNCC at night. 
 
3.4.4. Regulation of NCC phosphorylation rhythm by corticosteroids 
Both plasma corticosterone and aldosterone have similar circadian rhythms and both can 
bind the MR and GR, which are expressed in the DCT. In Uchida’s temporal NCC 
phosphorylation experiments, blockade of the MR using eplerenone, attenuated the rhythm 
of NCC phosphorylation [160]. GCs are well known to entrain local clocks in peripheral 
tissues [75] [164] [44, 74] and circulate at levels 100-1000 times greater than that of 
aldosterone [165]. The enzyme 11βHSD2 acts like a specific pre-receptor blocker of GC 
access, presumably to both receptors and it confers aldosterone sensitivity to the distal 
nephron. However the data in this chapter suggest that 11βHSD2 and NCC co-expression is 
limited. This confirms recent micro-dissection experiments performed in this lab [130] and 
other studies in reporter mice [87]. This suggests that NCC is GC sensitive, but the receptor 
through which GCs act is unknown. In light of Uchida’s work, one would speculate GCs 
would act through MR rather than GR. GR and MR are nuclear receptors, acting like 
transcription factors in order to promote transcription or inhibition of multiple downstream 
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processes. These genomic actions take in the region of 1-6 hours [166-168] and therefore we 
could expect this length of delay between the corticosterone zenith and downstream events. 
This fits with our work where marked NCC phosphorylation is preceded by a corticosterone 
peak 6 hours prior.  
 
It is important to note that, several other hormonal systems can induce phosphorylation of 
NCC including angiotensin II [169], AVP [97] and renal sympathetic nerve activity [104]. 
Although these hormonal systems also have circadian rhythms of release [170-173] and may 
contribute to the rhythmic control of NCC, their role was not investigated during my PhD 
studies.  
 
3.4.5. Summary of Chapter Findings: 
1. NCC phosphorylation at T53 has a diurnal rhythm 
2. Genes associated with the circadian clock and glucocorticoid action are also upregulated 
at our time points 
3. Plasma corticosterone levels are marginally raised at ZT18 compared with and ZT6 but 
peak at approximately 6hours prior to ZT18, giving enough time for genomic actions to 
occur and trigger downstream events that culminate in increased NCC phosphorylation. 






4. Effect of chronic GC manipulation on the diurnal rhythm of 
NCC phosphorylation  
4.1. Introduction 
In the previous chapter it was shown that NCC phosphorylation at T53 has a diurnal rhythm, 
with increased phosphorylation at night compared to the day in C57BL6 mice. There were 
correlations between NCC phosphorylation and corticosteroid-activated transcripts: SGK1 
and GILZ. Furthermore, urinary corticosterone was elevated at night with levels 200 times 
higher than urinary aldosterone. Although aldosterone can stimulate NCC phosphorylation 
[98, 99, 157], IHC experiments in the previous chapter indicate that the enzyme 11βHSD2 
seldom colocalises with NCC [87, 130].  Therefore the primary purpose of this chapter is to 
investigate the hypothesis that GCs regulate the diurnal rhythm of NCC phosphorylation.  
 
Two different approaches were taken to investigate this hypothesis. The first was examine 
the effect of adrenalectomy (ADX) on the diurnal rhythm of NCC phosphorylation. ADX 
reduces circulating aldosterone, GCs and catecholamines. Therefore we complemented this 
strategy with a more refined approach in adrenal intact animals, in which the diurnal rhythm 
of plasma corticosterone specifically was attenuated and plasma levels clamped within a 
mid-physiological range. The rationale behind this approach was that the rhythmicity of 
other adrenal hormone levels might still persist.  
 
4.1.1. Specific chapter aims 
1. Investigate whether ADX affects the diurnal rhythm of NCC phosphorylation and 
the abundance of key transcripts within the NCC regulation cascade, corticosteroid 
pathway and circadian clock  
2. Investigate whether clamping plasma corticosterone levels in adrenal intact mice 
affects the diurnal rhythm of NCC phosphorylation, abundance of key transcripts 
within the NCC regulation cascade, corticosteroid pathway and circadian clock and 





Detailed methods of each of the procedures in this chapter are outlined in the main methods 
section. For clarity, an outline of the experiments carried out and cohorts of mice used are 
presented here. 
 
4.2.1. Timed culls in adrenalectomised mice 
ADX was performed under isofluorane anaesthetic (Methods 2.7.1) after which these mice 
and adrenal intact controls were individually housed and allowed to recover and acclimatise 
for 9 days prior to timed culls. Following ADX mice were given ad libitim access to 0.9% 
saline as well as water. 9 days is sufficient for recovery and restoration of circadian rhythms 
of BP post anaesthetic yet should be before extra-nodular adrenal tissue regrowth [174]. As 
in the previous chapter these mice were then culled at 1am (ZT18) and 1pm (ZT6). Mice 
were culled on two separate days (batch 1 and batch 2), with 3 ADX and 3 intact animals 
culled each time to make up 6 in each group. Details of the cull and techniques used to 
analyse the tissue are presented in (Methods 2.3 and 2.4). A separate cohort of 4 ADX and 4 
adrenal intact mice underwent tail venesection for blood micro sampling at 7.15am (ZT 
0.15) and 6.45pm (ZT 11.45). ADX animals were not subject to the additional stress of 
metabolic cage experiments, due to welfare concerns. ADX animals are more prone to 
sudden death from adrenal insufficiency as they are unable to mount a full stress response. 
Saline intake was assessed by weighing water bottles daily on days 6-7 post-ADX.    
 
4.2.2. Metabolic cage and tail micro-sampling in mice implanted with 
corticosterone or vehicle pellets 
Corticosterone or vehicle pellets were subcutaneously implanted into C57BL6 mice under 
isofluorane anaesthetic (Methods 2.7.2). The mice were then individually housed in standard 
cages and allowed to recover for 5 days. Tail venesection was performed to sample blood at 
7.15am (ZT 0.15) and 6.45pm (ZT 11.45) on day 6. The animals were then housed in 
metabolic cages with a 12hour light/dark cycle and allowed to acclimatize for 5days. Food 
and water intake was measured and urine collected for 12-hour periods over 2 consecutive 
days (ZT0-12 “Day” and ZT12-0 “Night”). Details of the techniques used to analyse the 
urine samples are presented in (Methods 2.5).  
 
4.2.3. Timed culls of mice implanted with corticosterone or vehicle pellets 
Corticosterone or vehicle pellets were subcutaneously implanted into C57BL6 mice. Mice 
were pair housed and allowed to recover for 5 days. On day 5, the mice were culled at 1am 
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(ZT 18) and 1pm (ZT 6). Mice were culled on 3 separate days (batch 1-3), with 3 
corticosterone and 3 vehicle-treated mice culled at a time to make up 9 in each group. 




4.3.1. Effect of Adrenalectomy (ADX) on plasma corticosterone 
Figure 3.1A illustrates the reduction of corticosterone achieved by ADX in C57BL6 mice 9 
days following ADX surgery. It is a composite data set composed from a mixture of terminal 
or conscious plasma samples taken from several groups of adrenal intact or ADX C57BL6 
mice. Blue arrows indicate the times of culls. Assessing the plasma samples taken at these 
times (ZT 6 and ZT 18) in terminal experiments, plasma corticosterone was elevated at ZT 
18 in the intact group compared to the ADX animals but corticosterone levels were 
comparable at ZT 6 (Figure 3.1B).  
 
In a separate cohort of conscious mice, blood samples were taken via tail venesection at ZT 
0 and ZT 12  (Figure 4.1C). In intact mice, plasma corticosterone increased 4 fold at ZT 12 
compared to ZT 0 (p<0.0001, Figure 4.1C), whereas no such increase was seen in ADX mice 
(p>0.05, Figure 4.1C). Increased saline appetite is well described in ADX rats [175] but no 
such appetite has been found in mice [176]. Here we found that ADX animals drank ~ 2 fold 
greater proportion of saline than the intact animals (p=0.0004, Fig 4.1D). In terms of 
absolute volumes, ADX animals drank more saline than the intact group (3.16 ±0.92 ml/48 
hour compared to 1.86 ±0.28 ml/ 48 hour, mean ±95%CI, p=0.016, by t test with Welch’s 
correction, n= 11 ADX, n= 12 intact) but also drank less water than the intact animals 
(7.720±1.115 ml/48 hour compared to 9.80 ±0.66 ml/48 hour, mean ±95% CI, p=0.0015, by 
Student’s t test, n= 11 ADX, n= 12 intact).  The total fluid intake was not different (5.896 
±0.556 ml/48 hour compared to 5.59 ±0.47 ml/48 hour, mean±95% CI, p=0.37, by Student’s 







Figure 4.1: Composite graph of 24-hour plasma corticosterone in adrenal intact and 
adrenalectomised (ADX) mice (A), plasma corticosterone measured in terminal (B) and 
conscious (C) experiments and saline preference (D) in intact and ADX mice. 
Composite graph includes all samples taken in control mice (n=8-29). The terminal and 
conscious samples were taken from 2 different cohorts of ADX or adrenal intact mice (n=6 & 
n=4 respectively). Saline and water intake was measured over 2 days (day 6-7 post ADX). 
Saline intake here is expressed as a % of total fluid intake. Two-way ANOVA was carried out 
on data from terminal experiments, and matched two-way ANOVA carried out on the 
conscious experiments, with post hoc Sidak tests used for both. Saline intake data were 
analysed by t test with Welch’s correction for unequal variance. ****p<0.0001, ***p<0.001 ns, 










4.3.2. Effect of ADX on the diurnal rhythm of NCC phosphorylation 
As shown in Figure 4.2A & 4.3A, NCC phosphorylation at T53 was significantly higher at 
night compared to day in the adrenal intact group. This difference was absent in the 
adrenalectomised group and phosphorylation levels were not significantly increased at night. 
There were no day/night changes in pS71 levels in either the intact or ADX group, however 
levels of the phosphoprotein were significantly reduced by at nighttime compared to controls 
(Figure 4.2 & 4.3B). Total NCC protein was reduced at both night and day in the 
adrenalectomised group compared to the intact group (Figure 4.2 & 4.3C). 
 
 
Figure 4.2: Densitometry analysis of western blots for pT53 NCC (A), pS71 NCC (B) 
and total NCC (C) in intact and adrenalectomised (ADX) mice culled at night (ZT 18) or 
during the day (ZT 6). 
Data presented as mean±95% CI. Two way ANOVA was performed with post hoc Sidak 





Figure 4.3: Western blots for (A) pT53 NCC, (B) pS71 NCC and (C) total NCC in intact 
and adrenalectomised (ADX) mice culled at night (ZT 18) or during the day (ZT 6). 
Western blots were performed in 2 batches. A sample from the first batch was ran again in 
the third batch and used as a reference lane to normalise across the batches. ½ and 2x are 









4.3.3. Effect of ADX on the diurnal variation of renal mRNA  
Nine genes were selected from the larger panel of 21 candidate genes presented in chapter 3, 
for testing in this intact and ADX experimental cohort. These genes were selected on the 
basis that they were either: i) shown to be differentially expressed between day and night in 
Chapter 3; or ii) are key transcripts within the NCC regulation pathway (slc12a3 and 
WNK4). ADX had little effect on the diurnal rhythms of the selected genes. GILZ had a 
blunted diurnal rhythm in the ADX group, but all other rhythms of clock genes were similar 
between the intact and ADX group (Figure 4.4). SGK1 was not differentially expressed 
between day and night in either ADX or intact animals.  
 
Figure 4.4: Gene expression in kidneys of adrenalectomised (ADX) and adrenal intact 
C57BL6 mice culled at night (ZT 18) or during the day (ZT 6). 
Protein the gene transcribes is in brackets. Gene expression of each gene was normalised 
to the average expression of 18S, TBP and HPRT. Data are mean±95% CI. Data was 
analysed with two way ANOVA followed by post hoc Sidak tests, where ***p<0.001, **p<0.01 
*p<0.05, ns p>0.05 (n=5-6) 
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4.3.4. Effect of chronic corticosterone treatment on plasma corticosterone 
levels 
Adrenalectomy reduces to various degrees the level of endogenous glucocorticoids, 
mineralocorticoids and catecholamines [177-180]. In order to assess whether corticosterone 
in particular affects the rhythm of NCC phosphorylation in C57BL6 mice, the levels of 
plasma corticosterone were clamped at a constant physiologically intermediate between the 
normal peak and nadir.  Figure 4.5 C illustrates the midpoint level of plasma corticosterone 
achieved using silastic slow release pellets. It is a composite data set composed from a 
mixture of terminal or conscious plasma samples taken from several different groups of 
C57BL6 mice with or without subcutaneous slow release pellet implants.  
 
Blue arrows indicate the times of culls. Assessing only the plasma samples taken at these 
times (ZT 6 and ZT 18), corticosterone pellets significantly increased the plasma 
corticosterone levels at ZT 6 (Figure 4.5 A). In a separate cohort of mice, blood samples 
were taken at the known trough (ZT0) and peak (ZT 12) time points for plasma 
corticosterone levels. In vehicle treated mice a significant difference was seen in plasma 
corticosterone in blood sampled by tail venesection at ZT 0 compared to that from ZT 12 
(Figure 4.5C) but this was not seen in the corticosterone treated animals, which exhibited 
slightly higher day time plasma corticosterone and slightly lower night time corticosterone 





Figure 4.5: Composite graph of 24-hour plasma corticosteorne in control mice and 
mice receiving chronic corticosterone (A), plasma corticosterone measured in 
terminal (B) and concious (C) experiments. 
Composite graph includes all samples taken in control mice (n=8-29). The terminal and 
conscious samples were taken from 2 different cohorts of corticosterone or vehicle treated 
mice (n=9 & n=4 respectively). Two-way ANOVA was carried out on data from terminal 
experiments, and matched two-way ANOVA carried out on the conscious experiments, with 
post hoc Sidak test results for both indicated by ***p<0.0001, ***p<0.001 ns, p>0.05. No 





4.3.5. Effect of chronic corticosterone administration on urinary 
corticosterone and aldosterone 
In the absence of sufficient plasma for the measurement of aldosterone, urinary aldosterone 
as measured urine samples taken over 12-hour night (ZT 0 - ZT 12) and 12-hour day (ZT 0 –
ZT 12) was used as a surrogate. Urinary aldosterone exhibited a diurnal rhythm of excretion 
with significantly more excreted during the night than the day in both corticosterone and 
vehicle treated groups (Figure 4.6 A). In contrast, the diurnal rhythm of urinary 
corticosterone was absent in corticosterone treated animals (p>0.05, Figure 4.6 B) but 
present in vehicle treated animals (p<0.01 for day/night differences in urinary corticosterone, 
Figure 4.6 B).  
 
 
Figure 4.6: Urinary aldosterone (A) and corticosterone (B) in C57BL6 mice receiving 
chronic vehicle or corticosterone treatment. 
Urinary aldosterone and corticosterone was measured in pooled 12-hour urine samples from 
day and 12-hour urine overnight, collected between ZT0 and ZT12. Data presented as 
mean±95% CI. Data analysed by matched two way ANOVA with post hoc Sidak’s tests 
where **p<0.01 (vehicle) ##p<0.01 (corticosterone) ns p>0.05 (n=4). 
 
4.3.6. Effect of chronic corticosterone administration on the diurnal rhythm of 
NCC phosphorylation 
There was batch variability as seen in Figure 4.7 and 4.8 but overall NCC phosphorylation at 
pT53 was significantly increased at night compared to day in the vehicle treated group and 
this difference was not present in the corticosterone-treated group. Furthermore, NCC 
phosphorylation at pT53 was significantly raised during the day in corticosterone-treated 
animals (p<0.001, Figure 4.7A). Total NCC protein was unchanged by any of the treatments 
or at any of the time points (Figure 4.7C). pS71 NCC exhibited a significant difference 
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between night and day in the vehicle treated group (p<0.01, Figure 4.7 B) which was not 
present in the corticosterone treated animals (p>0.05, Figure 4.7 B).  
 
 
Figure 4.7: Densitometry analysis of western blots for pT53 NCC (A), pS71 NCC (B) 
and total NCC (C) in vehicle and corticosterone treated mice culled at night (ZT 18) or 
during the day (ZT 6). 
Data presented as mean±95% CI. Two way ANOVA was performed with post hoc Sidak 
tests where ****p<0.0001, ***p<0.001 **p<0.01 and ns p>0.05.  
 
Figure 4.8 (overleaf): Western blots for pT53 NCC (A) pS71 NCC (B) and total NCC (C) 
in vehicle and corticosterone treated mice culled at night (ZT 18) or during the day (ZT 
6). 
Westerns were performed in 3 batches (1-3). “R” is reference load, which was a pooled 












4.3.6. Effect of chronic corticosterone administration on the diurnal 
regulation of renal mRNA transcripts 
Nine genes were selected from the larger panel of candidate genes presented in chapter 3, for 
testing in this experimental cohort. As with the initial experiments, we found no differences 
in slc12a3 (NCC), WNK4 or clock-201 mRNA between night and day in any of the 
treatment groups (Figure 4.9). Both GILZ and SGK1 were significantly increased during the 
day in the corticosterone group compared to the vehicle group. Clamped plasma 
corticosterone levels affected several clock genes, such as bmal1 and cry1, which were 
moderately increased during the day in the corticosterone-treated group compared to the 
vehicle group (Figure 4.9). Per2 mRNA was unaffected by corticosterone treatment and the 
diurnal rhythm was maintained. However, Per1 mRNA levels were increased at both day and 






Figure 4.9: Gene expression in kidneys of corticosterone (Cort) or vehicle treated 
C57BL6 mice culled at night (ZT 18) or during the day (ZT 6). 
Protein the gene transcribes is in brackets. Gene expression of each test gene was 
normalised to the average expression of 18S, TBP and HPRT. Data are mean ± 95% CI. 
Data were analysed with two way ANOVA followed by post hoc Sidak tests, where 




4.3.7. Effect of chronic corticosterone administration on the diurnal rhythm of 
feeding and drinking 
Both treatment groups exhibited modest diurnal differences in food and water intake and 
urine output, with no significant differences between treatment groups but a significant 







































Food (A) and water intake (B) and urine output (C) over 2 consecutive days and nights 
in C57BL6 mice treated with corticosterone or vehicle.  
All measured between ZT0 and ZT12 (day) and ZT12 and ZT 0 (night). The mean of the two 
days and nights is displayed in the right hand panel. Data are presented as mean±95% CI. 
Data were analysed by matched two way ANOVA where ***p<0.001, *p<0.05, ns p>0.05.  
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4.3.8. Effect of chronic corticosterone administration on the diurnal rhythm of 
electrolyte excretion 
Urinary sodium excretion exhibited a strong diurnal rhythm in both corticosterone and 
vehicle treated groups (Figure 4.11 A). However, the corticosterone group had small but 
significant and reproducible reduction in sodium excretion during the night but interestingly 
not during the day when we see the NCC phosphorylation difference (Figure 4.11 A). There 
was no difference in overall mean 24-hour sodium balance over the 2 days, although faecal 
sodium was not measured (vehicle group values were 268.3±46.5 µmol/24 hour versus 
corticosterone group values of 280.3±62.6 µmol/24 hour with p= 0.64, by Student’s t test, 
n=4).  Potassium excretion was similar in both treatment groups with a strong diurnal rhythm 
of excretion (Figure 4.9 B).  
 
Figure 4.11: Sodium (A) and potassium output over 2 consecutive days and nights in 
C57BL6 mice treated with corticosterone or vehicle. All measured between ZT0 and 
ZT12 (day) and ZT12 and ZT 0 (night). The mean of the two days and nights is displayed in 
the right hand panel. Data presented as mean±95% CI. Data was analysed by two way 





In this chapter the diurnal rhythm of NCC phosphorylation was found to be dependent upon 
a diurnal rhythm of plasma corticosterone. ADX, which reduced circulating GCs, reduced 
the NCC phosphorylation level and rhythm, whereas clamping corticosterone within a 
physiological intermediate range “held” NCC phosphorylation at a higher level.  
 
4.4.1. Effect of ADX on levels of plasma corticosterone  
Plasma corticosterone levels were significantly reduced compared to the control animals at 
the peak (ZT 12) and differences between plasma corticosterone levels at the time of cull 
(ZT 6 and ZT 18) were also not present in the ADX animals. Levels within this range 54.6 
±6.6 nmol/l (mean ±SEM) are consistent with literature reported values of <55nmol/l [181] 
and 61.2 ±13.0 nmol/l (mean ±SEM) [174]. While ADX removes a major source of 
corticosterone production, there are extrarenal sources, which still produce corticosteroids 
(reviewed in [182]). It is not clear whether this extra-adrenal corticosteroid excretion 
exhibits a circadian pattern of release but in these cohorts any diurnal rhythmicity of plasma 
corticosterone was blunted. Other plasma hormones levels that may be affected by ADX 
include aldosterone and epinephrine. These were not measured here due to welfare concerns 
but the literature suggests that ADX reduces aldosterone and epinephrine levels by at least 5 
fold [181] and 20 fold respectively [183].  
 
4.4.2. Effect of ADX on NCC phosphorylation, total protein and mRNA 
The level and rhythm of NCC phosphorylation was significantly blunted in ADX animals 
compared to intact animals, with NCC phosphorylation being comparable during the day but 
failing to increase at night. Total NCC protein was significantly reduced at both time points 
but surprisingly mRNA was no different between ADX and intact animals. There was a 
reduction in total protein levels following ADX and this is consistent with the idea that 
adrenal hormones are required for the basal tone of thiazide-sensitive sodium transporter 
activity. It is curious that no changes were detected in mRNA, a phenomenon that has been 
reported previously by others [121, 184, 185]. One predicts that a similar quantity of NCC 
mRNA is produced and therefore there are two potential explanations for the changes seen in 
total protein: either a smaller proportion is translated or a significant amount of the protein 
product is turned over in the absence of adrenal hormones. The latter seems more feasible as 
NCC is constitutively internalised and phosphorylation both reduces this process of 
internalisation [101] and seems to protect NCC from ubiquitinylation through CUL3, 




4.4.3. Effect of ADX on diurnal changes of renal transcript abundance 
The adrenal gland has been described as the main temporal mediator of peripheral tissue 
oscillators [187] but intriguingly, ADX appeared to have very little effect on any of the renal 
transcripts examined here: differentially expressed genes that were present in the adrenal 
intact animals exhibited similar expression patterns in the ADX animals. It is possible that 
extra-adrenal corticosteroid sources release hormone rhythmically, but its amplitude was too 
low for detection in our setup but was enough to entrain the renal clock. However, whether 
extra-renal corticosteroid production exhibits rhythmicity is presently unknown. The second 
possibility is that the kidney has an intrinsic and autonomous clock that maintains a 24-hour 
rhythm that can oscillate independently of external cues if these cues are below a certain 
threshold. There are several lines of evidence that support the latter argument. ADX or 
specific targeted ablation of the adrenal clock does not abolish the rhythm of most renal 
clock genes, including clock, per2, bmal1 [75, 187] but does affect the rhythm of PER1 [75, 
187] [72]. In the current chapter, detectable changes in PER1 expression in intact animals 
were not found at our time points. The circadian rhythm of PER1 has been defined with the 
circadian gene expression atlas (CIRCA: http://bioinf.itmat.upenn.edu/circa/). The CIRCA 
data by Hogenesch and colleagues indicate that our time points, ZT6 and ZT 18 are likely 
during the trough of PER1 expression in the kidney [43]. Therefore it is perhaps unsurprising 
that no major differences were detected in per1 expression in this setting.   
 
4.4.4. Effect of ADX on sodium balance 
Welfare concerns prevented a metabolic cage experiment for an analysis of urinary output 
and sodium balance in these ADX versus intact animals. The literature does offer some 
insight. Previous findings in cats [188], dogs [189] and humans [190] have shown that ADX 
causes hyponatremia and volume constriction attributed to natriuresis and diuresis [191]. All 
ADX animals exhibit some degree of salt wasting, although morbidity and mortalities appear 
to be prevented by the replacement of drinking water with 0.9% saline. Consistent with the 
literature [192], the ADX animals in these experiments had a salt appetite. In rats, the 
circadian rhythm of sodium excretion was only mildly perturbed by ADX with acrophase 
appearing ~3 hours earlier with period comparable with intact rats [193]. Total sodium or the 
amplitude of sodium excretion in this case was not reported. Other transporters are also 
affected by ADX: the epithelial sodium transporter gamma subunit is markedly reduced in 




In conclusion, the activity of sodium transporters is clearly reduced in ADX animals. The 
work in this chapter has further demonstrated this in the reduction of NCC phosphorylation 
following ADX. However, the rhythmicity of sodium excretion is likely to persist, 
conceivably through the action of a retained autonomous renal clock affecting renal function 
but also perhaps as a result of the retention of normal circadian patterns of feeding and 
drinking behaviour.  
 
4.4.5. Effect of chronic corticosterone treatment on plasma and urinary 
corticosterone and urinary aldosterone 
Corticosterone levels were effectively clamped at an intermediate level using silastic slow 
release pellets, with daytime plasma levels markedly raised and nighttime levels slightly 
dampened. The day/night difference in urine corticosterone excretion levels was also 
markedly reduced in the corticosterone pellet group compared to the vehicle treated animals. 
The other major corticosteroid, aldosterone is unlikely to have been greatly affected by 
corticosterone in this context. Corticosterone feedback mechanisms may reduce ACTH 
levels, which could in turn affect the rhythm of aldosterone synthesis. However, several 
experiments in humans suggest that the circadian rhythms of ACTH and aldosterone are 
uncoupled, with aldosterone being more reliant on levels of angiotensin II and renin 
secretion in non-diseased states [195, 196]. Our data is in agreement with this, as 
corticosterone pellets, which may conceivably reduce ACTH levels, had no effect on the 
urinary excretion levels of aldosterone.  
 
4.4.6. Effect of chronic corticosterone treatment on NCC phosphorylation and 
total NCC 
The rhythm of NCC phosphorylation at T53 was perturbed in the corticosterone-clamped 
mice. The vehicle treated mice exhibited a robust difference in phosphorylation at pT53 at 
night compared to the day. Interestingly, a small difference in phosphorylation was also 
found at S71 in the vehicle treated group. It is unclear why this may be the case in these 
control animals but not in the previous cohort but one possible explanation is that the slightly 
larger sample size permitted the detection of this change. Again, this difference in pS71 was 
not seen in the corticosterone-treated animals. No change in total protein was seen in either 
treatment group. This either indicates that glucocorticoids cannot alter NCC protein levels 
but activate an existing pool controlled by other systems, or that the intermediate levels of 
GC over 5 days was not of long enough duration or magnitude to evoke a change in protein 
levels. There is currently no data in the literature describing the long-term effects of GC on 
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total NCC protein levels. But salt restriction, accompanied by an increase in both aldosterone 
and angiotensin II, evoked an increase in total NCC within 3 days in rats [197]. Our analysis 
was performed after 5 days; therefore it’s likely the small physiological change in GC levels 
was not a large enough stimulus to evoke total protein changes. Other investigators attribute 
the diurnal rhythm of NCC phosphorylation to aldosterone [160] showing that chronic MR 
blockade (with eplerenone) abolishes the phosphorylation rhythm. This does not necessarily 
prove aldosterone is causal as GCs can bind both MR and GR, but it does suggests that MR 
regulates the diurnal rhythm of NCC.  
 
4.4.7. Effect of chronic corticosterone treatment on the diurnal variation of 
renal transcripts 
Both GILZ and sgk1 expression was increased only during the daytime in corticosterone-
treated mice. This is consistent with the idea that the corticosterone treatment clamped 
various genes “ON”. Sgk1 and GILZ are expressed throughout the kidney. Sgk1 has a key 
role in both NCC and ENaC regulation, promoting the increase of both transporters’ activity. 
GILZ acts to recruit and stabilise SGK1 in the ENaC regulatory pathways [198]. The effect 
of GILZ in the NCC regulatory cascade is not well defined but appears to oppose the activity 
of sgk1 [199]. It is unclear therefore why GILZ was upregulated at night in our vehicle 
treated animals and during both night and day in our corticosterone treated animals, when 
NCC phosphorylation is increased. GILZ could be acting as part of a negative feedback 
system, acting in opposition to sgk1 to begin the process of turning NCC phosphorylation 
off. Another explanation is that since the qPCR data presented here are from whole kidney; 
these changes could reflect an increase in GILZ expression in other parts of the nephron. 
Indeed the pattern of the GILZ circadian rhythm is considerably shallower and very slightly 
phase shifted in CCD compared to DCT/CNT segments [42].  
 
While ADX did not affect circadian clock genes, clamped plasma corticosterone levels 
increased the daytime levels of cry1 and bmal1 and induced per1 at nighttime and daytime 
while per2 expression rhythms were unchanged. Many studies have shown similar changes 
in clock genes following GC treatment [75, 187] [72]. Per1 is particularly affected by GCs 
and this may be directly relevant to NCC activation. A proposed working model for how 
clamped corticosterone may affect per1 and the downstream consequences is illustrated in 
Figure 4.12. Recently Richard’s et al demonstrated that per1 could bind to WNK1, WNK4 
and slc12a3 promoters [56]. No differences were found in NCC or WNK4 transcript in this 
chapter, but changes in WNK1-KS were not explored. WNK1-KS does not require 
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posttranslational modifications to be activated and therefore a change in its transcription 
could directly affect NCC phosphorylation, but this remains to be explored. The authors did 
not investigate any per1-induced posttranslational modifications of proteins within the NCC 
regulation cascade, so it remains to be seen whether these changes are possible or relevant.  
 
 
Figure 4.12: Diagram illustrating the current paradigm for the regulation of the sodium 
chloride co-transporter (NCC) including implicated clock genes. Enlarged arrows 
highlight the pathways affected by clamped corticosterone levels.  
Corticosteroid (C) induced MR or GR activation, dimerization and translocation to the 
nucleus, promotes the transcription of NCC and inhibits WNK4 expression following 
prolonged corticosteroid exposure. WNK4 is generally accepted to be an inhibitory 
regulatory kinase of NCC and how WNK4 is activated is still unknown. SGK1 and L-WNK1 
inhibit WNK4 and thus promote NCC activity through relief of WNK4-mediated inhibition of 
the STE20/SPS-1-related-proline/alanine-rich kinase and oxidative stress response kinase 1 
(SPAK/OSR1) complex. Mouse protein 25 (mo25) is a positive regulator of SPAK/OSR1. 
SGK1 is also postulated to inhibit Nedd4/2, which can also ubiquitinylate NCC. GILZ on the 
other hand acts in opposition to SGK1. Kidney specific WNK1 (KS-WNK1) is a negative 
regulator of L-WNK1 and thus promotes WNK4 driven inhibition of NCC. Further WNK4-
mediated inhibitory pathways include inhibition of the NCC-stimulatory kinase WNK3 and 
stimulation of inhibitory protein ERK1/2 and the adaptor protein 3 (AP3). AP-3 facilitates 
lysosomal transport and thus WNK4 redirects NCC to the lysosome. Cullin 3 (CUL3) acts to 
promote NCC ubiquitinylation. Per1 can promote NCC and WNK1 transcription and prevent 
the binding of clock and per2 to the WNK4 promoter. (Red connectors represent inhibition 
through phosphorylation (P) or otherwise, while green arrows indicate stimulation by 







4.4.8. Effect of chronic corticosterone administration on sodium handling 
Clamped plasma corticosterone reduced the amount of sodium excreted at nighttime. This 
was not an effect of altered sodium intake, as food intake was similar between groups. The 
literature has conflicting reports on the effect of GCs on sodium excretion. Chronic GC 
treatment evokes natriuresis, but can also activate anti-natriuretic sodium transporters in both 
the DCT [103] and the ASDN [200]. Systemic GR expression means that GCs have 
pleotropic actions that are often countervailing [92].  In this case a physiologically subtle 
change in GC levels did not drastically alter natriuresis but reduced natriuresis only at night. 
Conceivably this could be as a result of increased NCC activation although it is unclear why 
this is not temporally aligned with NCC activation (aberrant NCC activation as measured by 
phosphorylation levels occurs in corticosterone clamped animals at midday but dampened- 
natriuresis appears during the 12 hour night urine collection with no differences in the 12 
hour day collection). It is possible that our urine collections lacked the temporal resolution 
required to reveal any differences present during the day. During the daytime it is possible 
that the mice are retaining sodium but a reduction in micturition and bladder retention of 
urine that occurs during the day means that differences that may have occurred as a result of 
daytime sodium excretion can only be seen at night when this urine is voided. It is 
interesting that Bankir et al suggest that BP is raised during rest as a result of an inability to 
excrete sufficient sodium during wakefulness [26]. It certainly appears that there is reduced 
sodium excretion during wakefulness in corticosterone-clamped mice but whether this leads 
to changes in BP is yet to be determined.  
 
4.4.9. Summary of Chapter findings 
1) ADX blunted NCC phosphorylation rhythm and reduced the total NCC protein.  
2) Rhythms of clock proteins bmal1, cry1, per2 are retained in ADX animals 
3) The implantation of slow release corticosterone pellets suppressed the rhythmicity of 
plasma corticosterone without changing urinary aldosterone excretion.  
4) Clamped plasma corticosterone levels abrogated the diurnal rhythm of NCC 
phosphorylation at T53 without any changes in total NCC.  
5) Day time levels of Bmal1, cry1, GILZ and SGK1 were raised in mice with clamped 
corticosterone levels 
6) Both day and nighttime levels of per1 were increased while per2 was unaffected in 
mice with clamped corticosterone levels.  
7) Clamped plasma corticosterone caused perturbations in the rhythm of sodium 




5. Role of NCC and GCs in the circadian regulation of BP and 
sodium balance  
5.1. Introduction 
In the previous chapter it was shown that GCs affect the diurnal rhythm of NCC 
phosphorylation: NCC phosphorylation is inappropriately elevated during the day in mice 
with chronically clamped plasma corticosterone levels. NCC reabsorbs 5-10 % of the total 
filtered load and plays important roles in BP homeostasis. Therefore this chapter aims to 
investigate the functional consequences of this perturbed NCC phosphorylation rhythm.  The 
two major aims of the experiments in this chapter were to assess whether day and night 
differences in NCC phosphorylation translated into day and night differences in thiazide-
sensitive sodium transport and to investigate the effect of corticosterone clamping of NCC 
activity on the circadian rhythm of BP.  
 
To carry out these experiments we collaborated with iPRECIO (Japan, 
http://www.iprecio.com), a company that have designed state-of-the art programmable 
micro-osmotic minipumps (model SMP300, iPRECIO) suitable for implantation in mice. 
This product was in the late beta testing phase and we were one of the first centres to use 
these pumps in experimental animals.  This chapter addresses the series of experiments 
leading up to the design of a small pilot experiment using these programmable pumps.  
  
5.1.1. Aims 
1. To investigate whether there is a difference in thiazide sensitive sodium transport during 
the day compared to the night.  
2. To assess the effects of chronically clamped corticosterone and HCTZ treatment on BP, 
HR and activity.  
 
5.1.2. Strategy for addressing the chapter aims: 
1. A series of pilot experiments was designed in order to select an appropriate NCC inhibitor 
and dose for use in the beta phase testing experiments using iPRECIO micro-osmotic 
programmable mini-pumps. The second half of this chapter outlines the series of 
experiments and the final pilot experiments performed in an attempt to resolve diurnal 
differences in NCC-mediated sodium reabsorption.  
2. In order to assess rhythmic blood pressure changes, recordings need to be made in 
conscious unrestrained animals using radio-telemetry. Following 10 days of baseline 
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measurements, mice were randomised to receive either vehicle or corticosterone slow release 
pellets. Initial experiments were designed with the intention to resolve differences in 
nighttime and daytime dosing of HCTZ by injection. However, pilot experiments showed 
that any blood pressure lowering effects of HCTZ were masked by large increases in blood 
pressure caused by handling and injection of the drug; therefore a simple chronic approach 
was taken. All the telemetered mice were treated with a dose of ~80 mg/kg/day HCTZ in 
their drinking water. This minimised experimenter interference, allowing changes in 
rhythmicity to be more clearly defined.   
 
5.2. Methods 
Detailed methods of each of the major procedures in this chapter are described in the main 
methods chapter. For clarity, an outline of the experiments is presented here. The full 
experimental protocols for the programmable minipump experiments are also described here.  
 
5.2.1. Experimental work up for micro-osmotic minipump experiment 
Several key experiments lead to the decision to use HCTZ at 20 mg/kg in the final 
“Programmable micro-osmotic mini-pump” pilot experiment. These are explored in this 
chapter. The limitations of the iPRECIO pumps meant that the selection criteria for a 
suitable drug were strict. The drug should display: 
 
Criteria: 
1) Specific and efficacious inhibition of NCC  
2) Good bioavailability via subcutaneous administration 
3) Solubility to achieve desired concentration in 200 µl reservoir and achieve desired 
dosing with a maximum delivery rate of 10 µl/hour  
 
5.2.1.1. Thiazide diuretic choice 
Both bendroflumethiazide (BFMZ) and hydrochlorothiazide (HCTZ) have been used in 
experimental animals [147, 201]. BFMZ has greater selectivity for NCC [202] whereas 
HCTZ can also inhibit carbonic anhydrase [202]. At higher doses thiazide diuretics can 
reduce GFR through tubulo-glomerular feedback effects [203]. The first experiments, 
performed in terminally anaesthetised C57BL6 mice, compared the effects of BFMZ and 
HCTZ on renal blood flow, GFR and sodium handling. Mice (n=8-12) underwent renal 
clearance surgery (described in detail in Methods 2.8) and following 40-minute baseline 
urinary collections, either 6 mg/kg BFMZ, 20 mg/kg HCTZ or 2% DMSO was administered 
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(i.v.). Following 20 minutes equilibration, urine was collected for 40 minutes. Urine was 
analysed as outlined in the main methods section (2.8.3).  
 
5.2.1.2. Bioactivity of BFMZ 
These experiments were designed to test whether BFMZ was effective when administered 
subcutaneously and therefore suitable for use in the programmable mini-pumps. A secondary 
aim was to assess the time course for natriuresis so that we could design experiments to 
capture the “peak” natriuresis. C57BL6 mice (n=10) were housed in metabolic cages and fed 
a gelled diet (outlined in main methods section). Following acclimatisation (5 days) mice 
were injected (i.p. or s.c.) with BFMZ or 50 % DMSO at ZT 12 (7 pm local time) and urine 
was collected for 12 hours. A further 12-hour collection was made without any prior 
injection. 24 hours was allowed between injections to allow for the clearance of the drug. An 
initial dose of 6 mg/kg BFMZ was used but evoked no natriuresis. The maximum that was 
soluble in 50 % DMSO (24 mg/kg) was then tested. An injection volume of 40 µl was used 
to mimic the maximum volume that would be delivered by micro-osmotic mini-pumps at 
any single time-point.  
 
In order to test whether natriuresis was followed by a period of anti-natriuresis, which could 
mask the natriuretic effect of BFMZ, hourly urine collections were performed during the day 
after BFMZ or vehicle injection at ZT 0. Urinary sodium and potassium concentration were 
measured by ion sensitive electrode (9180 Roche Electrolyte Analyser, Roche Diagnostics, 
UK). BFMZ did not cause natriuresis at any point during these experiments and was 
therefore rejected as a suitable drug for use in micro-osmotic mini-pump experiments.  
 
5.2.1.3. Bioactivity of HCTZ  
Two experiments were performed to assess the extent and time course of natriuresis in 
response to HCTZ (20 mg/kg). First, C57BL6 mice (n=10) were acclimatised in standard 
cages to a reverse day/night cycle (for 14 days) and then acclimatised to metabolic cages 
with standard powdered chow for 5 days. HCTZ (20 mg/kg in volume of 150 µl/30 gbw in 2 
% DMSO i.p.) or vehicle (2 % DMSO) was administered at 8am (ZT 1) and urine collected 
for 6 hours. The second experiment tested whether subcutaneous administration of HCTZ 
produced natriuresis. A small group (n=4) of mice underwent renal clearance surgery under 
terminal inactin anaesthetic (as described in Main Methods). A 30-minute baseline collection 
was made followed by injection (s.c.) of 30 µl 20 mg/kg HCTZ and urine was collected 
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every 30 minutes for 2 hours thereafter. These 2 studies were used to decide upon the 
thiazide diuretic for the micro-osmotic mini-pump experiment.   
 
5.2.2. Programmable micro-osmotic pump experiments 
5.2.2.1. In vitro testing of programmable micro- osmotic mini-pumps 
The drug administration protocol was first assessed in vitro. One pump was programmed to 
release pink tissue culture fluid at a rate of 10 µl/hour for 4 hours (Figure 5.1, B). The pump 
was positioned on a fine balance (ISO9001, Sartorius) and the pump catheter placed into a 2 
ml eppendoff tube, which was positioned off the balance. The volume released by the pump 
was calculated by loss of weight of the pump. The eppendoff was weighed at the end and 
fluid loss from the pump matched the fluid gained by the tube.  
 
5.2.2.2. Surgical implantation of micro-osmotic mini-pumps 
As the mice would be housed in metabolic cages throughout the duration of the experiment, 
the placement of the micro-osmotic mini-pumps needed to be carefully considered. 
Implantation down the flank through an incision made at the nape of the neck was chosen as 
the wound would be difficult for the mice to manipulate and the pump position would place 
limited pressure on the wound. The orientation of the incision site (Figure 5.1 D) meant that 
movement of the head did not open the wound but instead put pressure on wound closure. 
 
Mice were anaesthetised under isofluorane using a 5 ml syringe nose-cone adaptation, given 
vetergesic (0.05 mg/kg) and positioned in ventral recumbency. Hair was removed from the 
dorsal cervical area with clippers and scrubbed with iodine scrub and ethanol. A ~15 mm 
transverse dorsal cervical incision was made and a subcutaneous pocket to the right of the 
midline.  The device was prepared by trimming the catheter and the antenna was wrapped 
around the width of the device. These manipulations made the device more compact for 
implantation. The wound was then held open with forceps and device gently inserted, 
catheter-end first, using clean, gloved hand. The device was positioned down the left side, 
well away from the wound so as to not put any pressure on the wound.  
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Figure 5.1: Micro-osmotic mini-pump (A), in vitro testing (B) & implantation site (C-D)  
A programmable micro-osmotic mini-pump (A) SMP-300 (iPRECIO, Japan) was 
programmed to release at a rate of 10 µl/hour.  The pump was placed on a fine balance with 
the long catheter emptying into an eppendoff tube. The release rate (B) was estimated by 
the reduction of weight over the programmed time period. Following programming pumps 
were implanted subcutaneously down the left flank in >25 g C57BL6 mice via a dorsal 
cervical incision (C, D). 
 
The wound was closed with 3-4 Michel suture clips (7.5 x 1.75 mm). Mice regained 
consciousness in a hotbox (34oC) within 5-15 minutes and were returned to their metabolic 
cages. Mice were given soft mash and vetergesic jelly for 24hours post op and were checked 





5.2.2.3. Experimental setup for micro-osmotic pump experiments 
A pilot experiment using programmable micro-osmotic mini-pumps (iPRECIO, Japan) was 
designed to administer HCTZ in conscious unrestrained mice without handling or injection. 
8 male C57BL6 mice were acclimatised to metabolic cages for 6 days. The acclimatisation 
period included cage changeovers of all metabolic cage parts that come into contact with 
urine, i.e. funnel, filter, pots and metal grid at 12-hour intervals. Gelled diet dries out after 24 
hours and requires daily replacement. The mice tend to eat large quantities of gelled diet 
when they are first introduced it to it, therefore if this was performed daily it would cause a 
surge of eating and urinarting at the point of food introduction. To evenly distribute this bias 
between day and night fresh gel diet was given at 12-hourly intervals. After acclimatisation 
micro-osmotic pumps and either vehicle or corticosterone slow release pellets were 
implanted under isofluorane anaesthetic. These pumps were pre-programmed via wireless 
technology using the accompanying software and programme set to start several hours after 
surgical implantation. The programmable pumps could only administer one drug and with a 
limited supply of pumps (we were donated a total of 10 pumps, two of which were used for 
in vitro experiments and surgical optimisation), a vehicle group could not be included. A “no 
drug” period of urine collections, which was performed at the same times but on the 
consecutive day/night after drug release when the pumps were set to release at a rate of 0 
µl/hour was used as a control in the absence of a vehicle group.  
 
The experimental protocol is illustrated in Figure 5.2. The pump rate was set at 0 µl for the 
first 3 days after implantation to allow recovery. This was the maximum length of time the 
pumps could be programmed to release at a rate of 0 µl/hour without compromising drug 
release. Furthermore the maximum battery life for the devices was ~10 days. HCTZ was 
administered at a rate of 10 µl/hour over 3 hours local time 11.30-14h30 (ZT 4.5-7.5) to 
achieve a dose of 20 mg/kg. Following a 33-hour break, where the pumps were programmed 
to administer at a rate of 0 µl/hour, HCTZ was released again between 23.30-2h30am (ZT 
16.5-19.5). These HCTZ-administration times were chosen to span the period over which 
kidneys had previously been taken for NCC phospho-analysis (i.e. at 1am and 1pm local 
time). At these time points the difference in NCC phosphorylation was at least 2 fold and 
therefore we hypothesised that differences in thiazide-sensitive sodium transport should be 
high at these points. This cycle of dosing was repeated. Overall this experiment produced 2 
day and 2 night collections under: (i) no drug and (ii) HCTZ infusion. During the first cycle 
of dosing, urine was collected hourly over 6 hours to span the period of drug release. 
However the experimenter (Ivy/Bailey) noted significant disturbance of the animals, most 
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evident during the “sleep” period, rendering unambiguous interpretation of the data difficult. 
During the second cycle, therefore, 5-hour urine collections were made to minimise 
disturbance of the animals. Only these data are presented here (Urine samples 5-8).  
 
 
Figure 5.2 (overleaf): Timeline of experimental setup for micro-osmotic minipump 
experiment 
8 male C57BL6 were individually housed in metabolic cages. After 6 days acclimatisation, 
mice were anaesthetised under isofluorane and implanted with programmable micro-osmotic 
minipumps and either vehicle or corticosterone slow-release pellets (n=4). Pumps were 
programmed to release no drug (i.e. at a rate of 0 µl/hour) for 3 days to allow recovery from 
anaesthetic. After this, pumps released HCTZ at a rate of 10 µl/hour for 3 hours at ZT 4.5 – 
7.5 to give a dose of 20 mg/kg this was followed by a 33-hour gap in drug release during 
which control urine collections were performed. HCTZ was administered again for 3 hours at 
a rate of 10 µl/hour at ZT 16.5-19.5 followed by another 33-hour gap in drug release. This 
protocol was repeated and urinary collections from two rounds of day and night HCTZ 























5.2.3. Experimental setup for radio-telemetry experiments 
Radio-telemeter devices were implanted and experiments were performed in a single cohort 
of 14 C57BL6 mice. Telemetry implantation surgery was performed as outlined in Methods 
Chapter and mice were single-housed in quiet 12-hour light dark conditions. BP waveforms 
were assessed once a week for quality control. In 3 of the 14 mice, blood pressure 
waveforms were inconsistent (Figure 5.3), with shallow waveforms (Figure 5.3 B, E) or 
huge fluctuating measurements after 2 weeks of recording (Figure 5.3 H). These devices 
were from both vehicle and corticosterone groups with one from the vehicle group (Figure 
5.3. A, B, C) and two from the corticosterone treated group (D, E, F & G, H, I). All three of 
these mice were excluded from the analysis and all three device failures reported to the 
manufacturers (DSI) for further investigation.  
 
The experimental timeline is outlined in Figure 5.4. Routine husbandry and HCTZ 
administration were performed under red light during the active phase (between ZT 12 and 
ZT 0) to minimise inactive phase disturbances. Water bottles were weighed in order to 
estimate the concentration of HCTZ required for a ~80 mg/kg/day dose and further weighed 
post dosing. The mice did not change their intake of water following HCTZ dosing.  
Adequate HCTZ dosing was assessed by mass spectrometry of terminal plasma samples 
taken between ZT 14-ZT 16 (Methods 2.9). In order to verify that the plasma corticosterone 
clamping was sustained throughout the experiment, blood was sampled at ZT 0 and ZT 12 in 
vehicle and corticosterone treated mice on the last day of the telemetry experiment i.e. four 





Figure 5.3 (overleaf): Wave forms from before and after device failure 
Three/fourteen devices produced inconsistent readings during this experiment and were 
therefore excluded from the analysis. Waveforms were steady during recovery post surgery 
(A, D, G), but each deteriorated at different points during experimental recording (B, E, H). 
The inconsistencies in the recordings can be seen in the moving average systolic blood 
pressure data for the entire experiment where each failed recording is compared to vehicle 




Figure 5.4: Time line of experimental setup for telemetry experiment.  
Male C57BL6 were implanted with radio telemeter devices under isofluorane anaesthetic. 
After 7 days of recovery 11 days of baseline recordings were made. Corticosterone or 
vehicle pellets were then implanted under isofluorane anaesthetic. Following 4 days 
recovery further recordings were taken. For the final 8 days of the experiment drinking water 








5.2.4. Analysis of telemetry data 
Recordings were taken for 1 minute every 30 minutes throughout the duration of the 
experimental timeline. Five-day bins of experimental recordings were taken forward for the 
analyses; these were chosen on the basis that systolic blood pressure was in steady state 
during these windows (by visual assessment of the entire data set).  Data analysis was 
performed using several different methods. In the first instance, to allow better visualisation 
of the data, the data were smoothed using a simple moving average over 5 hours (performed 
using DSI Data Quest ART software). Day versus night differences were compared by using 
the mean day (ZT 3-8) or mean night (ZT 15-20) averaged over the selected 5 days. Finally 
as systolic blood pressure is most associated with pathology [204] we next undertook a more 
sophisticated cosinor analysis of these data. The method for this is detailed in the main 
methods chapter (Methods 2.6.3).  
 
5.3. Results 
A series of experiments was conducted with the primary objective of designing an 
experiment using programmable minipumps (iPRECIO, Japan) to administer NCC inhibitors 
differentially at night/day in conscious unrestrained animals.  
 
5.3.1.1. Drug choice: BFMZ or HCTZ 
Renal clearance experiments in anaesthetised C57BL6 mice were designed to test the effect 
of vehicle (2% DMSO), HCTZ (20 mg/kg) or BFMZ (6 mg/kg) on electrolyte excretion and 
renal function. Both diuretics caused a marked increase in sodium excretion (p=0.0002, 
HCTZ and p<0.0001 for BFMZ, Figure 5.5, A). Both diuretics increased potassium 
excretion (p=0.0002, HCTZ and p<0.0001 for BFMZ, Figure 5.5, B). GFR as measured by 
inulin clearance was unchanged by vehicle (p=0.15) or BFMZ (p=0.98) but decreased with 
HCTZ treatment (p=0.013, Figure 5.5 C). BFMZ and vehicle had little effect on renal blood 
flow (p=0.18, p=0.83 respectively) but HCTZ increased renal blood flow (p=0.03, Figure 
5.5, D). The change in fractional sodium excretion with diuretic was greatest with BFMZ at 
~8% of the total load, with HCTZ ~6% of the total sodium load (Figure 5.5 E). BFMZ 
offered considerably better stability of renal function and therefore was taken forward for 






Figure 5.5: Renal clearance parameters and electrolyte excretion in anaesthetised 
C57BL6 mice at baseline and following a bolus injection of 2% DMSO, 
hydrochlorothiazide (HCTZ) or bendroflumethiazide (BFMZ) 
Sodium excretion, (A) potassium excretion (B), glomerular filtration rate (GFR, C) and renal 
blood flow (RBF, D) in anaesthetised C57BL6 mice at baseline and following bolus injection 
of 2% DMSO, HCTZ (20mg/kg), or BFMS (6mg/kg). Change in fractional sodium excretion 
from baseline following DMSO, HCTZ, BFMZ (E). Data were analysed by matched two-way 




5.3.1.2. Does subcutaneous BFMZ injection induce natriuresis?  
6 mg/kg BFMZ was administered (s.c.) and urine collected over the next 12 hours. This dose 
did not cause natriuresis therefore the dose was increased to the maximum soluble in 50% 
DMSO for a volume of 40 µl, which was 24 mg/kg. This was injected s.c. and i.p. and urine 
collected over 12 hours after injection. 24 hours was allowed between injections to allow the 
drug to clear (half life ~6-8 hours [205]). Sodium excretion following injection (s.c. or i.p.) 
was not different to sodium excretion following vehicle injection or following no injection 
(Figure 5.6, A). Potassium excretion was also unchanged by any injection (Figure 5.6 B). 
Diuretic braking can occur in response to loop diuretics and involves a period of 
compensatory sodium retention post diuretic administration [206]. To test whether this 
phenomenon was affecting these experiments, hourly urine collections were carried out 
following s.c. injection of BFMZ (during the day). Sodium excretion was comparable at 
every time point following sub-cutaneous injection of BFMZ or vehicle (50% DMSO) 
(Figure 5.6, C). We hypothesised that BFMZ may have poor bioactivity when administered 
subcutaneously. Further increases in BFMZ dose would not be possible in the mini-pump 





Figure 5.6: Sodium (A) and potassium (B) excretion 12 hours following 24 mg/kg 
BFMZ or vehicle (50% DMSO) subcutaneous (s.c.) and (C) intra-peritoneal (i.p) 
injection and hourly sodium excretion following 24 mg/kg BFMZ or vehicle injection 
(s.c) 
Data in (A) and (B) was analysed by repeated measures one way ANOVA, no differences 
were found between BMFZ and controls. Area under the curve (AUC) data was analysed by 






5.3.1.3. Bioactivity of HCTZ 
HCTZ also inhibits NCC and is considerably more soluble than BFMZ. Urine was collected 
in C57BL6 mice for 6 hours following HCTZ (20 mg/kg) injection (i.p). HCTZ injection 
caused natiuresis (Figure 5.7 A, p=0.0058, n=10) in 8 out of 10 mice. However, this was via 
the i.p. route and micro-osmotic mini-pump experiments would require s.c. administration. 
Therefore, experiments were conducted in anaesthetised mice to assess whether HCTZ was 
efficacious via s.c. route. A dose of 20 mg/kg caused natriuresis in anaesthetised mice within 
30 minutes of s.c. injection, which lasted for 2 hours (Figure 5.7 B). Therefore this drug was 
taken forward for use in micro-osmotic mini pump experiments.  
 
 
Figure 5.7: Sodium excretion following 20 mg/kg HCTZ injection (i.p) in conscious (A) 
and anaesthetised (B) C57BL6 mice. 
Urinary sodium excretion in conscious animals (A) was analysed by paired t test, n=10. 
Urinary excretion in anaesthetised animals (B) was analysed t-test analysis of the area 




5.3.2. Micro-osmotic mini-pump experiment 
All the pump reservoirs were empty at the end of the experiments, indicating release of 
HCTZ. To confirm release, urinary HCTZ was measured by mass spectroscopy in the “intra-
drug” 5-hour urinary collection period during HCTZ release and during “no drug” release. 
Samples used here were the nighttime samples as this is the period where the most urine was 
available. Urinary HCTZ excretion was low in the “no drug” time period (Figure 5.8) but 
was not 0 (mean = 0.81 µg/hour, p=0.0003, one-sample t-test against a theoretical mean of 
0).  HCTZ was detected in all urine collected during HCTZ administration. However, the 




Figure 5.8: Urinary HCTZ excretion during no drug or HCTZ administration via 
programmable micro-osmotic mini-pump 
Urinary HCTZ was measured by tandem liquid chromatography mass spectroscopy (LCMS) 
in mice administered HCTZ at a dose of 20 mg/kg via programmable micro-osmotic 
minipumps (iPRECIO, Japan) and during ”no drug” administration. Urinary excretion data 
were analysed by paired t-tests.  
 
Urinary sodium excretion was measured before and during HCTZ administration in mice 
treated with chronic vehicle or corticosterone. This was assessed for both night and day 
dosing.  As expected, the overall rate of urinary sodium excretion was higher at night (306 ± 
59 µmol/hour vehicle and 289 ± 70 µmol/hour, corticosterone) compared to the day (118± 
41 µmol/hour, vehicle and 161 ± 38 µmol/hour, corticosterone) in both vehicle and cort 
groups.  The day/night difference in sodium excretion was significantly blunted in the 
corticosterone treated animals compared to the vehicle group (p=0.018, Student’s t-test, 
n=4), consistent with the findings of Chapter 4. HCTZ did not cause statistically significant 
natriuresis in any group (corticosterone or vehicle) at any time point (day or night, Figure 5.9 
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A, C). Urinary sodium excretion during the baseline or “pre” drug period was then 
subtracted from the “intra” drug period to get ∆HCTZ/no drug values. The change in urinary 
excretion with HCTZ or no drug was not different at any time or in any group (Figure 5.9, B, 
C).  
 
Figure 5.9: Urinary sodium excretion in C57BL6 mice implanted with programmable 
micro-osmotic mini-pumps and vehicle (A, B) or corticosterone (C, D) silastic slow 
release pellets 
Pre-drug urinary sodium excretion was measured from ZT 0/12 (7 am/pm) to ZT 3.5/15.5 
(10.30am/pm), intra-drug sodium excretion was measured from ZT 3.5/15.5 (10.30 am/pm) 
to ZT 8.5/20.5 (3.30 am/pm). HCTZ/no drug summary values are “pre” drug urinary sodium 
subtracted from the “intra” drug/no drug sodium excretion during the day and night. These 






Figure 5.10: Urinary sodium excretion during nighttime HCTZ or “no drug” 
administration via programmable micro-osmotic mini-pump (A) and corresponding 
correlation between urinary HCTZ excretion and urinary sodium excretion (B) 
Urinary excretion data were analysed by paired t-tests. Pearson correlation was performed 
on delta sodium excretion versus urinary HCTZ data.  
 
HCTZ was released by the micro-osmotic mini-pumps as evidenced by the substantial 
increase in urinary HCTZ excretion during the release period (Figure 5.8). Interestingly, the 
variation in HCTZ excretion (Figure 5.8) was considerably larger than the variation seen in 
the sodium excretion for the same time periods (Figure 5.10 A) and there was no correlation 
between urinary HCTZ and a change in sodium excretion with HCTZ (p=0.51, r2=0.075 by 




5.3.3. Effect of corticosterone and HCTZ treatment on BP  
We next addressed the role of NCC and corticosterone on the diurnal rhythm of BP. To 
verify that the clamping of plasma corticosterone persists throughout 4 weeks of pellet 
implantation, plasma was sampled at ~7am (ZT 0) and ~ 7pm (ZT 12). In vehicle treated 
mice, a significant difference was seen in plasma corticosterone in blood sampled by tail 
venesection at ZT 0 compared to that from ZT 12 (Figure 5.11 A) but this was not seen in 
the corticosterone treated animals, which exhibited slightly higher day time plasma 
corticosterone and slightly lower night time corticosterone (Figure 5.11 A). In order to verify 
that the dose of HCTZ taken by the mice was sufficient, plasma HCTZ was measured in 
terminal samples by mass spectroscopy. HCTZ levels were similar between vehicle and 
corticosterone treated animals (p=0.54, Figure 5.11 B) being on average ~15 µmol/l, ~ 40X 
higher than required in hypertensive humans for a 20 mmHg drop in mean blood pressure 
[207]. This value for human therapeutic level is indicated on the graph by a dotted line 




Figure 5.11: Plasma corticosterone at week 4 post vehicle/corticosterone silastic 
pellet implantation (A) and plasma HCTZ following 1 week of HCTZ treatment (B). 
Following 4 weeks with slow-release silastic pellet implantation blood was sampled at ZT0 
and ZT 12 in conscious mice via tail venesection. After 1 week of chronic HCTZ treatment 
administered in drinking water mice were culled and a terminal plasma sample analysed for 
HCTZ by LCMS. The dotted line indicates the human plasma concentration at which a 
20mmHg blood pressure drop occurs in hypertensive individuals. Data are mean± 95% CI. 
Plasma corticosterone data was analysed by matched two-way ANOVA with post hoc Sidak 
tests.  Plasma HCTZ data was analysed by Student’s t tests. **p<0.01, ns p>0.05, n=6 






5.3.4. BP is increased with corticosterone treatment and rescued with HCTZ  
Systolic blood pressure (SBP) was measured in conscious unrestrained C57BL6 mice. At 
baseline, both groups had identical daily rhythms of SBP (Figure 5.12 A, B, C, F). All mice 
were then anaesthetised with isofluorane and silastic slow release corticosterone pellets were 
implanted. Following recovery from anaesthetic, the vehicle group immediately regained its 
daily rhythm of SBP (Figure 5.12 A), which was no different from pre-implant values 
(Figure 5.12 E, F). The corticosterone-treated group took longer to regain their daily rhythm 
of SBP and when they did (~3 days post surgery, Figure 5.12 A) their daytime SBP was 
raised compared to baseline values (Figure 5.12 A, C, E). All the mice were then treated with 
HCTZ in their drinking water. This treatment did not affect daytime or nighttime SBP in the 
vehicle group (Figure 5.12 A, E, F) but improved daytime SBP in the corticosterone treated 
group (Figure 5.12 A, E, F) with no effect on nighttime SBP.  
 
At baseline, both groups have identical rhythms of diastolic blood pressure (DBP, Figure 
5.13 A). Corticosterone treatment increased both daytime and nighttime DBP (Figure 5.13 
A, B, C). Daytime DBP was reduced by HCTZ treatment but nighttime DBP remained 
elevated. There were no changes in nighttime or daytime DBP following vehicle treatment or 
HCTZ treatment in the vehicle group. Pulse pressure steadily decreased throughout the 
experiment (Figure 5.13 D) and was significantly reduced in both vehicle and corticosterone 
groups following pellet implantation and decreased further following HCTZ treatment. 
There were no differences in pulse pressure between vehicle and corticosterone groups 
(Figure 5.13 E). It is unclear why pulse pressure should reduce over time but it is unlikely to 
be a physiological phenomenon and may relate to the deterioration of the catheter patency 





Figure 5.12: Systolic blood pressure (SBP) in C57BL6 mice following treatment with 
corticosterone or vehicle and chronic HCTZ. 
SBP was measured by radio telemetry in C57BL6 mice. (A) Moving averages (over 5 hours) 
throughout the duration of the experiment. After baseline recordings (11 days), all mice were 
anaesthetised under isofluorane and received either vehicle or corticosterone slow-release 
silastic pellets (s.c.). After 8 days recording all mice were treated with chronic HCTZ (80 
mg/kg) in their drinking water. The blue rectangles indicate 5-day bins that were taken 
forward for further analysis. In the first instance a mean over 5-day bin for each half hour for 
24 hours was displayed at baseline (B), post corticosterone/vehicle pellet (C) and following 
HCTZ treatment (D). Mean daytime (E) and nighttime (F) blood pressure was obtained by 
taking the mean systolic blood pressure over the 5-day bins between ZT 3-8 (day) and ZT 
15-20 (night), data are mean± 95% CI. Data were analysed by matched two-way ANOVA 





Figure 5.13: Diastolic blood pressure (DBP) and pulse pressure in C57BL6 mice 




DBP was measured by radio telemetry in C57BL6 mice. (A) Moving averages (over 5 hours) 
of diastolic (A) and pulse pressure (D) throughout the duration of the experiment. After 
baseline recordings (11 days), all mice were anaesthetised under isofluorane and received 
either vehicle or corticosterone slow-release silastic pellets (s.c.). After 8 days recording all 
mice were treated with chronic HCTZ (80mg/kg) in their drinking water. The blue rectangles 
indicate 5-day bins that were taken forward for further analysis. Summary mean daytime (E) 
and nighttime (F) diastolic pressure was obtained by taking the mean diastolic pressure over 
the 5-day bins between ZT 3-8 (day) and ZT 15-20 (night). Mean pulse pressure is the 24 
hour mean over each 5 day bin (E). Data are mean± 95% CI. Summary mean were analysed 
by matched two-way ANOVA with post hoc Sidak tests. ****p<0.0001, ***p<0.001, **p<0.01, 
*p<0.05 ns, not significant p>0.05, n=6 (vehicle) n=5 (corticosterone).  
  
 
5.3.5. HR and activity are unchanged by corticosterone treatment  
At baseline both groups had identical daily rhythms of HR (Figure 5.14 A, B, C). Following 
recovery from surgery, animals in the vehicle group regained their daily rhythms of HR, with 
mean HR returning to pre-implant values. The corticosterone group exhibited a transiently 
lower heart rate than the vehicle group for the first 4 days following corticosterone 
implantation, and in the 5 proceeding days nighttime heart rate was significantly lower than 
prior to corticosterone pellet implantation (Fig 5.14 C), with no change in daytime HR 
(Figure 5.14 B). HR appeared to decrease over time throughout the experiment in both 
groups: heart rate following HCTZ was lower than baseline HR. No differences were found 
in daytime or nighttime HR between corticosterone and vehicle groups with any treatment 
(Figure 5.14 B, C).  Activity as measured by radiotelemetry device, exhibited strong day-
night differences and was unchanged by either corticosterone or HCTZ treatment (Figure 
5.14 D, E, F).  
 
Figure 5.14 (overleaf): Heart rate (HR) and activity in C57BL6 mice following treatment 
with corticosterone or vehicle and chronic HCTZ 
HR and activity was measured by radio telemetry in C57BL6 mice. Data displayed here are 
the moving average (over 5 hours) of heart rate (A) and activity (D) throughout the duration 
of the experiment. After baseline recordings (11 days), all mice were anaesthetised under 
isofluorane and received either vehicle or corticosterone slow-release silastic pellets (s.c.). 
After 8 days recording all mice were treated with chronic HCTZ (80 mg/kg) in their drinking 
water. The blue rectangles indicate 5-day bins that were taken forward for further analysis. 
Summary mean daytime and nighttime heart rate (B, C) and activity (E, F) were obtained by 
taking the mean over the 5-day bins between ZT 3-8 (day) and ZT 15-20 (night). Data are 
mean± 95% CI. Summary data were analysed by matched two-way ANOVA with post hoc 
Sidak tests. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05 ns, not significant p>0.05, n=6 






























































































































































































































































































































































































































































































5.3.6. Cosinor analysis of SBP 
A cosinor analysis was performed on SBP data from the “bins” of experimental time periods 
highlighted in Figure 5.12 A. All the descriptive data produced from this analysis is 
presented in Table 5.1 with the same data plotted in Figures 5.15 and 5.16 for better 
visualisation. The MESOR was similar between vehicle and corticosterone groups at 
baseline (i.e. prior to pellet implantation). MESOR of the vehicle is unchanged by vehicle 
pellet implantation or HCTZ treatment. However, corticosterone treatment caused an 
increase in MESOR (p<0.0001, Figure 5.15 B), which was reduced by HCTZ treatment 
(p=0.012, Figure 5.15 B) to levels similar to baseline MESOR (p=0.07, Figure 5.15 B). The 
amplitude of SBP rhythm was again similar between groups at baseline. Corticosterone 
treatment induced a reduction in SBP amplitude (p<0.0001, Figure 5.15 A), which was 
increased by HCTZ treatment (p=0.013, Figure 5.15 A). Vehicle SBP amplitude was 
unchanged by pellet implantation (p=0.12, Figure 5.15 A) or HCTZ treatment (p=0.99, 
Figure 5.15 A). Robustness is a measure of how “rhythmic” the data is or rather how well a 
cosinor curve can be fitted to the data. Robustness levels of <20% are defined as not 
different from noise or “not rhythmic”[144, 208]. Robustness was high and similar between 
groups at baseline at ~ 75%. Robustness remained consistent in the vehicle-treated group 
throughout the entire experiment. Corticosterone treatment caused a sharp reduction in 
robustness to about 40% (p=0.0002, Table 5.1, Figure 5.15 C, post hoc Sidak test) and 
HCTZ treatment restored robustness to ~63% (Table 5.1 p=0.0092, Figure 5.15, post hoc 




Figure 5.15: Analysis of rhythmic parameters of SBP in C57BL6 mice following 
treatment with corticosterone or vehicle followed by chronic HCTZ. 
SBP was measured by radio telemetry in C57BL6 mice. Following baseline measurements 
mice received vehicle or corticosterone slow release silastic pellets, this was followed by 
chronic HCTZ treatment (80mg/kg). SBP data from 5-day bins during each treatment period: 
baseline, after pellet and after HCTZ treatment was subject to cosinor analysis. Data are 
mean ± 95% CI. Data were analysed by matched two-way ANOVA followed by post hoc 
Sidak tests, where ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, n.s p>0.05. 
 
Acrophase is the time point at which oscillating variables, such as systolic blood pressure 
here, reach their peak. Figure 5.16 is a polar plot that displays acrophase against amplitude. 
There were no statistically significant differences between any of the groups’ acrophases but 
there are some trends particularly with regard to the spread of the acrophase data with 
treatment. At baseline both groups’ acrophases were between ~14-17 ZT (Figure 5.16 A). 
Following pellet implantation, the vehicle group’s acrophases remained between ~14-17 ZT 
(Figure 5.16, B). The corticosterone group exhibited a greater distribution of acrophases 
after pellet implantation with values between ~10 - 18 ZT (Figure 5.16, B). HCTZ treatment 
shifted the corticosterone group’s acrophases to between ~13-16 ZT but also appeared to 





Figure 5.16: Polar diagram of acrophase and amplitude of SBP in C57BL6 mice at 
baseline (A) following corticosterone or vehicle treatment (B) and following chronic 
HCTZ treatment (C). 
SBP was measured by radio telemetry in C57BL6 mice. Following baseline measurements 
mice received vehicle or corticosterone slow release silastic pellets, this was followed by 
chronic HCTZ treatment (80 mg/kg). SBP data from 5-day bins during each treatment period: 
baseline, after pellet and after HCTZ treatment was subject to cosinor analysis. Data are 







5.4.1.  What are the functional consequences of NCC phosphorylation? 
The major aim of this chapter was to assess the functional consequence of a perturbed 
day/night rhythm of NCC phosphorylation. NCC phosphorylation is associated with 
increased activation in many in vitro [98, 100] [99] and in vivo studies [86]. However its use 
as a surrogate reporter of NCC activity should be taken with caution as reports from our lab 
[86] and others [105, 159] indicate that NCC phosphorylation and thiazide-sensitive sodium 
transport are not always associated. For example, in 11βHSD2 null mice, NCC 
phosphorylation at all residues as well as total NCC protein is increased but thiazide-
sensitive sodium transport is not elevated above wild-type levels [86]. Therefore it was 
important to investigate what the diurnal rhythm of NCC phosphorylation means 
functionally. The major challenge of the work in this chapter was how to design an 
experiment to detect circadian changes in NCC function.  
 
5.4.2. Thiazide diuretic choice: How to inhibit NCC? 
One way of assessing NCC function in vivo is to measure the natriuretic effect of NCC 
inhibitors (thiazide diuretics). This thiazide-sensitive sodium excretion gives an estimate of 
how much of the sodium reabsorption is occurring through NCC. To this end, two thiazide 
diuretics were investigated for potential use in thiazide-sensitivity experiments:  
hydrochlorothiazide (HCTZ) and bendroflumethiazide (BFMZ).  Both inhibit NCC but 
BFMZ is considerably more potent than HCTZ [209]. Thiazide diuretics reduce GFR 
through their effects on tubuloglomerular feedback [210-212]. HCTZ has greater carbonic 
anhydrase inhibiting capacity and can cause dilatation of blood vessels through alkalinisation 
of smooth muscle cells [202]. In our experiments in anaesthetised animals, HCTZ had a 
greater effect on renal haemodynamics: 20 mg/kg HCTZ significantly lowered GFR in 
anesthetised mice but there was no such difference with 6 mg/kg BFMZ. HCTZ also caused 
a mild elevation of RBF. Both drugs induced a large and rapid natriuresis. The change in 
fractional sodium excretion was 5-10 % consistent with the reported proportion of filtered 
sodium reabsorbed by NCC [150, 213]. Therefore in terms of specificity and potency BFMZ 
was superior but is also 7X less soluble than HCTZ (108 mg/l compared to 722 mg/l at 
25oC) and no natriuretic effects could be seen at the maximum dose soluble in our required 
volume of 50% DMSO (25 mg/kg). HCTZ was chosen for use in thiazide-sensitivity studies 





5.4.3. How to design a functional circadian experiment to test NCC activity?  
The next major challenge was how to administer HCTZ. We first considered administration 
by injection. This has the advantage that one would know the exact timing of drug 
administration. However this route was rejected as restraint and handling of mice causes 
large increases in corticosterone levels [174, 214]. Indeed, our pilot telemetry experiments 
showed injection of saline vehicle during the day caused a sustained surge in BP to levels 
normally seen during peak activity at night. We also considered a renal clearance approach, 
as it would allow measurement of renal function and HCTZ-sensitive fractional sodium 
excretion measurements. However, this approach requires anaesthetic, surgery and saline 
infusion.  Studies in rats found that circadian variations in renal function seen in conscious 
animals did not persist when anaesthetised and the renal clearance preparation abolished the 
aldosterone rhythm [215]. Finally oral HCTZ was considered as the diuretic has good oral 
bioavailability and large intake would mean the low solubility would be less of an issue. 
However, this approach was rejected, as it would be difficult to control when HCTZ dosing 
occurs without resorting to gavage.  
 
Finally, we were given the opportunity beta test a new miniaturised programmable micro-
osmotic minipump system SMP-300 (iPRECIO, Japan). These pumps can accurately 
administer one substance at a maximum rate of 10 µl/hour. It is pre-programmable, so no 
animal handling is required for drug administration. Studies using the same technology in 
larger SMP-200 devices have established the accuracy and reliability of the osmotic pump 
technology [216].  
 
5.4.4. Experiments using micro-osmotic minipumps to deliver HCTZ 
In our experiments the SMP-300 mouse device exhibited great accuracy in vitro (within 
~4%). The in vivo results were also promising with high levels of HCTZ appearing in urine 
collected during infusion periods; little HCTZ was detected when the pump was 
programmed to be off. There was however, huge variability in HCTZ excretion rates with a 
13-fold difference between the highest and lowest HCTZ excretion rate. This could either be 
a result of pump variability or a biological phenomenon  (filtration/secretion/micturition). 
There are several points at which biological variability could occur: these can be thought of 
in terms of either absorption or elimination. In terms of reabsorption, 70% of HCTZ is 
absorbed by the GI tract [217] and although HCTZ has been administered subcutaneously in 
many experimental settings [218-220] there is a paucity of data on the pharmacokinetics of 
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this route of administration. More variability could be present during HCTZ elimination. At 
least 95% of an intravenous dose of HCTZ is excreted, unchanged by the kidneys  [217] and 
as 90% of plasma HCTZ is bound to protein tubular secretion is thought to be the major 
route of HCTZ elimination. OAT1 channels are major contributors to HCTZ secretion 
allowing uptake across the basolateral membrane [221] but it is unclear whether these 
transporters undergo dynamic regulation. However, that HCTZ elimination may not undergo 
considerable regulation is evidenced by experiments in anaesthetised animals and in the 
clinic. Using the same LCMS methods as used here the proportion of urinary HCTZ 
excretion only varied in proportion to the intravenous dose administered [147]. This has also 
been found in patients receiving different oral doses [207]. Therefore it is unlikely that 
HCTZ secretion was a major factor in the variability seen here. The other possibility for 
biological variation was the timing of bladder emptying. i.e. the mouse with the lowest 
reported HCTZ levels may have urinated right at the start of the 5 hours of urine collection, 
prior to HCTZ secretion and the animal with the highest may have urinated at the peak time 
for HCTZ secretion. 24-hour urinary HCTZ elimination experiments would have been 
helpful to rule out this possibility. It would also have been useful to include in the pump 
reservoir a freely filtered labelled tracer (such as FITC-inulin) or dye in order to determine 
the variability of the pumping rates in vivo.  
 
5.4.5. What was the biological outcome of the experiment? 
In previous chapters, it was shown that NCC phosphorylation was twice as high at night 
compared to the daytime. Corticosterone treatment eliminated this day/night difference. 
However, we were unable to detect any increases in thiazide-sensitive sodium transport at 
night compared to the daytime in this cohort of mice. Moreover, although there were 
changes in rhythmic sodium excretion, no such differences in thiazide-sensitive sodium 
transport were detected between vehicle and corticosterone treated groups. We have shown 
that HCTZ caused a reduction in GFR in renal clearance experiments, and this may result in 
an underestimation of sodium excretion. We do not know the renal haemodynamic profile of 
these mice. Normalising urinary excretion data to creatinine was considered as other groups 
[222] employ this approach. However, creatinine has a secretory rhythm that restricts its use 
as a reliable marker of GFR in circadian experiments [223] and so this strategy was not 
employed in these experiments. As we have explored, variability in HCTZ excretion was 
very large. Furthermore, there were no correlations between urinary concentration of HCTZ 
and sodium excretion (p= 0.57, r2=0.056, Pearson’s Correlation). A lack of correlation 
between peak plasma levels and urinary sodium excretion has also been seen in healthy 
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volunteers [207]. The thiazide-sensitive excretion studies in this chapter must be treated as 
preliminary as they are underpowered and there were clear limitations in these experiments. 
It is interesting to note that considerably higher doses of HCTZ are required to achieve 
detectable and reproducible natriuresis in conscious mice and rats [220, 222] compared to 
humans or indeed anaesthetised mice. This may be indicative of compensatory changes that 
occur in mice, which are blocked by anaesthetic.  
 
5.4.6. Effect of HCTZ on rhythmicity on BP: an alternative approach 
We also developed a complementary strategy to test whether HCTZ affected the diurnal 
rhythm of BP in mice implanted with vehicle or corticosterone pellets. The SMP300 
iPRECIO system was no longer available to us and therefore a change in strategy was 
required. A chronic oral dose of HCTZ was chosen based on [222]. This large dose (~80 
mg/kg/day) was chosen in order to achieve high plasma levels throughout the 24-hour cycle. 
We do not know the 24-hour plasma HCTZ levels. However, based on the estimated half-life 
~6 hours [205] and the plasma HCTZ levels, which were sampled at ~ 13 ZT i.e. during the 
main feeding/drinking time in the active phase, it is likely that the plasma concentration of 
HCTZ does not decrease below therapeutic levels [207] (Figure 5.17). This approach may 
still introduce some variability in amount drank by each mouse and the timing of ingestion 
but the substantial dose should mean that the level of plasma HCTZ was consistently in an 
efficacious range.   
 
Figure 5.17: Hypothetical worst-case scenario for estimated HCTZ elimination in 
C57BL6 mice treated chronically with 80 mg/kg HCTZ (p.o.) HCTZ treatment (C). 
Hypothetical worst-case scenario estimated HCTZ elimination in C57BL6 mice treated 
chronically with 80 mg/kg HCTZ (p.o.). HCTZ was measured in termainal plasma sampled at 
~13 ZT. This estimate assumes the 13 ZT sample was at the plasma HCTZ peak, that no 
further ingestion would take place overnight. This very rough estimation also uses the 
shortest reported half-life for HCTZ (6 hours). Using this rough projection, HCTZ levels 
would only reach below the therpeautic plasma levels for hypertensive humans at ZT 12, 
whereby the animals enter the active phase again. Data are mean ± 95% CI of all vehicle 





5.4.7. BP rhythmicity following corticosterone treatment and NCC inhibition 
SBP was increased in corticosterone-treated animals during the daytime but was unchanged 
at nighttime. HCTZ improved daytime BP in corticosterone-treated animals but did not 
affect vehicle SBP. One of the consequences of corticosterone-treatment (explored in-depth 
in Chapter 4) is an inappropriate elevation of daytime NCC phosphorylation. The 
observation that HCTZ can decrease daytime BP in corticosterone-treated mice gives weight 
to the role of NCC in diurnal BP rhythm. The cosinor analysis of SBP gave very similar 
conclusions to the day/night mean analysis. Importantly this type of analysis makes use of 
each point within the 24-hour cycle and therefore gives a more accurate and complete 
description of the data. The amplitude of SBP was greatly decreased by corticosterone 
treatment and the MESOR was increased. The day/night mean analysis shows that these 
changes are likely a result of elevated daytime BP without any major changes in nighttime 
BP. There were no changes in period length but corticosterone and indeed HCTZ treatment 
appeared to cause a slight change in the phase as denoted by acrophase, although this did not 
reach statistical significance. These changes appeared to introduce greater group variation of 
the acrophases rather than shifting of all of the data points. Robustness or prominence of the 
cosinor fit was drastically reduced by corticosterone treatment, indicating a loss of 
rhythmicity [144].  This can be as a result of increased noise; corticosterone could increase 
the mice’s sensitivity to sleep disturbances [224]. Another reason for a change in rhythmicity 
is a non-repeating phase of the daily rhythm or in other words, a loss of stationarity. This 
means that the SBP curve may not be repeating reproducibly every day, leading to a 
perceived loss of rhythmicity. HCTZ partially restored this rhythmicity of SBP increasing 
robustness levels back to baseline levels.  
 
5.4.8. HR following corticosterone & HCTZ treatment 
The major changes in BP with corticosterone and HCTZ do not appear to be as a result of 
any changes in HR or activity. Aside from a small, transient reduction in heart rate in the 
first 4 days immediately following corticosterone pellet implantation, HR was not affected 
by corticosterone or HCTZ treatment. A reduction in HR following acute GC treatment has 
been reported in healthy volunteers [225] and the finding that diurnal HR rhythm remains 
intact despite alterations to SBP rhythm with GC treatment has been reported in the 
literature, where both Cushing’s patients and those treated with high levels of GCs have no 
nocturnal dip despite having an intact HR dip [226] [227]. It is peculiar that heart rate 
decreased over time. This occurred to a similar extent in all mice in both vehicle and 
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corticosterone groups. The reasons for this gradual decline are unclear but it may be linked 
to slow adaptations to single housing. The literature reports alterations to HR in single 
housed/versus pair-housed male mice [228], with lower HR in pair-housed mice than single 
housed. Unfortunately, single housing in this experimental setup was unavoidable. Every 
effort was made to minimise the stress of single housing: mice were acclimatised for 14 days 
before recordings were taken, 1 cage change was made (following pellet implantation) and 
the room was heated to 25oC to limit the impact of temperature on the mice.  
 
5.4.9. Mechanisms of HCTZ-induced restoration of BP rhythmicity 
HCTZ lowers daytime BP in corticosterone treated mice. Corticosterone treated mice have 
elevated NCC phosphorylation during the day and have perturbed sodium excretion rhythms. 
However, we were unable to show that these findings specifically relate to a functional 
change in sodium handling by NCC. That HCTZ improves daytime BP and rhythmicity does 
give some evidence that NCC may be involved in the maintenance of diurnal BP rhythms. 
Furthermore, experiments where genetic alterations in the pathway molecules that regulate 
NCC have also shown interesting variations in their BP rhythm. A WNK4 hypomorphic 
mouse, with greatly reduced NCC phosphorylation, had a reduction in SBP amplitude 
characterised by reduced nighttime BP [229]. A mouse model of Gordon’s syndrome, in 
which NCC is hyperactive, exhibits enhanced BP amplitude compared to wild type mice, 
accompanied by both increased daytime and night time SBP [108]. In clinical studies, a 
dipping profile of SBP was restored following 4 weeks of chronic HCTZ [27] or sodium 
restriction [28], indicating an important role for renal sodium transport in non-dipping. BP 
control and other cardiovascular indices such as left ventricular mass are improved by 
nighttime administration of HCTZ [230, 231].  
 
However, non-renal effects of HCTZ cannot be ruled out. The route for BP lowering in acute 
HCTZ treatment is a reduction in cardiac output as a result of increased sodium excretion 
reducing extra-cellular fluid (ECF) and plasma volume [212, 232]. However this mechanism 
seems to be transient as ECF volume returns to baseline with chronic HCTZ use [233]. 
Reduction in total peripheral resistance is proposed as the major mechanism of BP lowering 
during steady state HCTZ treatment ([106] and Reviewed in [232]). HCTZ can directly alter 
vascular tone through changes in ion transport [234, 235] and carbonic anhydrase inhibition 
[202]. However, as previously explored, thiazides have different capacities for carbonic 
anhydrase inhibition, therefore if this is the major mechanism for BP lowering it follows that 
drugs like BFMZ, with low potency for carbonic anhydrase inhibition [232] would be poorer 
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anti-hypertensive drugs, which is not the case [209]. Furthermore, sodium depletion appears 
to be necessary for BP lowering [236] and BP in patients undergoing haemodialysis is 
unresponsive to HCTZ [237]. Chronic GC exposure (be it though Cushing’s disease or 
iatrogenic) can cause sodium retention (Reviewed: [92] and increased vascular tone 
(Reviewed: [238]) both of which might be ameliorated by HCTZ. Finally HCTZ can also 
inhibit the sodium dependent chloride and bicarbonate exchanger (NDCBE, SLC4A8) in the 
CCD, which may also contribute to renal sodium absorption and regulation of sodium 
balance in vivo [222]. 
 
5.4.10. Summary of Chapter Findings: 
1. We were unable to show any difference in HCTZ-sensitive sodium transport between day 
and night in vehicle or corticosterone treated C57BL6 mice 
2. Daytime SBP and DBP were markedly increased by chronic corticosterone treatment.  
3. Chronic corticosterone treatment disrupted rhythmicity of SBP: increasing MESOR and 
decreasing amplitude. 
4. Chronic HCTZ treatment partially rescued raised daytime SBP and improved rhythmicity, 
increased amplitude and decreased MESOR.  





6. Acute regulation of NCC by glucocorticoids 
6.1. Introduction 
In Chapter 4, it was shown that corticosterone affected the diurnal NCC phosphorylation 
rhythm. However, the experimental setup is not readily tractable for investigations into the 
pathways involved. The available cell lines do not adequately model NCC transport in vivo 
([239] and personal communication from Prof. Robert Fenton, University of Aarhus). 
Therefore the overarching aim of the experiments presented in this chapter was to establish 
an in vivo system within which these networks leading to NCC phosphorylation could be 
probed. In particular the steroid receptor (GR or MR) through which GCs act to induce NCC 
phosphorylation was investigated.  
 
6.1.1. Aims 
1. To investigate whether acute corticosterone administration in ADX mice can induce 
phosphorylation of NCC.  
2. To investigate whether changes in NCC phosphorylation can be resolved in adrenal intact 
(AI) mice 
3. To explore whether GC-mediated NCC phosphorylation is MR dependent.  
 
6.1.2. Strategy for addressing the chapter aims: 
1. ADX was initially used as a manoeuvre to reduce circulating adrenal hormones and thus 
minimise the background effect that these hormones may have on NCC phosphorylation. 
This was considered important as handling mice for injection evokes stress responses leading 
to an upregulation of plasma corticosterone or adrenaline [240, 241] This might contribute to 
the phosphorylation of NCC. Initial experiments used an acute dose of 500 µg/kg 
corticosterone and compared NCC phosphorylation after 4 hours.  
2. In the second experiment, a pharmacological dose (6 mg/kg) was chosen to more robustly 
and reproducibly induce NCC phosphorylation. Concomitantly, a pilot experiment (n=2) 
tested whether NCC phosphorylation differences could be resolved in AI mice.  
3. 6 mg/kg corticosterone evoked a robust increase in NCC phosphorylation in both ADX 
and AI mice. MR-antagonist experiments were therefore carried out in AI mice, as this is a 
more humane approach. Blockade of MR was chosen as this receptor has been implicated in 






Detailed methods of each of the procedures in this chapter are outlined in the main methods 
section, however for clarity, an outline of the experiments carried out and cohorts of mice 
used are presented here. 
 
6.2.1. Acute physiological corticosterone treatment in ADX mice 
In the first experiment, C57BL6 male mice were adrenalectomised. An AI group (n=8) was 
anaesthetised but not surgically manipulated. Post operatively, mice were single housed and 
the drinking water replaced with 0.9% saline. At day 9, post-op, ADX animals were injected 
at ZT 0 with either vehicle (n=8, vehicle: 2% DMSO in 0.9% sterile injectable saline, s.c.) or 
0.5 mg/kg corticosterone (n=8) (Based on those used in [82]). All the animals were culled in 
pairs 4 hours after injection at ZT 4 by cervical dislocation (Methods 2.3.1). Intact animals 
(n=8) were not injected but culled at the same time as ADX animals. Kidneys were taken for 
western analysis (Methods 2.3).  
 
6.2.2. Acute pharmacological corticosterone treatment in ADX mice 
In these experiments a pharmacological dose (6 mg/kg, [174]) of corticosterone was 
administered acutely to assess whether this induced robust and reproducible effects on NCC 
phosphorylation. 20 animals were ADX (maximum of 4 surgeries a day) and allowed to 
recover with access to 0.9% saline. At day 9-post surgery, mice were injected at ZT 0 with 
either vehicle (n=10, vehicle: 2% DMSO in 0.9% sterile injectable saline, sub cut) or 6 
mg/kg corticosterone (n=10). All mice were culled in pairs 4 hours later at ZT 4 (4 culls per 
day). In a small pilot experiment conducted concomitantly, AI animals were also injected 
with either vehicle or corticosterone (n=2) and culled 4 hours later. The objective being to 
assess whether an effect on NCC following corticosterone treatment could be resolved in AI 
animals with normal levels of adrenal hormones. Kidneys were taken for western analysis 
and qPCR (Methods 2.3 and 2.4 respectively) 
 
6.2.3. Acute pharmacological corticosterone treatment of adrenal intact mice 
Following the success of the small pilot experiment in adrenal intact mice, naïve C57BL6 
mice were pair housed in a quiet room for 1 week. Mice were injected at ZT 0 with either 
vehicle (n=6, vehicle: 2% DMSO in 0.9% sterile injectable saline, s.c.) or 6 mg/kg 
corticosterone (n=6, s.c.). Mice were culled in pairs 4 hours later with a maximum of 3 pairs 
culled per day to minimise disturbance. Miss Theresa Peltz performed western analysis in 
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these experiments under the author’s supervision during her Physiological Society-sponsored 
summer studentship.  
 
6.2.4. MR inhibition followed by corticosterone treatment of adrenal intact 
mice 
C57BL6 mice were acclimatised to pair housing in quiet room for 1 week. Mice were then 
anaesthetised under isofluorane and 2 x 30 mg silastic slow-release spironolactone pellets 
were implanted s.c (surgery described Methods 2.7.2). The mice were then injected with 
vehicle (n=6, vehicle: 2% DMSO in 0.9% sterile injectable saline, s.c.) or 6mg/kg 
corticosterone (n=7, s.c.). They were culled in pairs 4 hours later with a maximum of 3 pairs 
culled per day to minimise disturbance. Western analysis for pT53 NCC and total NCC was 
performed as in Methods 2.3.  
 
6.3. Results 
6.3.1. Acute physiological corticosterone treatment does not increase NCC 
phosphorylation  
NCC phosphorylation at T53 was unchanged by acute physiological (0.5 mg/kg, s.c) 
corticosterone treatment (Figure 6.1 A, C) of ADX mice. AI mice (Figure 6.1) were 
investigated alongside ADX animals as a control to assess the success of the ADX surgery. 





Figure 6.1: Western blots and corresponding densitometry analysis for pT53 NCC (A, 
C) and (B,D) total NCC in ADX C57BL6 mice 4 hours post 0.5 mg/kg corticosterone 
(cort) or vehicle (veh) injection 
A group of untreated, adrenal intact (AI) animals were also culled contemporaneously as a 
control to assess the success of the ADX surgery. All ADX animals (cort and vehicle) versus 
AI animals total NCC levels are analysed in E. Data are mean ± 95% CI. Data was analysed 





6.3.2. Acute pharmacological corticosterone treatment induces NCC 
phosphorylation in ADX mice 
pT53 NCC was increased by acute pharmacological corticosterone treatment (6 mg/kg, s.c.) 
compared to vehicle (2% DMSO in 0.9% saline) (p= 0.0002, Figure 6.2 A, Figure 6.3 A) in 
ADX C57BL6 mice. No such difference was evident for either pS71 (p=0.6299, Figure 6.2, 
6.3 B) or total NCC (p=0.9030, Figure: 6.2, 6.3 C). AI animals are adrenal intact animals 
from a pilot experiment to test whether pT53 differences could be detected in adrenal-intact 
animals. pT53 in AI animals is slightly elevated in the corticosterone treated group by visual 
inspection (Fig 6.2 A batch 2 IN).  
 
 
Figure 6.2: Western blots for (A) pT53 NCC, (B) pS71 and (C) total NCC in ADX or 
intact (AI) C57BL6 mice 4 hours post 6mg/lg corticosterone (cort) or vehicle (Veh) 






Figure 6.3: Densitometry analysis of Western blots for (A) pT53 NCC, (B) pS71 NCC, 
(C) total NCC in ADX C57BL6 mice after 6 mg/kg corticosterone (cort) or vehicle (veh) 
injection. 
Data are mean ±95% CI. Unpaired Student’s t tests were carried out on the densitometry 
analyses ***p<0.0001 **p<0.001 *p<0.05 ns p>0.05 (n=10). pT53:NCC was analysed using 




6.3.3. Acute pharmacological corticosterone treatment induces NCC 
phosphorylation in adrenal intact mice 
As shown in Figure 6.4, pT53 NCC and total NCC was measured in whole kidneys taken 4 
hours post corticosterone (6 mg/kg, s.c.) or vehicle (2% DMSO in 0.9% saline, s.c.) in 
adrenal intact C57BL6 mice. NCC phosphorylation at T53 was markedly raised in the 
corticosterone treated compared to the vehicle treated animals (p= 0.004, Figure 6.4 A). No 
difference was evident for total NCC (p=0.21, Figure: 6.4 B). These data indicate that the 
effect of acute high dose corticosterone treatment on NCC phosphorylation can still be 
resolved in adrenal intact animals. This is a much-preferred experimental route as it avoids 
an invasive surgery and is better for animal welfare. Therefore this experimental setup was 
taken forward into inhibitor studies.  
 
 
Figure 6.4: Western blots and corresponding densitometry analysis for (A) pT53 NCC 
and (B) total NCC in C57BL6 mice following a 6mg/kg corticosterone (cort) or vehicle 
(2%DMSO in 0.9% saline) injection. 
Data are mean ±95% CI. Unpaired Student’s t tests were carried out on the densitometry 





6.3.4. Receptor pathways involved in NCC phosphorylation stimulation by 
corticosterone  
In mice treated chronically with the MR inhibitor, spironolactone, NCC phosphorylation at 
T53 was markedly raised following corticosterone treatment compared to the vehicle treated 
animals (p= 0.017, Figure 6.5 A). There was no difference in total NCC between vehicle and 
corticosterone treated animals (p=0.40, Figure: 6.5 B). Therefore corticosterone-mediated 
NCC phosphorylation persists during MR inhibition.  
 
 
Figure 6.5: Western blots and corresponding densitometry analysis for (A) pT53 NCC 
and (B) total NCC in chronically spironolactone treated C57BL6 mice post 6 mg/kg 
corticosterone (cort) or vehicle (2 % DMSO in 0.9% saline) injections. 
Data are mean ± 95% CI. Unpaired Student’s t tests were carried out on the densitometry 





The primary goal of this series of experiments was to design an in vivo system in which the 
pathways through which GCs can stimulate NCC phosphorylation could be investigated. 
Cell models were considered for this work but the current cell-lines available do not model 
NCC activity particularly well ([239] and personal communication from Prof. Robert 
Fenton, University of Aarhus). Therefore an in vivo system was chosen.  
 
6.4.1. Physiological corticosterone and NCC phosphorylation 
In the first instance, animals were adrenalectomised to minimise background corticosteroid 
levels and a high physiological dose was tested. The rationale for this dose was that it would 
mimic the daily peak plasma corticosterone levels. A very small rise in NCC 
phosphorylation was seen with corticosterone treatment but this did not reach statistical 
significance. The vehicle-treated group exhibited large variation in pT53 levels. It is possible 
that without corticosterone treatment, the vehicle group may have been more sensitive to 
other influences on rapid NCC phosphorylation such as feeding and saline drinking. It is also 
peculiar that the first sample from each gel has considerably low signal. This may be 
indicative of loading issues with these wells, but it is unclear how this arose. This approach 
was not carried forward, as any further pharmacological manipulations to the system would 
be difficult to interpret.  
 
6.4.2. Pharmacological corticosterone and NCC phosphorylation 
A 6 mg/kg dose of corticosterone robustly stimulated NCC phosphorylation within 4 hours 
in both adrenal intact and ADX animals. Experiments in C57BL6 mice show that this dose 
achieves a plasma concentration of ~ 3700 nmol/l within 15 minutes [174] that is sustained 
for at least 120 mins. This is ~2X the plasma corticosterone levels following acute restraint 
stress in C57BL6 mice (~1700 nmol/l, [174]). Interestingly a similar size of increase (~2X) 
in NCC phosphorylation compared to vehicle was evoked by corticosterone in both ADX 
and intact animals. ADX increases GR and MR levels [242], reduces circulating 
corticosteroids and may reduce 11βHSD2 levels, which need corticosterone to maintain 
activity [243]. In the ADX mice, it is likely that the difference in plasma corticosterone 
between corticosterone and vehicle treated groups would have been very large, with baseline 
corticosterone levels in ADX animals ~50 nmol/l (chapter 4) and stimulated levels ~3700 
nmol/l. However ADX reduces total NCC and therefore the amount of total protein available 
to phosphorylate may have been the limiting factor. In intact animals the difference in 
plasma corticosterone levels between vehicle and corticosterone treated animals may not 
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have been as large (~1700 nmol/l estimate for handling for injection, [240] versus >3700 
mmol/l) but total protein levels are higher allowing a higher maximum NCC 
phosphorylation.  
 
NCC can undergo rapid phosphorylation and dephosphorylation: NCC dephosphorylates 
within 15 minutes following a K+ gavage and phosphorylates during a 15-minute 
vasopressin infusion [97]. However, there is very little data in the literature regarding the 
acute corticosteroid effects on NCC phosphorylation or activity. Most investigators have 
assessed the effect of several days of chronic infusion of aldosterone or corticosterone on 
NCC activity or phosphorylation [90, 91, 244]. In a DCT cell line, aldosterone stimulation 
induced NCC-dependent Na+ uptake within 12 hours; a shorter time frame was not 
investigated [157].  In an alternative approach, nuclear shutting of GR and MR occurred 
after 4 hours of aldosterone infusion [82]. Following the time course of NCC 
phosphorylation in response to a change in corticosterone would provide important 
information including the speed of response (any lag phases) and its maintenance and 
whether non-genomic effects are also observed. This may be particularly important in the 
context of circadian rhythms where temporal changes in plasma corticosteroids may precede 
effects on sodium reabsorption by several hours.  
 
6.4.3. Role of MR in corticosterone-mediated NCC phosphorylation 
An adrenal intact approach was taken forward for inhibitor experiments as this minimized 
animal suffering while still allowing detection of robust differences in NCC phosphorylation 
with corticosterone stimulation. Investigations on the role of MR in NCC phosphorylation 
were carried over GR as others demonstrated a role for MR in the diurnal rhythm of NCC 
phosphorylation [160]. These investigators found chronic eplerenone blockade inhibited the 
diurnal rhythm of NCC phosphorylation [160]. In our experiments however, upregulation of 
NCC phosphorylation occurred despite chronic MR blockade. There are several explanations 
for this finding: 1) incomplete inhibition of MR, 2) direct activation of GR in DCT or 3) 
indirect effects of GR activation elsewhere.  
 
That MR may not have been adequately inhibited is unlikely. The same drug-formulation 
and dose was used to successfully block MR in 2 previous studies [200, 245]. Although not 
measured in the present study, this dosing regimen was previously shown to achieve terminal 




The other obvious explanation is that corticosterone induces NCC phosphorylation through 
direct interactions with GR in the distal nephron. GR has a 10X higher Kd for both 
corticosteroids than MR [246], i.e. MR will be fully occupied at 10X lower concentrations of 
hormone. It has been suggested that even if 11βHSD2 inactivated 99% of corticosterone in 
the ASDN, all of MR would be still bound to corticosterone [247]. In the DCT, total MR 
occupation by corticosterone is even more likely as 11βHSD2 expression is low [86](see 
Chapter 3). Therefore in AI animals it may be in the case that no further regulation can occur 
through MR and all dynamic regulation has to occur through GR. There is evidence to 
support this proposal in the literature. In ADX rats 1 µg/100gbw/d aldosterone induced the 
maximum thiazide-binding sites achievable for aldosterone. i.e. any further increases in 
aldosterone did not increase thiazide binding. However, RU-28362, a potent and highly 
selective GR agonist, on top of 1 µg/100gbw/d aldosterone induced a twofold increase in the 
thiazide binding sites. This indicates two mutually exclusive MR and GR pathways. A 
similar finding was reported by Velazques and co workers [91]. In conflict with this work, in 
an immortalised DCT cell line NCC activity was dependent on MR signalling and was not 
affected by GR inhibition with RU486.  However, how this cell line work translates in vivo 
was not shown and it is not clear whether GR and MR expression levels are similar to in vivo 
levels [157].  
 
There is strong evidence for the involvement of GR in pathological perturbations in sodium 
handling. Salt sensitive BP in 11βHSD2 heterozygous mice is unchanged by spironolactone 
but ameliorated by RU486 [245]. Aberrant ENaC regulation in these animals is also GR 
rather than MR dependent [248]. Recently, renal clearance experiments in these animals 
have revealed inappropriately raised thiazide-sensitive sodium transport following a high 
sodium diet compared to wild type controls (own observation, Appendix 9.1) suggesting a 
potential additional role for NCC in the aetiology of salt-sensitive blood pressure in these 
mice. Furthermore salt-sensitive BP induced by β-adrenergic stimulation was GR-dependent 
and accompanied by inappropriate NCC activation [103].  
 
In immunofluorescent experiments in vivo low dose corticosterone infusion caused shuttling 
of GR to the nucleus of DCT cells [82] but not in principal cells of rat kidneys, where 
presumably GR is protected by 11βHSD2.  However, MR shuttling to the nucleus of DCT 
cells also occurred with corticosterone infusion. MR certainly has a role in the regulation of 
NCC. Spironolactone treatment decreases the total amount of NCC protein [185]. Although 
not directly tested in this work, total NCC protein was likely reduced in our experiment: the 
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exposure time required to detect NCC protein in blots in these experiments was ~ 10X 
greater than that usually required for total NCC in untreated mice using the same protocols 
and antibodies. It might be that MR activation contributes to the setting of the level of NCC 
protein and then phosphorylation-dependent activation is then induced by GR.  
 
GCs may indirectly affect NCC through extra-renal GR-activation. Dexamethasone induces 
an increase in blood pressure in mice that is GR, not MR dependent [249]. Interestingly, this 
DEX-induced high blood pressure is still evident in mice with conditional deletion of GR in 
the distal nephron (floxed using Ksp cadherin- CRE animals [250]). However, while the 
authors demonstrated a reduction of GR in AQP2-positive collecting ducts, no data was 
available for the presence of GR in NCC positive DCTs. Ksp cadherin is expressed in the 
DCT so one would expect at least a reduction in GR expression in DCT. It has therefore not 
been possible to definitely rule out GR-mediated NCC upregulation by DEX treatment. If 
tubular GR is not required for GC-induced high BP, this implicates extra-tubular GR in the 
genesis of GC-induced high blood pressure. This prompts the question: could the 
upregulation of NCC phosphorylation be an indirect result of GR activation? Both GFR and 
RBF increase with GC treatment within 2-3 hours [123, 251, 252]. An increase of GFR 
likely increases the delivery of sodium to the distal nephron [253], which will cause sodium-
delivery dependent NCC activation [147, 254, 255]. Renal clearance experiments to measure 
thiazide sensitive sodium transport would allow the assessment of whether corticosterone-
induced NCC phosphorylation has relevance for thiazide-sensitive sodium transport. 
Furthermore it would allow the assessment of any changes in renal haemodynamics with 
corticosterone treatment. 
 
6.4.4. Limitations of experimental work 
Financial and time constraints restricted the breadth of experimentation that could be 
conducted during this last phase of my PhD research. The limitations of these experiments 
are discussed here. Firstly, our data suggest that GCs do not activate NCC via MR but an 
alternative explanation is that we did adequately inhibit MR. Spironolactone is not the 
preferred MR antagonist as it has complex pharmacokinetics and off target effects. The 
majority of spironolactone’s pharmacological effects are as a result of it’s active metabolite 
canrenone. Spironolactone is rapidly metabolised to canrenone and both residual 
spironolactone and canrenone have off target effects [256]. A superior drug would have been 




We have not measured canrenone in the samples taken from the current analysis due to the 
costs of the LCMS analysis. However, this is a key future experiment, as it will permit us to 
rule out inadequate MR inhibition as a reason for persistence of corticosterone-induced NCC 
phosphorylation in chronic MR blockade. Indeed, plasma analysis of canrenone may be 
particularly important to validate successful delivery in the vehicle treated group: this group 
has one outlier exhibiting both higher total NCC and higher pT53 than the other members of 
this group. This may be biological variation but could also indicate a failed spironolactone 
pellet.  
 
These experiments are also restricted by the single dose used, followed by assessment at a 
single time point. A dose response curve experiment would yield valuable information about 
the relevance of GC signalling for “normal” physiology. The time point (4 hours post 
injection) chosen was an educated guess, based on a rough estimate for lag-time of genomic 
actions of corticosteroids (> 1 hours, [165]) and on a previous experiment in which 
aldosterone infusion evoked changes in GR/MR nuclear translocation in renal tubules within 
4 hours [82]. It is possible that changes in NCC phosphorylation may have occurred earlier 
and were not sustained at our 4-hour time point with the lower corticosterone dose but the 
larger dose caused sustained NCC phosphorylation that was detectable at 4 hours. Time 
course experiments would be useful in this regard. Experiments using RU486 to inhibit GR 
are necessary to confirm the importance of this receptor in NCC regulation.  
 
6.4.5. Summary of Chapter Findings: 
1. Acute corticosterone treatment induces NCC phosphorylation at T53  
2. Chronic inhibition of MR with spironolactone does not prevent upregulation of pT53 





The major findings of this thesis were that NCC has a diurnal rhythm of phosphorylation, 
which requires an intact GC rhythm. I further demonstrated that NCC phosphorylation is 
stimulated by corticosterone and that overstimulation reduces BP dipping, which is partially 
restored by thiazide diuretics.  
 
7.1. Proposed model for role of NCC in diurnal rhythm of blood pressure 
The kidney is important for the long-term control of BP homeostasis with the pressure 
natriuresis response serving to efficiently maintain extracellular fluid balance. 
Unsurprisingly evidence is accumulating for a role for renal sodium handling in the genesis 
of a circadian rhythm of BP ([26, 28] reviewed in: [257]). Our data indicates that NCC may 
contribute to BP rhythm; an effect on sodium balance would be the most plausible 
explanation for this but I was not able to demonstrate such an effect using the experimental 
approaches employed. My data (and that of others) suggest NCC’s diurnal rhythm is not 
transcriptionally regulated at least at the level of the NCC transcript itself, but rather by 
phosphorylation of the protein [160].  
 
The potential role of NCC and GCs is presented as a hypothesis in Figure 7.1. Here I 
propose that GCs regulate the circadian rhythm of NCC phosphorylation, which evokes 
rhythmic changes to sodium reabsorption; this in turn contributes to BP rhythmicity. Chronic 
GC treatment clamps NCC phosphorylation “on” during the day causing inappropriate 
sodium retention and elevated daytime BP. I showed that flattening the GC rhythms changed 
renal clock gene rhythms, altered daytime NCC phosphorylation, caused a small shift in 
day:night sodium balance and reduced BP dipping. There are several components of this 
hypothesis that we were unable to demonstrate experimentally. This includes specific NCC-
induced changes in sodium reabsorption between day and night (i.e. HCTZ sensitive 
transport experiments in Chapter 4) and it is unclear whether the clock genes have a direct 
role to play in the regulation of NCC phosphorylation. Further experiments testing the 
assumptions of this model are needed. These should define GC-induced changes in NCC 
activity and identify whether natriuresis is the mechanism for BP lowering following HCTZ 
treatment in corticosterone-treated mice. Experiments in renal-specific clock mutants would 
allow the assessment of the role of the renal clock in NCC phosphorylation rhythms. A 
major limitation of this work is the use of only two time points for the assessment of NCC 
phosphorylation and transcriptional changes over 24 hours. These time points were initially 
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chosen to coincide with the peak and trough of blood pressure however, dynamic changes in 
NCC activation may occur before and facillitate this peak/trough in BP. Greater resolution of 
NCC phosphorylation over 24 hours is needed to investigate this possibility.  
 
In a fully integrated system BP rhythmicity is the product of many interacting factors. In this 
regard, the model has limitations: 24-hour sodium balance is the product of total renal 
sodium transporter activity (including that in the proximal tubules, loop of Henle and distal 
nephron).  Furthermore, transporter activity is influenced by multiple hormonal systems e.g. 
the RAAS, insulin, vasopressin and rSNA and changes in ultrafiltration capacity over 24 
hours will also influence BP. Finally, GCs, through their effect on peripheral organ circadian 
clocks, will evoke multi-system effects outwith the kidney. Although limited, this figure is 
used here as a framework for a discussion on the clinical implications of this work. 
 
7.2. Stimulation of NCC by GCs 
The major emphasis of this work has been the role of GCs in the regulation of NCC 
phosphorylation. Two groups discovered a role for GCs in the regulation of NCC activity in 
the 1990s. These included experiments that showed an increase in metolazone-binding sites 
with dexamethasone treatment in adrenalectomised rats [90] and thiazide-sensitive sodium 
transport was increased by dexamethasone in micropuncture experiments [91]. Furthermore, 
GR was required for salt sensitive hypertension induced by β adrenergic receptor stimulation 
via modification of the WNK4 promoter [103]. This hypertension was accompanied by 
inappropriately raised HCTZ-sensitive sodium transport [103]. 
 
We have shown via 2 routes that GCs can evoke changes in NCC phosphorylation: (i) 
chronic administration of GCs alters the diurnal rhythm of NCC phosphorylation and (ii) 
acutely GCs stimulate NCC phosphorylation within 4 hours. This is a clinically relevant 
finding. There are many pathophysiological situation in which high or chronic GC levels 
feature, particularly in salt sensitive hypertension. Polymorphic variants of both the gene 
encoding GR (NR3C1) and 11βHSD2 (hsd211b), both involved in GC-sensitivity are found 
in the human population. GR (NR3C1) polymorphisms are associated with obesity and high 
BP [258, 259] and 11βHSD2 polymorphisms with salt sensitive hypertension [260] [261]. 
Whilst specific changes in NCC activity in humans with GC excess have not been 
documented, subtler GC abnormalities often feature in salt sensitive hypertension. Salt 
sensitive individuals exhibit augmented stress-induced activation of the HPA axis [262] and 





Figure 7.1: Hypothesis for the involvement of NCC and glucocorticoids (GCs) in the regulation of BP rhythm 
Plasma GC rhythms may act through the GC receptor (GR) to entrain renal clocks, which may regulate the NCC phosphorylation rhythm. NCC activity 
through its contribution to the daily rhythm of sodium reabsorption affects the daily SBP (systolic blood pressure) rhythm. If the circadian rhythm of GCs 
is abolished through chronic treatment NCC phosphorylation is clamped on during the day leading to abrogation of sodium reabsorption rhythm and 
dampening of SBP rhythmicity. NCC inhibition with HCTZ through restoration of sodium reabsorption rhythms partially rescues SBP rhythmicity. 
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Furthermore, metabolic syndrome, which is highly prevalent in the western world, features 
the upregulation of GC tissue availability [264] and salt-sensitive hypertension [265] [266] 
[267]. 
 
Two mouse models within our lab featuring altered GC signalling indicate NCC 
perturbations contribute to their BP phenotypes. 11βHSD2 heterozygous mice, which exhibit 
salt sensitive hypertension [245], fail to downregulate BFMZ-sensitive sodium transport 
when on a high sodium diet (own observations, Appendix 9.1). Similarly GR haplo-
insufficient mice [268] have salt sensitive BP and inappropriately elevated HCTZ-sensitive 
sodium transport upon high sodium feeding [269, 270]. Both have rhythms of corticosterone 
with a peak at ~ZT 12 and trough at ~ZT 0 but in the GR haploinsufficient mice both peak 
and trough levels are raised and in the 11βHSD2 heterozygous mice high sodium feeding 
causes an elevation in the peak levels but no change in the trough [248]. It would be 
intriguing to investigate both the GC rhythms and NCC phosphorylation rhythms are present 
in the full 11βHSD2 knock out mouse, which model the syndrome of apparent 
mineralocorticoid excess (SAME). In other labs, NCC activity is enhanced in salt-sensitive 
norepinephrine and isoproterenol-infused mice [103]. This is dependent on GR signalling 
and is abolished with RU486 treatment or adrenalectomy [103].  
 
Our data would suggest that targeting NCC with thiazide diuretics might be a strategy for 
attenuating BP arhythmicity in metabolic syndrome or chronic stress. Indeed, in an 
experimental model of metabolic syndrome NCC phosphorylation was enhanced [271].  
Conversely, chronic stress combined with salt loading caused high SBP in baboons that was 
not attenuated with HCTZ although BP rhythm was not studied [272]. Chlorthalidone, which 
is a thiazide-like diuretic with a longer half-life than HCTZ, has cardiovascular benefit in 
metabolic syndrome [273]. However, thiazide diuretics also exacerbate metabolic 
derangements and cause endothelial dysfunction [274]. It has been argued that the 
cardiovascular benefits outweigh the adverse metabolic side effects [275] and it has also 
been suggested that correcting hyperuriceamia and hypokalaemia may prevent the adverse 
metabolic side-effects associated with thiazide treatment while maintaining the BP lowering 
benefits [274].  
 
7.3. How do GCs and the clock integrate with the NCC regulatory system? 
The mechanism through which GCs and the clock integrate with intracellular pathways 
regulating NCC is unknown. Our work (in Chapter 6) suggests that this might be through the 
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GR but MR involvement cannot be ruled out and further investigations to this end are in 
progress using pharmacological approaches. However ideally further experiments to 
interrogate the receptor pathways underlying GC regulation of rhythmic NCC 
phosphorylathion would be undertaken using inducible kidney-specific GR/MR knock out 
mice.  
 
The regulatory networks that link receptor activation to NCC phosphorylation/activation 
have also not been elucidated. GCs can alter the level of per1, per2 and rev-erbα directly 
through GREs and thus can directly influence the renal clock [76-79]. We confirmed this 
effect in a cohort of ADX mice, which showed induction of cry1, bmal1, per1 and per2 
within 4 hours of corticosterone treatment (Figure 7.3).  But this acute GC treatment also 
induced SGK1 and GILZ expression (Figure 7.3) and both are involved in the NCC 
regulatory cascade (discussed in Chapter 4). We have no temporal profile for these GC-
induced genes. Furthermore these experiments were carried out in whole kidney. Therefore 
these findings prompt many more questions. Firstly what does the GC-induced gene 
expression profile look like in DCT? What is the order of gene induction? Does GILZ/SGK1 
upregulation precede or result from clock gene induction or are these pathways independent? 
Finally are all or only a selection of these genes required for a change in NCC 
phosphorylation? What other genes are involved?  
 
One way of approaching some of these questions would be to investigate whether NCC 
upregulation via GCs can occur in the absence of clock genes. Here, GC stimulation of 
NCC-p in a renal specific (or better yet DCT-specific) knock out of multiple clock genes 
would be informative. Furthermore defining any abnormalities in the intra-cellular 
regulatory kinases (WNKs/SPAK/OSR1) in these mouse models would be valuable in 





Figure 7.2: Gene expression in kidneys of ADX C57BL6 mice 4 hours following 
corticosterone (6mg/kg) or vehicle (2% DMSO in 0.9% saline) injection. 
Protein the gene transcribes is in brackets. Expression of each gene was normalised to the 
average expression of 18S, TBP and HPRT. Data are mean±95% CI. Data were analysed by 
two way ANOVA with post hoc Sidak tests ****p<0.0001, ***p<0.001, *p<0.05 (n=10). 
 
7.4. The importance of GCs in rhythmic BP  
In our experiments we found a loss of rhythmicity, decrease in amplitude and increase in 
MESOR of BP in C57BL6 mice treated chronically with corticosterone. The finding that 
perturbations in GC signalling can evoke changes in BP rhythms is not new. In the clinic, 
both an excess of GCs, as seen in Cushing’s disease [226] or with exogenous GC intake 
[227], and deficiency, as seen in Addison’s disease [276] are associated with a lack of BP 
rhythmicity. The mice described in Chapter 5 exhibit marked changes to their BP rhythms 
despite having physiological levels of corticosterone. This gives further credence to the 
concept that it not only the level of GCs but also their temporal release that plays a role in 
disease [44, 277].   
 
Alterations to the circadian rhythm of plasma GCs may be fairly common in the population 
featuring in jetlag, shift-work, chronic stress, metabolic syndrome and depression. Jetlag is 
the result of a rapid switch of external light/dark cues causing a misalignment of the internal 
circadian clocks and external time This is also accompanied by desynchrony of the tissue 
clocks as a result of differing kinetics of the peripheral oscillators and central clock. 
Although it is transient and perhaps of little long-term consequence for most holiday goers, 
those who travel frequently for business or indeed flight workers risk the long-term 
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consequences of chronic jet lag. These include adverse metabolic changes [278], increases in 
MAP [278], [279] and accelerated mortality with age [280].  
 
Misalignment of circadian clocks also occurs with shift work, which is defined as 
employment in any work schedule that is not during regular daytime hours (9am to 5pm). A 
meta-analysis of ~ 2 million people from 34 studies links shift work to an increased risk of 
myocardial infarction, and ischaemic stroke [281]. Rotation shift work seems to pose a 
particular problem with a higher risk of death by cardiovascular disease than fixed-schedule 
work found in both Japanese [282] and African American but not in Caucasian workers 
[283]. Disruption of GC signalling is implicated in peripheral clock desynchrony in both 
shift work and jetlag [73, 284]. Interventions using timed GC treatment to resynchronise the 
peripheral clocks [74] may be a valuable approach for protection against the long term 
effects of jetlag and shift work. However, the practicalities of GC treatment are complicated 
by the need for both circadian and ultradian GC signalling for normal physiology as 
discussed later.  
 
Jetlag and shift working are examples where external lighting cues or behaviours affect 
circadian rhythms of several systems as a result of mistimed sleep/feeding/awake cycles. 
However, there are also common examples of “internal” disruption of circadian GC rhythms 
for example in metabolic syndrome [285], chronic stress [286] and depression [287, 288]. 
This may have implications for circadian BP control with higher incidence of non-dipping 
BP reported in metabolic syndrome [289], depression [290], and chronic stress [291]. Renal 
sodium handling is implicated in the metabolic syndrome (reviewed: [292]) and in a rat 
model of metabolic syndrome NCC activity is inappropriately upregulated [271]. The role of 
sodium transporters in BP accompanying affective disorders has not been explored but may 
be an overlooked consequence of these disorders.  
 
7.5. Chronotherapy: timely treating 
In humans, non-dipping SBP is more closely associated with cardiovascular-associated 
morbidity and mortality than office BP or MAP [293] [13] [294]. In this work we have 
shown that NCC phosphorylation has a diurnal rhythm that is important for diurnal BP 
control in mice. Therefore some patients with non-dipping BP might too have miss-timed 
regulation of renal transporters.  Evidence for this includes transformation of non-dipper to a 
dipper profile following sodium restriction or diuretic treatment in patients with essential 
hypertension [27, 28]. However, these individuals may benefit from targeting transporters at 
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the time at which they are most aberrant. This strategy, aptly named chronotherapy, is the 
timed administration of therapies to complement intrinsic circadian rhythms.  
 
The MAPEC trial investigated the effect of taking at least one anti-hypertensive medication 
at bedtime rather than the conventional morning dosing schedule [295]. MAPEC was an 
open label, blinded end-point trial involving 2156 patients with essential hypertension taking 
at least 1 antihypertensive agent. Bedtime dosing improved mean arterial pressure control, 
decreased prevalence of non-dipping and importantly decreased cardiovascular morbidity 
and mortality [294, 295]. Furthermore nighttime dosing improved outcomes in resistant 
hypertension, hypertension during chronic kidney disease and hypertension with diabetes 
(reviewed in: [296]). There are several small trials that look at HCTZ chronotherapy in 
particular. In a randomised, open-label, blinded end-point study, HCTZ was added to the 
treatment regimen for 204 essential hypertension patients as BP was poorly controlled in 
patients with valsartan alone [231]. They found here that nighttime dosing increased the 
proportion of non-dipping patients [231]. HCTZ monotherapy was trialled in 165 African 
patients with essential hypertension with either bedtime or waking dosing regimen [230]. 
The major limitation of this work was that ambulatory BP was not measured. However, there 
was evidence of reduced target organ damage with bedtime dosing: left ventricular mass was 
reduced and diastolic function improved. MAP failed to reach significance (p=0.07, [230]).  
 
According to our model for NCC’s involvement in the circadian rhythm of BP, it might be 
assumed that HCTZs would be an effective treatment for BP alterations in states of high GCs 
such as Cushing’s syndrome. As discussed earlier HCTZ treatment can exacerbate 
hypokalaemia in these individuals. An alternative strategy to target the BP effects of 
misaligned GC rhythms might be to try and mimic the circadian rhythm of GCs but this is no 
trivial task. In normal physiology temporal release of GCs can be spilt into both circadian 
and ultradian release. GCs are released in 1-2 ultradian pulses every hour, which increase in 
both amplitude and frequency towards the daily circadian peak and decrease towards the 
trough [297]. The ultradian GC release causes GR-mediated gene pulses. These pulses seem 
to modulate stress responses in rodents [298] but it is not clear what effect these might have 
on sodium balance and cardiovascular disease.  
 
Currently available technology is unable to deliver pulsatile GCs and thereby replicate the 
true ultradian pattern of HPAA activity in vivo [277]. Nevertheless, attempts have been made 
to mimic the circadian rhythm of GCs in order to circumvent the disturbances to circadian 
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BP. In double blind cross over study in ADX patients investigators examined the difference 
between two treatment regimens: administration of 10 mg hydrocortisone first thing in the 
morning followed by 20 mg at night or 20 mg first thing in the morning followed by 10mg at 
night. The concept being that the higher dose first thing in the morning may more closely 
mirror the “morning surge” of cortisol experienced in adrenal intact individuals. They found 
little improvement in office MAP with either regimen and day/night differences in MAP 
remained minimal in both groups [299]. However, neither regimen replicated the 
physiological GC rhythm: causing two surges of cortisol at the beginning and end of the day. 
Modified release hydrocortisone has been more successful in mimicking the diurnal pattern 
of cortisol in patients [300]. This has very recently been shown to improve SBP compared to 
conventional cortisol replacement in Addison’s patients [301].  
 
There are two major reasons why chronotherapy is so important for treatment efficacy. 
Firstly consideration of any inherent circadian rhythms of the drug targets themselves is 
crucial. For example, HCTZs may have better efficacy at night because that’s when NCC is 
inappropriately active and this corrects the aberrant sodium transport and restores the 
dipping SBP profile. Secondly, systems pertinent to the pharmacokinetics of drugs also have 
circadian rhythms. Gastric pH, emptying and motility have circadian rhythms that are 
important for absorption of oral drugs [302]. The liver, the organ with the highest number of 
circadian genes [43], is key in drug metabolism. GFR has a circadian rhythm with reduced 
GFR at night reducing excretion of drugs at night [303]. A recent study has shown that over 
50% of the drugs on the market today target the product of a genes with a circadian rhythm 
and importantly almost half of these drugs have half lives <6 hours [43] and therefore timing 
of the dosing of these drugs in particular will be important for their efficacy.  
 
In this work we have made a case for chronotherapeutic administration of thiazide diuretics 
and GCs but this is just the tip of the iceberg. A greater understanding of how we can 
harness the circadian rhythms of the intrinsic clocks controlling both drug targets and 
pharmacokinetics will mean better control of pathologies. Advances in our understanding of 
the mechanisms involved in the GC-induced entrainment of peripheral clocks may aid with 
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9.1. Thiazide-sensitive sodium transport in 11βHSD2 heterozygous mice 
 
Figure 9.1: Fractional sodium excretion (FeNa) in HSD2-11b wild type (+/+) and 
heterozygous (+/-) mice 
Hsd2-11b wild type and heterozygous littermate mice underwent renal clearance surgery. 
The experimenter was blinded to the genotype.  Following a 40-minute baseline urine 
collection, mice were given bendroflumethiazide (BFMZ, 6 mg/kg i.v.) and a further 40-
minute collection was made. Data are mean±95% CI. Data were analysed by matched two-
way ANOVA with post hoc Sidak tests, ****p<0.0001, **p<0.01, *p<0.05, n=13.  
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